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Abstract
Thesynthesisofaseriesof1aryl2fluoroethanonesandtheiruse in thepreparationof
enantioenriched 1aryl2fluoroethanols and 1aryl2fluoroethylamines has been
investigated. Several chiral analogues of the antimycotic agents Butenafine and
Terbinafinehavealsobeenpreparedandtheirantifungalactivityassessed.
Startingwiththecorresponding1arylethanones,onenucleophilicandthreeelectrophilic
fluorination methods towards 1aryl2fluoroethanones were compared. The target
compounds containing electron donating aromatic substituents were isolated in high
yields (9176%) by fluorinating the trimethylsilyl ethers of the 1arylethanones with
Selectfluor®. For substrates bearing more electron withdrawing substituents, however,
themicrowave (MW)mediatedSelectfluor® fluorinationof1arylethanones inmethanol
gavethebestresults(8641%yield).Comparedtothethermalsynthesis,theMWassisted
methodresultedinasignificantreductioninreactiontimeandchemicalconsumption.For
the nucleophilic fluorination of 1aryl2bromoethanones using tetrabutylammonium
bifluoride,moderatetopooryieldswereexperienced(5120%).
Followingtheirsynthesis,twoapproachesfortheasymmetricreductionofeight1aryl2
fluoroethanones were investigated. Catalysed by the proline based (R)MeCBS in 1,2
dimethoxyethane,alltheketoneswerereducedwithexcellenttogoodenantioselectivity
(99.591.5% ee). A ruthenium catalysed asymmetric transfer hydrogenation was also
investigated. Four catalytic systems were tested, each constructed of a ruthenium
complex coordinated to a chiral diamine ligand. The best results were achieved using
[RuCl2(mesitylene)]2 coordinated to (1S,2S)N(ptoluenesulfonyl)1,2
diphenylethylenediamine in a formic acid/triethylamine mixture. The overall
enantioselectivity (99.585.0% ee) was lower than for the (R)MeCBS reductions. The
absolute configurationof theproductswasdeterminedby circulardichroism (CD)using
theexcitonchiralitymethod.
AMitsunobu inversionof theprepared (R)1aryl2fluoroethanolswasemployed in the
synthesis of the corresponding (S)1aryl2fluoroethylamines. For six of the substrates,
clean inversionof stereochemistrywasobserved.However, racemisationand lowyields
weretheresultwhenelectrondonatingsubstituentswerepresentatthearomaticringof
the substrates. When substituted with a cyano or a nitro group, fluorine elimination
occurred,therebylimitingtheyieldforthesetransformations.Togainaccesstothe(R)1
aryl2fluoroethylamines, a Novozym 435 catalysed kinetic resolution of the racemic 1
aryl2fluoroethylamines was performed. This gave the (R)amines in excellent to good
vi

enantiomeric excess (99.096.0%). The absolute configuration of the amines was
determinedbyCD.
FivechiralderivativesofbothButenafineandTerbinafineweresynthesisedandevaluated
fortheirantifungalactivitytowardsCryptococcusneoformans.ThemostactiveButenafine
derivative,havingamethyl substituent at thecarbon connected to the central nitrogen
atom,performedequallywellastheparentcompound.Testingeachoftheenantiomers
of this compound against Cryptococcus neoformans, Cryptococcus diffluens and
Trichosporon cutaneum revealed that most of the activity originated from the (R)
enantiomer.Againsteachoftheteststrains,the(R)enantiomershowedequalorhigher
antifungalactivitythanButenafine.
 
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1. Introduction

1.1 Whyorganofluorine?
Despite the fact that fluorine is the 13th most abundant element in the earth’s crust
(Figure 1.1),1 organic compounds containing fluorine are virtually absent in nature. No
major biological pathways rely on fluorinatedmetabolites and there is only one known
naturally occurring enzyme which catalyses carbonfluorine bond formation.24 This
seeminglyinsignificantspotmissedbynaturemeansthatorganicchemistsarenowdoing
the work evolution has done over billions of years for the other elements in organic
chemistry. This presents many great challenges but it also gives an entirely synthetic
dimensiontoorganicchemistry,withuniquechemistryandnovelmaterialswithextreme
propertiesdiscoveredeveryday.5

Figure1.1:Therelativeamountsofthe15mostabundantelementsintheearth’scrust.1
Incorporatingoneormorefluorineatomsintoamoleculeoftenhasaprofoundeffecton
the physical, electronic and physiological properties of an organic compound. The
usefulnessofthiseffect,sometimescalled“fluorinemagic”,canbevisualisedby looking
at thevast rangeofadvancedmaterials,pharmaceuticalsandagrochemicalswhichowe
theirvaluablepropertiestothepresenceofoneormorefluorineatoms.
Due to the sometimes extreme effects it can have on the properties of organic
compounds,fluorineisoftenreferredtoas“asmallatomwithabigego”.Someofthese
8O
14Si
13Al
26Fe
20Ca
11Na
12Mg
19K
22Ti
1H
15P
25Mn
9F
56Ba
38Sr
Element Abundance [%]
8O 46,10 
14Si 28,20 
13Al 8,23 
26Fe 5,63 
20Ca 4,15 
11Na 2,36 
12Mg 2,33 
19K 2,09 
22Ti 0,57 
1H 0,14 
15P 0,11 
25Mn 0,10 
9F 0,06 
56Ba 0,04 
38Sr 0,04 
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effectscanberationalisedandexplainedfromaquantumchemicalpointofview,others
arecomplicatedbythecooperativeworkoftheseeffects.6Thissectionwillpresentabrief
overviewofsomeofthemostpronouncedeffectsfluorinehasonthephysical,electronic
and physiological properties of organic compounds, and how they are utilised in the
designofnewpharmaceuticals.
1.1.1 Physicalproperties
Thephysicalpropertiesoffluoroorganiccompoundsaremainlygovernedbytwofactors;
(1)Thecombinationofhighelectronegativitywithmoderatesizeandtheexcellentmatch
betweenthefluorine2sor2porbitalswiththecorrespondingorbitalsofcarbonand(2)
theresultingextremelylowpolarizabilityoffluorine.7
As a consequence of the low polarizability, perfluorinated compounds have very weak
intermolecular dispersion interactions. This explains the perhaps most characteristic
physicalproperties formostperfluorocarbons; theirunusually lowboilingpoints.Unlike
mosthalogenatedcompoundswhichattainhigherboilingpointsalongwiththeincreased
numberofhalogenspresent,perfluorinatedcompoundsareextremelyvolatileandmust
behandledwithcaution(Figure1.2).

Figure1.2:Boilingpointsofhalomethanes.
Despite the very high electronegativity of fluorine (4.0 at the Pauling scale),8
perfluorinatedorganiccompoundsaresignificantlymorelipophiliccomparedtothenon
fluorinatedcounterparts.Thisapparentcontradictionisexplainedbythefactthatallthe
local dipolemoments cancel each other out, resulting in a global nonpolar compound.
This makes the introduction of perfluorinated moieties a useful tool when highly
hydrophilicmoleculesneedtobemademorelipophilic.6,9
CH3Cl
CH2Cl2
CHCl3
CCl4
CH4
CH3F
CH2F2
CHF3
CF4
CH3Br
CH2Br2
CHBr3
CBr4
200
150
100
50
0
50
100
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200
Bo
ili
ng
p
oi
nt
[°
C]
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Perfluorinated carbon chains are far more stiff and rigid than the corresponding non
fluorinatedchains.Thisphenomenoncanbevisualisedwhencomparingthewellknown
rigid Teflon® polymer (polytetrafluoroethene), used among other things as coating in
fryingpans,with thehighly flexibleplasticpolyethene.The reason for thisdifference in
physicalpropertiesisattributedtothelargersizeoffluorinecomparedtohydrogen.This
makestheenergybarrier for the internal rotationof thecarboncarbonbondhigherfor
perfluorinatedchains,therebyincreasingtherigidity.6
1.1.2 Electronicproperties
The electronic effect of a fluorine substituent is largely dependent on whether it is
attachedtoaelectronsystemortoaelectronsystem.Asaconsequenceofthehigh
electronegativity of the fluorine atom, fluorine substituents are strongly inductively
electronwithdrawing, therebyactivatingnearbyreactioncentres fornucleophilicattack.
Thelonepairelectronsoffluorinecan,however,donateelectronsbackthroughbonds.
Thisresonanceeffect,althoughweak,willaffectthereactionratesandtheregiochemistry
ofreactionssuchaselectrophilicaromaticsubstitutionreactions.10,11
As with other electronegative substituents, fluorine insertion increases the acidity of a
molecule.However,duetotheelectrondonatingresonanceeffectdiscussedabove,this
increaseinacidityissmallercomparedtotheotherhalogenswhenattachedtoelectron
systems.12
Unlikethefluorineatom,thetrifluoromethylgroupandperfluoroalkylgroupsarealways
net electron withdrawing substituents. For perfluoroalkyl groups the inductive effect
increases with increasing number of fluorine atoms until it levels off from CF2CF3. The
trifluoromethylgrouphasanelectronwithdrawingeffectcomparabletonitroandcyano
groupswhen attached to electron system. This effect is rationalised by the ability of
thesegroupstodelocalizelonepairelectronsbynegativehyperconjugationasillustrated
forthetwoparasubstitutedanilinesinFigure1.3.6
Introduction
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
Figure1.3:NegativehyperconjugationasexplanationforthesimilarityinelectronwithdrawingeffectbetweentheCF3
andNO2group.
6
Negative hyperconjugation was proposed in 1950 to explain the strongmetaorienting
influenceoftrifluoromethylgroupsinelectrophilicaromaticsubstitutionreactions.13The
phenomenon has been debated and an alternative interpretation of the experimental
data has been proposed.14 It is now, however, widely recognised that the
hyperconjugationplaysanimportantroleinthestabilisationofthe	carbanionA,inthe
shorteningandstrengtheningoftheC
C	bondinthesystemsA,CandD,andinthehigh
reactivityoftheCFbondinsystemD(Figure1.4).6

Figure1.4:Someeffectsofnegativehyperconjugation.6
The near optimum overlap between the 2s and 2p orbitals of fluorine with the
corresponding orbitals of carbon makes the CF bond extraordinarily stable. The bond
length of a carbonfluorine bond is typically 1.35 Å, making it the most stable bond
betweencarbonandanotherelement.Asaconsequence,fluorineisapoorleavinggroup
for aliphatic nucleophilic substitution. Even when reacted with strong nucleophiles,
alkylfluoridesmostlyreactviaelimination(E2orE1CB)ratherthansubstitution(SN2).
15
1.1.3 Fluorineinpharmaceuticals
Over the past years fluorine has become a common substituent in pharmaceutical
compounds.16,17 Itsuniqueabilityto influenceamolecule’spropertiescombinedwith its
small size makes fluorine a valuable tool in drug discovery. The effect in terms of
physiological and pharmacological properties is often difficult to predict but the
introductionofafluorineatomrarelypassesunnoticed.
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Stability toward metabolic degradation is an important factor when designing a drug.
Fluorine insertion has frequently been used as a tool to selectively block positions in a
molecule prone to metabolic degradation.18,19 Oxidation of aromatic rings can, for
instance, be prevented by fluorination of the paraposition (Figure 1.5). While other
electronwithdrawingelementsmayplay the same role, theuseof fluorine substitution
hastheadvantageofavoidinglargestericalterationsinthemolecule.20
F CF3
oxidation site
f luor inated analogues
protected f rom metabolic hydroxylation 
Figure1.5:Preventionofbiologicaloxidationofanaromaticringbyfluorination.
Drugscontainingbasicnitrogenatomsareoftentroubledbyloworalbioavailabilitydueto
the high pKa value of the nitrogen atom. Whether or not basic nitrogen atoms are
protonatedinthebiologicalenvironmentmaynotonlybecritical forbindingpotencyat
the target but also affects properties such as lipophilicity andmembrane permeability.
Introducing a fluorine atom in the molecule reduces the pKa value and higher oral
bioavailabilityisoftentheresult.2123Theorallyadministeredthrombineinhibitorshownin
Figure1.6illustratesthisbytheelevatedlevelofthedrugfoundinthebloodofrats(Cmax)
giventhefluorinateddruganalogue.24
S
H
N
O O
N
NH2
NH2
R
N
O R = H
R = F
Cmax = 1.6 M at 30 mg/kg
Cmax = 4.1 M at 30 mg/kg

Figure1.6:Theeffectoffluorineontheoralbioavailability.24
Bioisosteres are substituents or groupswith similar physical or chemical properties and
arefrequentlyusedindrugdesign.Thereasonforchangingonebioisostereforanotheris
to enhance the desired biological or physiological properties of a compound without
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making significant changes in the chemical structure. Fluorine is involved in several
bioisosteres, the most common being the well known hydrogenfluorine replacements
(Figure1.7).25,26Other fluorinebioisosteresare fluoroalkenes foramides,27CCF3groups
forcarbonylgroups28andfluorineforhydroxylgroups.29,30
OH FH F
NH
O CF3
O CF3

Figure1.7:Someexamplesofbioisosteresinvolvingfluorine.
“Suicide inhibition” is a term which describes the irreversible binding of a ligand to a
protein followedby loss of theoriginal activity. This is a commonmodeof action for a
numberofpharmaceuticalsand thereare severalexampleswhere fluorine is theactive
partintheinhibitionprocess.31,32
More recently, an increased focus has been put on unveiling the interactions between
fluorinatedligandsandtheactivesiteinproteins.Fluorinesubstituentsinteractefficiently
withpeptidebonds(Figure1.8)and,byperformingsocalled“fluorinescans”onleaddrug
candidates, the goal is to strengthen the proteinligand binding. This would result in a
morepotentdrugintermsofincreasedbindingefficacyandselectivity.33

Figure1.8:InteractionsbetweenpeptidicC=OandNHmoietiesintheenzymethrombinandtheCFresidueoftwo
differentinhibitors.33


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1.2 Chirality
Chirality isapropertyassociatedwiththreedimensionalobjects.Anobject isdefinedas
chiral if it is nonsuperimposablewith its ownmirror image. Theword chiral originates
fromtheGreekwordforhand(kheir)andperhapsthemostrecognisablewaytoillustrate
chirality is by looking at our hands. They are mirror images of each other but not
superimposable.
Inchemistry,chirality is relatedto thethreedimensionalpropertiesofmolecules.Some
molecules can exist in two forms which are constitutionally equal but the three
dimensional arrangement of the atoms makes them into nonsuperimposable mirror
images(Figure1.9).Thesetwoformsofamoleculearereferredtoasenantiomers.
 

Figure1.9:Illustrationofthenonsuperimposablemirrorimagesofchiralmolecules.
Themost common group of chiral compounds aremoleculeswith stereogenic centres.
These stereogenic centres are atoms,usually carbon, attached to fourdifferent groups.
Themajorityofchiralcompoundsowetheirchiralitytosuchtetrahedralatomsbutitcan
alsooriginatefromstereogenicaxesorstereogenicplanes.34
In an achiral environment, two enantiomers will have identical chemical and physical
properties,excepttheabilitytorotateplanepolarizedlightinoppositedirections.Inchiral
surroundings,however,thetwoenantiomersmaybehavedifferently.
1.2.1 Chiralityinbiologicalsystems
Very often, living organisms utilise only one of the enantiomers of a chiral compound.
Proteins are, for instance, exclusively made up of Lamino acids and nucleic acids are
basedonDsugars.35Sincebiologicalsystemsarechiral,thetwodifferentenantiomersof
a bioactive compound can interact differently with bioreceptors, giving rise to two
different responses. Our sense of smell is a good illustration of such interactions, one
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example being the chiral compound 3methylthiobutanal, where the (R)enantiomer
smellslikecookedpotatoeswhilethe(S)enantiomerisodourless(Figure1.10).36

Figure1.10:Thedifferentodoursoftheenantiomersof3methylthiobutanal.36
Asaconsequenceoftheabilityoftwoenantiomerstointeractdifferentlywithabiological
system like the human body, the focus on chirality in medicinal chemistry has been
increasingoverthe lastdecades.Manypharmaceuticalsarechiralmoleculesand,often,
thedesiredeffectoriginatesfromonlyoneoftheenantiomers.Theotherenantiomermay
beinactivebutinworstcaseithasaninhibitingorharmfuleffect.Thisisillustratedbythe
drug penicillamine, where the (S)enantiomer is used to treat Wilson´s disease and
rheumatoid arthritis while the (R)enantiomer is highly toxic (Figure 1.11). The drug is,
therefore, soldas theenantiomericallypure (S)form.37 Even if it hasnoharmfuleffect,
theunwantedenantiomerrepresentsunnecessarystrainenforcedonthebody’sliverand
kidneys.Forthisreasonitisdesirabletomakeenantiomericallypurepharmaceuticals.In
2005, singleenantiomer therapeuticshad salesof$225billion, representing37%of the
total final formulation pharmaceutical market.38 The pharma companies’ increased
interest insingleenantiomerdrugs is,however,alsopartlyeconomicallymotivated.The
timeandcosts tobringadrug to themarketcanbesignificantly reducedby turningan
existing racemic drug into the singleenantiomer formulation. This “chiral switch” also
prolongsthecompany´spatentprotectionforthedrug.

Figure1.11:Thebiologicaleffectsoftheenantiomersinpenicillamine.

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2. 1Aryl2fluoroethanones

ThischaptersummarisesPaperIandPaperII.MasterofScienceThorHåkonKraneTvedt
isacknowledgedforoptimisingthemicrowaveassistedfluorinationmethod,aswellasfor
performing several of the fluorination reactions discussed in this chapter. Master of
Technology Tor Arne Krakeli and Master of Technology Maria Førde Møll are
acknowledged for their contributions regarding fluorination reactions performed on
1acetonaphthoneandonthe4Fand4CNsubstitutedacetophenones.
2.1 Introduction
With very few fluorinated organic compounds occurring in nature, any fluorinated
compoundwewish toaccesshave tobe synthesised. Fluorinatedbuildingblockswhich
can be incorporated into larger structures are, therefore, highly valuable in the field of
medicinal andmaterial chemistry. 1Aryl2fluoroethanones are a class of such building
blocksandofferanexcellentstartingpointforthesynthesisofawiderangeoffluorinated
compounds.AsScheme2.1illustrates,reactionscanbeperformedatthecarbonylgroup,
the 
carbon or the aromatic ring, providing routes to, among others, fluorinated
tetralones,39 pyrozoles40 and thiadiazoles.41 1Aryl2fluoroethanones are also suitable
starting materials for compounds such as 1,1,2trifluoroethyl aryl ethers,42 1aryl2
fluoroenamines,431aryl1,1,2fluoroethanes44andallylicfluorides.45,46
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
Scheme2.1

2.1.1 Syntheticroutesto1aryl2fluoroethanones
When this work was undertaken, no systematic study on the synthesis of 1aryl2
fluoroethanones had been conducted. Most of the reported work treated approaches
targeting
fluoroacetophenone(1c)asproductandonlya limitednumberofanalogues
had been synthesised. Various synthetic routes towards these compounds have been
reported.SomeoftheseroutesareshowninScheme2.2anddiscussedbrieflybelow.
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Scheme2.2
Thefluorideionisapowerfulnucleophileandthedisplacementofhalogenatomsorother
good leaving groups with a fluoride anion is a well known strategy for incorporating
fluorineintoamolecule.Startingwith1aryl2bromoethanones,thereareseveralreports
onfluorinationshavingbeenperformedwithKF.Themoreclassicconditionswithphase
transfercatalysis47haverecentlybeenimprovedbytheuseofionicliquids48,49andvarious
cocatalysts,50,51 resulting in milder reaction conditions and enhanced activity of the
fluoride ion. Introduced in 1987,52 tetrabutylammonium bifluoride (TBABF) is another
nucleophilicfluorinatingagent.Thereactionconditionsforthisreagentaregenerallymild
anda few1aryl2fluoroethanoneshavebeensynthesisedusingTBABF.5355The related
tetrabutylammonium fluoride (TBAF) has also shown promising results as a fluorinating
reagentforstructurallysimilarcompounds.56
Friedel Crafts acylation is another common route to arylketones. It has been utilised
successfullyonbenzeneand someof itselectron richderivatives to synthesise1aryl2
fluoroethanones.57,58 Electron poor benzenes are, however, unreactive as the aromatic
ring is deactivated towards electrophilic aromatic substitution.Naphthyl derivatives are
alsopoorsubstratesforthisreaction,resultingincomplexmixturesofisomers.59Another
drawbackistheuseofthehighlytoxicfluoroacetylchloride,knowntoblockthecitricacid
cycleinhumanmetabolism.60
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Reactions involvingorganometallic reagents like theGrignard reaction can alsobeused
for the introduction of a fluoroacetyl functionality in aromatic compounds. Ethyl
fluoroacetate,alsohighlytoxic,hasbeenusedtoprepare
fluoroacetophenone(1c)ina
moderate63%yield,61while88%yieldwasreportedwiththeuseofaWeinrebamide.62
A more cumbersome procedure, starting with a benzaldehyde, has previously been
reported.63 This three step reaction involves the reductive addition of CFCl3 to the
aldehyde followedbypyridiniumchlorochromateoxidationof thealcoholbefore the

fluoroacetophenone is released by dechlorination. Not surprisingly, the method was
hamperedbypooryields(3525%).
Benzoic acid derivatives have also been used as substrates formaking several 1aryl2
fluoroethanones.43,64 They are inexpensive and readily available compounds but the
method involves the use of diazomethane, which is explosive, and hydrogen fluoride
whichishighlytoxicandcorrosive.
Moresafefluorinationscanbeperformedusingelectrophilicfluorinatingagents.Although
earlyroutesto1aryl2fluoroethanones involvedtheuseofF2gas
65andtrifluoromethyl
hypofluorite,66 lesshazardous reagents suchasAccufluor®,63,67,68Selectfluor®69,70andN
fluorobenzenesulfonimide (NFSI)71 (Figure 2.1) have later been developed. Using these
reagents,severalstartingmaterialshavebeenutilisedtoaccess1aryl2fluoroethanones,
includingtrimethylsilylenolethers,65,66,72metalenolates,73,74enaminesandimines.71The
directfluorinationof1arylethanonesusingSelectfluor®40,75orAccufluor®76hasalsobeen
performed, giving the corresponding 
fluoroketones in decent yields. Accufluor® has
been used to fluorinate styrene, providing the corresponding fluorinated secondary
alcoholin90%yield.63Thesubsequentoxidationto
fluoroacetophenone(1c)hasnotyet
beenreportedbutresultsfromsimilarcompoundsmakethisapromisingroute.77

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Figure2.1:Structuresofsomeelectrophilicfluorinatingagents.
Crosscouplingreactionsbetweenvariousacylchloridesandarylboronicacidshavebeen
shown to produce acetophenones in decent yields.78,79 Several trifluoroacetophenones
havealsobeenpreparedfromsimilarreactions.80,81However,nodatahasbeenreported
on the monofluorinated analogues. This might be a useful approach to access the 

fluoroacetophenones,althoughinvolvingtheuseofhazardousandexpensivechemicals.
2.1.2 Microwaveirradiationinorganofluorinechemistry
Microwaveirradiationisapowerfulandeasilycontrollableheatingsource. Itspopularity
in organic synthesis is primarily attributed to the rate acceleration that can be seen in
manyreactions,especiallythoseinvolvingpolartransitionstates.8285Inadditiontohigher
reactionrate,theuseofmicrowaveirradiationhasbeenshowntogiveincreasedyields,86
inductionofregioorchemoselectivity87,88andachangeofreactionmechanism.88
Althoughnomicrowaveassistedfluorinationsofacetophenoneshadbeenreportedasthis
project was started, there were several examples of successful fluorinations of other
substrates. The earliest reports generally focused on nucleophilic approacheswhile,8993
more recently, an increased interest in electrophilic reagents such as Selectfluor® has
emerged.9498
2.2 Electrophilicandnucleophilic sidechain fluorinationof substituted
1arylethanones
The initial goal of this project was to synthesise a series of eight parasubstituted 

fluoroacetophenones(1ah)(Figure2.2).Toreachthistarget,theoriginalstrategywasto
performanucleophilicfluorinationofthecorresponding
bromoacetophenones2ahby
usingKFunderclassicphasetransferconditions.47Earlyexperiments,however, revealed
thisrouteasunsuitableforthesesubstratesandtheuseofthenonhazardousandmild
fluorinatingagentTBABFwasinsteadinvestigated(Scheme2.4).Reportsintheliterature
proposedthisasapromisingroutebut,astheworkcommenced,itwasrealisedthatthis
strategywouldnotgivethedesiredproductsinadequateyields.55
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Thus, two new strategies were identified and examined. Trimethylsilyl enol ethers had
previously been shown to readily undergo electrophilic fluorinations,65,66,72 while the
direct fluorination of acetophenones using Selectfluor® also appeared promising.40 A
possible improvement of the lattermethod by the use ofmicrowave irradiation as the
heatingsourcewasalsoinvestigated.Theresultsfromthedifferentstrategiesarebriefly
describedandcomparedbelow.

Figure2.2:Theinitialtargetcompoundsforthefluorinationreactions.
2.2.1 Nucleophilicdisplacement
The initial nucleophilic fluorination experiments were performed on the 

bromoacetophenones2cdand2ghusingdryfinepowderedKF99(2equiv)and18crown
6 (0.08equiv) in refluxingacetonitrile.Unfortunately,all thereactionsweretroubledby
pooryields(378%)duetotheformationofseveralbyproducts,themaintypebeingthe
cyclopropane derivative3 (Scheme 2.4). Based on these early results, itwas concluded
thatthisapproachwasnotsuitableforpreparingthe
fluoroacetophenones1ah.
SimultaneouslywiththeKFfluorinations,attemptsto fluorinate2dand2gwithTBAF(2
equiv) in acetonitrile (60 °C) were performed. Unfortunately, these experiments also
failed,yieldingonlytracesofthefluoroketones1dand1g.
As the fluorinationswithbothKF andTBAFwereunsuccessful, attentionwas turned to
TBABF.Landiniandcoworkershadreportedaprocedureforpreparingthereagentbyan
anionexchangereactionbetweentetrabutylammoniumhydrogensulphateandpotassium
bifluoride (Scheme 2.3).100 After conducting this procedure, however, the obtained
producthadadarkredcolourandshowedpooractivityintestreactions.Theproductalso
proveddifficulttoanalyse,asitappearedtobepurebystandardorganicanalysismethods
(NMR,MS and IR). Attempts to analyse the product by titration and ICPMSwere also
1Aryl2fluoroethanones
15

madebutnouniformresultsregardingitspuritycouldbeobtained.Followingthis,TBABF
wasattemptedpreparedbyreactingTBAFwithaqueousHF(Scheme2.3).101Theresults
were, however, similar to the former method. TBABF was, therefore, purchased as an
acetonitrilesolution.
n-Bu4N HSO4
KHF2
CHCl3
KHCO3 (aq)
n-Bu4N HF2
TBABF
F
HF (aq)
TBAF
THF
n-Bu4N

Scheme2.3
The original literature based setup for the nucleophilic displacement of the 

bromoacetophenones2ahwithTBABFinvolvedtheadditionofpyridineasabase.54,55In
ourhands,however,theuseofeitherpyridineortriethylamineresultedintheformation
of significantamountsof theammoniumsaltbyproducts4 and5, shown inFigure2.3.
Themorestericallyhindered2,6dimethylpyridinegavelessbyproductformationbutno
benefit could be found in the use of these bases. The best reaction conditions were
eventually found to be refluxing the 
bromoacetophenones 2ah in THF with two
equivalentsofTBABFpresent(Scheme2.4).

Scheme2.4
Themoderate to lowyields (Table2.1)experienced for these reactions couldmainlybe
attributed to two different sidereactions. Themain byproductswere identified as the
cyclopropanes 3ah, probably formed by a cycloaddition reaction.102,103 1H NMR
spectroscopyalsoindicatedtheformationofcompounds6ah,productsofaDarzentype
condensation.104106Theextentofboththesesidereactionsincreasedwiththeincreasing
electronwithdrawingpropertiesofthearomaticsubstituentsofthesubstrates, lowering
theyieldssignificantly.
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Figure2.3:Isolatedbyproductscausedbyadditionofpyridineandtriethylamine.

2.2.2 Electrophilicfluorinationviatrimethylsilylenolethers
As the nucleophilic fluorination of the 
bromoacetophenones 2ah failed to provide
satisfactory results, the electrophilic fluorination of the corresponding enolates quickly
emergedasanalternativeapproach.Lithiumenolateshadpreviouslybeenfluorinatedby
electrophilic reagents but the acetophenone derivative was troubled by a competing
dimerisation reaction.73 Lal and coworkers had, however, reported a successful
fluorinationoftrimethylsilylenolethersinasteroidsynthesis.107Theacetophenones7ag
were, therefore, transformed into the trimethylsilyl enol ethers 8ag by reacting them
withlithiumhexamethyldisilazaneandtrimethylsilylchlorideinTHFatroomtemperature
(Scheme2.5).Duetoinsufficientconversionundertheseconditions,thepreparationof8h
was performedwith DBU as base. The crude trimethylsilyl enol ethers 8ahwere then
treatedwithSelectfluor®(1.01.2equiv)atambienttemperatureinacetonitriletogivethe
1aryl2fluoroethanones1ah.

Scheme2.5
Asshown inTable2.1, thisstrategyresulted inexcellent togoodyields for the1aryl2
fluoroethanones 1af. However, compounds 1g and 1h, bearing strongly electron
withdrawingcyanoandnitrogroups,were isolated inratherpooryields.Thereasonfor
this loss in yield could mainly be attributed to the low stability of the corresponding
trimethylsilyl enol ethers 8g and 8h. This resulted in product mixtures containing
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significant amounts of starting material (7g and 7h) and subsequent troublesome
purificationsteps.
2.2.3 Electrophilicfluorinationof1arylethanones
Parallelwiththetrimethylsilylenoletherapproach,astrategywithdirectfluorinationof
theacetophenones7ahwasinvestigated.Again,Selectfluor®wasthereagentofchoice,
using refluxingmethanol as solvent. The procedure,whichhas the advantage of a very
simple experimental setup, proved to be a two step reaction as the corresponding
dimethyl acetals 9ah were formed in considerable amounts. These acetals could be
hydrolysedtothe1aryl2fluoroethanones1ahbystirringwithtrifluoroaceticacid(TFA)
inachloroform/watermixture(Scheme2.6).

Scheme2.6
Unlike the twoprevious routes, theyieldsof thisapproachwere lessdependenton the
electronicpropertiesofthesubstrates(Table2.1).Duetotheirhigherstability,elevated
amounts of the dimethyl acetals were formed for the substrates containing electron
withdrawingsubstituentsbut,astheacetalswereeffectivelyhydrolysedbyTFA,thishad
noeffectonthetotalyieldofthereactions.Thecompoundscontainingthemostelectron
donating groups, however, were troubled by a sidereaction giving the ring fluorinated
ketones 1k and 1m and the corresponding dimethyl acetals 9k and 9m (Scheme 2.7).
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Anotherdrawbackwiththestrategywastheprolongedreactiontimesrequired,especially
forsubstratescontainingelectronwithdrawingsubstituents.

Scheme2.7
To investigate the scope and limitations to this method further, the four additional 1
arylethanones7il(Scheme2.6)werealsofluorinated.Asexpected,1acetonaphthone7j
resultedinacomplexmixtureconsistingofseveralringfluorinatedcompounds.Interms
ofsusceptibility towardsaromatic fluorination,7k representedaborderlinecaseand,as
compared with compound 7a, the additional fluorine in 7k suppressed further ring
fluorination.Notsurprisingly,boththetwonitrocontainingcompounds7iand7lreacted
very slowly under the given conditions. The dinitro compound 7l clearly illustrates the
limitationofthismethod,requiringfiveweekstoreach39%conversion.
2.2.4 Microwaveassistedelectrophilicfluorinationof1arylethanones
Theuseofmicrowave irradiationasaheating source is known toenhance the reaction
rate for certain reactions in organic chemistry.82,83 It was, therefore, considered
worthwhile to investigate if it could reduce the reaction times for the electrophilic
fluorinationof the1arylethanones7al (Scheme2.8).Preliminaryexperiments revealed
promisingresultsandareevaluationofthechoiceofsolventwasperformed.Amongthe
sixsolventstested,methanolwasfoundtogivethehighestconversion.Inthissolvent,the
mostsuitableirradiationeffectwasfoundtobe80W.
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
Scheme2.8
Ashopedfor,microwaveirradiationreducedthereactiontimessignificantly.Thereaction
whichpreviouslyhadtakenfiveweekstocompletecouldnowbeperformedinlessthan
two hours. Moreover, it was discovered that the fluorination and hydrolysis could be
performedintwosubsequentstepsinthesamereactionvessel.Bysimplyaddingwaterto
thereactionmixtureandfurther irradiating,Selectfluor®wasprobablyactingasaLewis
acid, catalysing the cleavage of the dimethyl acetals 9al to give the 1aryl2
fluoroethanones1al.
Comparedtothethermalprocess,theobtainedyieldsdidnotchangedramaticallybutthe
microwavemethodgavesomewhatloweryieldsforthemostelectronrichcompounds1a
b(Table2.1).Thiswasattributedtotheelevatedlevelsofringfluorinatedbyproducts(1k
and 1m), aswell as the
,
difluoroketones10ab and the
,
difluorodimethyl acetals
11ab shown inScheme2.9.Themicrowavemethodgave improvedyields for thepCF3
(1f) and pCN (1g) substituted derivatives. The dimethyl acetal 9f is a highly volatile
compound,andthisprobablycausedalossinyieldinthethermalreaction.However,this
was not the case in themicrowave assisted reaction as no isolation of the acetal was
required.Thereasonfortheloweryieldof1g inthethermalreactioncouldprobablybe
attributedtosidereactionstakingplaceatthecyanogroupduetotheprolongedreaction
time.

Scheme2.9

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2.2.5 Summary
Asystematicstudyofthesynthesisofaseriesof1aryl2fluoroethanones(1al)hasbeen
performed. Starting with the corresponding 1arylethanones and using nonhazardous
procedures,onenucleophilicandthreeelectrophilicapproacheswerecompared.Ascan
beseenfromTable2.1,thetrimethylsilylenolethers8ad,containingelectrondonating
andmoderatelyelectronwithdrawingaromaticsubstituents,werefluorinatedinexcellent
togoodyields.Whenmovingfurtherdownthetable,however,theyieldsofthismethod
decrease.Thedirectelectrophilicfluorinationofthe1arylethanones7alwasnotaffected
bythesubstituents inthesameway.Consequently,thisapproachwasmoresuitablefor
fluorinating compounds containing more electron withdrawing substituents. The
microwaveassistedprocedurewassuperiortothethermalapproachduetosignificantly
shorterreactiontimes,simplerexperimentalsetupandlesschemicalconsumption.None
of the tested approaches seemed suitable for fluorinating substrates with strongly
electronwithdrawingsubstituents.
Table2.1:Isolatedyieldsof1alforthecomparedfluorinationstrategies.
  Isolatedyields[%]
Product Ar Nucleophilic

Electrophilicvia
TMSenolether
Electrophilic
thermal
Electrophilic
microwave
1a 4OMeC6H4 48 91 67 46
1b 4OBnC6H4 51 89 58 46
1j 1Naphthyl   50 38
1k 3F,4OMeC6H3   67 59
1c C6H5 42 76 66 65
1d 4FC6H4 36 74 25 74
1e 4BrC6H4 33 69 77 81
1f 4CF3C6H4 26 69 73 69
1g 4CNC6H4 20 55 64 86
1h 4NO2C6H4 20 44 70 82
1i 3NO2C6H4   73 72
1l 3,5diNO2C6H3   39 41

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3. Enantiomericallyenriched1aryl2fluoroethanols

This chapter summarises results presented in Papers IIIV.Master of TechnologyMaria
FørdeMøll isacknowledgedfortheearlyworkperformedwiththeMeCBSreductionsof
the
fluoroacetophenones1dand1g.
3.1 Introduction
1Arylethanolsarefrequentlyusedmotifsinbothpharmaceuticalsandagrochemicals.108
112 The use of the fluorinated 1aryl2fluoroethanols have, however, been far more
limited. The reason for this can probably be attributed to their somewhat troublesome
preparation but, as we had synthesised the 1aryl2fluoroethanones 1ah, the
corresponding 1aryl2fluoroethanols 12ah (Scheme 3.4) were now easily accessible.
Prochiral ketones are excellent substrates for asymmetric reductions and this is a well
known route to enantiomerically enriched alcohols. Numerous catalytic systems have
beendevelopedand,comparedtoresolutionmethods,thismethodhastheadvantageof
a100%theoreticalyield.113
3.1.1 Syntheticroutestoenantiomericallyenriched1aryl2fluoroethanols
Whenthisprojectwasstarted,surprisinglylittleworkhadbeenreportedonthesynthesis
of enantioenriched 1aryl2fluoroethanols. Among the target alcohols 12ah, both
enantiomers of alcohol 12c had been prepared by asymmetric reduction of the
correspondingketone1c,usingseveralcatalyticsystems.77,114117Thefluoroketone1ehad
beenreducedwithBaker’syeast,giving (R)12e in94%ee,although inamoderate46%
yield.77 No work had been reported on the remaining target alcohols 12ab, 12d and
12fh.
The chiral oxazaborolidine catalysed reductionof prochiral ketones is oneof the classic
reactions inasymmetricsynthesis. Itwasdevelopedbythepioneeringworkof Itsuno in
1983,118 and further improved by Corey, Bakshi and Shibata.119,120 Due to their broad
substrate specificity and high turnover numbers, these proline based catalysts have
becomeincreasinglypopularandhavefoundseveralindustrialapplications.121123Agreat
number of catalysts have been developed and, methyl oxazaborolidine (13) (MeCBS)
shown in Scheme 3.1, is among themost utilised versions.When exposed to a borane
source it forms the borane complex 14 which is the active catalyst responsible for the
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observed enantioselectivity. The proposed reaction mechanism for the reduction of
acetophenone(7c)to(R)1phenylethanol((R)15)isshowninScheme3.1.124

Scheme3.1124
MeCBS (13) has previously been reported to reduce several acetophenone derivatives,
providing the corresponding alcohols in high enantiomeric excess (ee).125,126 Several
studieshavealsobeenconductedregardingtheeffectsofthesolventandtheelectronic
characterofthesubstratesontheenantioselectivityinMeCBSreductions.127129Thus,the
MeCBScatalyst13appearedasapromisingstartingpointfortheasymmetricreductionof
the1aryl2fluoroethanones1ah.
AlthoughbeingmorestablethanmanyotherCBScatalysts,MeCBSissensitivetoairand
humidity and, consequently, requires inert atmosphere protectionwhenhandled. From
an industrialpointof view,amore robust andenvironmentally friendly reactionwould,
therefore, bemore attractive. Asymmetric transfer hydrogenation (ATH)matches these
specifications and has over the last years become an alternative to other asymmetric
reductionmethods.
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InspiredbytheworkofNoyoriandcoworkers,ATHexperiencedarenaissanceinthemid
1990s.130,131Themainadvantagesofthemethodarethemildreactionconditionsandthe
hydrogen sources used.132134 Traditional hydrogenation reactions normally require the
use of hydrogen gas which, when performed on a large scale, represents a potential
hazard.ThishazardiseliminatedinATHsastheyutilisemuchsaferhydrogensourcessuch
assodiumformateorisopropanol.Asnohydrogengasisused,theATHmethodalsohas
the advantage of requiring only a simple experimental setup. Moreover, asymmetric
transfer hydrogenations can be performed inwater and in the presence of airwithout
significantlossinenantioselectivity.135139Thisisinsharpcontrasttomosttransitionmetal
catalysedreactions.Recently,a reactionmechanismexplainingtheenantioselectivity for
the RuCl(pcymene)(R,R)TsDPEN (16) catalysed ATH in water has been proposed
(Scheme3.2).140

Scheme3.2140
A large number of ATH catalysts are available and the majority consist of a transition
metalcomplexcoordinatedtoachiralligand.Themetalcomplexesarenormallybasedon
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anaromaticunitcoordinatedtoeitherruthenium(II),rhodium(III)or iridium(III).Chiral
diaminesand	aminoalcoholshavebeenshowntobethemosteffectiveligands.141,142
Acetophenones have been widely used as substrates for asymmetric transfer
hydrogenationsand the reactionshavebeenshown tobe influencedby factors suchas
temperature, catalyst species, solvent and pH.134,142 Although some
trifluoromethylketones had been used as substrates,143 the ATH of monofluoroketones
wasanunexploredareaasthisprojectwasundertaken.
3.2 Asymmetricreductionof1aryl2fluoroethanones
To obtain the 1aryl2fluoroethanols12ah in enantiomerically enriched form, the two
differentreductionsystemsdiscussedabovewereinvestigated.Asonly12cand12ehad
previously been reported and characterised as single enantiomers,61,77 the absolute
configurationoftheremainingcompoundshadtobedetermined.Thiswasachievedusing
circulardichroism(CD)andisdescribedinChapterV.
3.2.1 Asymmetricreductionusing(R)MeCBS
To synthesise the active catalyst (R)14, (R)
,
diphenyl2pyrrolidinemethanol ((R)17)
and trimethylboroxine were stirred in toluene at ambient temperature. After the
elimination of methylboronic acid and complexation to BH3 from borane dimethyl
sulphide, the MeCBS borane complex (R)14 could be obtained in 73% overall yield
(Scheme3.3).125

Scheme3.3
Initial screening experiments with the synthesised catalyst (R)14 showed that the
enantioselectivity in the asymmetric reduction of 1a was strongly dependent on the
solvent.Ninesolventsweretestedand,asFigure3.1(A)shows,thereactionsperformedin
ethersgenerally gave thebest results. Theonlyexceptionwasdiisopropyl ether,where
significantly lowerenantioselectivitywasobserved. This couldprobablybeexplainedby
the low solubility of both substrate and catalyst in the reactionmedium. Following the
initialexperiments,theketones1bhwerealsoreducedinthreeofthebestsolvents.The
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results,illustratedinFigure3.1(B),revealedthattheoverallhighestenantioselectivitywas
obtainedinDME.

Figure3.1:(A)Enantiomericexcessofthealcohol(R)12aafterMeCBSreductionsof1aindifferentsolvents.
(B)Enantiomericexcessofthealcohols(R)12ahafterMeCBSreductionsof1ahindiethylether,dichloromethaneand
DME.Lowsolubilityof1gindiethyletherresultedinlowconversion.
Inadditiontobeingsolventdependent,theenantioselectivityofMeCBSreductionshave
alsobeenknowntobeaffectedbybothreactiontemperatureandthesubstrateaddition
time.144 These effectswere investigated closer for the reduction of1a by performing a
series of reactions at different temperatures andwith varying substrate addition times.
The results, illustrated in Figure 3.2, revealed that, while the substrate addition time
seemed less important, the ee of the product (R)12a increased significantly as the
temperaturewasloweredfrom40°Cto20°C.

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Figure3.2:Surfaceplotshowingtherelationshipbetweentheenantiomericexcessoftheproductalcohol(R)12a,the
temperatureandthesubstrateadditiontimeinthe(R)MeCBS(14)catalysedreductionof1ainDME.
Basedonthefindingsaboveandon literaturereportsstatingthathighcatalyst loadings
resultedinbetterenantioselectivity,125the
fluoroacetophenones1ahwerereducedin
DMEat20°CwiththeMeCBSboranecomplex(R)14inequimolaramounts(Scheme3.4).
As Table 3.1 shows, the products (R)12ah could be obtained in good yields andwith
excellent to good enantiomeric excess (99.591.5%). A slight decrease in the ee of the
products was observed for the compounds bearing more electron withdrawing
substituentsat thearomatic ring.Similarobservationshavepreviouslybeenrationalised
bythedecreasedabilityofthecarbonyloxygenatomintheelectrondeficientsubstrates
tocoordinatetotheboronatominthecatalyst.128Thiscouldresultinlargeramountsof
thesubstratebeingreducedbyfreeboraneandasubsequentlossofenantioselectivity.

Scheme3.4

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3.2.2 Asymmetrictransferhydrogenation
Although theMeCBS reductions gave themajority of the product alcohols (R)12ah in
excellent enantiomeric excess, therewas still room for improvement for the substrates
bearing electron withdrawing substituents. Therefore, it was decided that a second
reduction system should be examined. Asymmetric transfer hydrogenation was the
methodofchoiceand,toinvestigatethisreactionthoroughly,abroadsmallscalescreen
was initially performed. Reducing the 
fluoroacetophenones 1ah, all combinations of
twodifferent ruthenium complexes coordinated to four different chiral diamine ligands
(Figure3.3)weretestedintwodifferentsolvents(Scheme3.5).Thebestconditionsfound
fromthisscreenwerethenusedforgramscalereactions.
While the precatalyst [RuCl2(pcymene)]2 was commercially available,
[RuCl2(mesitylene)]2 had to be synthesised. This was accomplished by refluxing
ruthenium(III)chloride hydrate and 1,3,5trimethyl1,4cyclohexadiene in methanol
according to literature procedures.145 The catalysts 16 and 1820 (Figure 3.3) were
prepared in situ from the precatalysts [RuCl2(pcymene)]2 and [RuCl2(mesitylene)]2 and
the ligands (R,R)TsDPEN and (R,R)TsCYDN. The (R,R)configuration of the ligands was
chosen for the small scale screening experiments as this was expected to give the (S)
enantiomers of the products 12ah, thereby, complementing the (R)MeCBS reduction
products.Forthegramscalereactions,however,theneedforthe(R)enantiomersofthe
alcoholsasfurtherbuildingblockshadarisen.Thesereactionswere,therefore,performed
using the (S,S)ligands. The results from the preparative scale reductions are shown in
Table3.1,whilethescreeningexperimentsareshowninFigure3.4andFigure3.5.

Figure3.3:CatalystsusedintheATHofthe
fluoroacetophenones1ah.
BasedonnumerousreportsoftheATHofacetophenones,thereactionswereperformed
withbothwaterandformicacid/triethylamine(5/2)assolvents.132,134All reactionswere
conducted at 40 °Cwith a substrate/catalyst ratio of 100,without an inert atmosphere
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protection.Forthereactionsperformedinwater,sodiumformatewasaddedashydrogen
source.
F
O
R
F
OH
R
HCOOH:Et3N 5:2or
H2O
Catalyst 16,18-20
1a-h (S)-12a-h
40 °C
R = OMe (a), OBn (b), H (c), F (d), Br (e), CF3 (f), CN (g), NO2 (h) 
Scheme3.5


Figure3.4:Enantiomericexcessofthealcohols(S)12ahafterATHofthe
fluoroacetophenones1ahinwater.
In both solvents, catalyst 19 gave the overall highest enantioselectivity. The reactions
conductedinwater(Figure3.4)gavegenerallylowerenantioselectivitycomparedtothose
informicacid/triethylamine(Figure3.5).Theexceptionswerethereactionswithcatalyst
20which gave significantly higher enantioselectivity inwater. The only substratewhich
0
10
20
30
40
50
60
70
80
90
100
12a 12b 12c 12d 12e 12f 12g 12h
En
an
ti
om
er
ic
e
xc
es
s
[%
]
[RuCl(pcymene)(R,R)TsDPEN](16) [RuCl(pcymene)(R,R)TsCYDN](18)
[RuCl(mesitylene)(R,R)TsDPEN](19) [RuCl(mesitylene)(R,R)TsCYDN](20)
Enantiomericallyenriched1aryl2fluoroethanols
29

wasreducedwiththehighestenantioselectivityinwaterwasthepCF3substitutedalcohol
12f,catalysedby[RuCl(mesitylene)(R,R)TsDPEN](19).

Figure3.5:Enantiomericexcessofthealcohols(S)12ahafterATHofthe
fluoroacetophenones1ahin
formicacid/triethylamine(5/2).
Based on the results from the screening experiments, the best conditions for each
substratewereusedingramscalereactions.Theproductswereobtainedinexcellentto
goodee(99.585.0%)and,comparedtothesmallscalereactions,onlyminordeviationsin
enantioselectivitywereexperienced.Theobtainedyieldsweregenerallysatisfactorybut
thereductionof1f inwatergaveonlyamoderate52%yield (Table3.1).Thereasonfor
thiswas not investigated but 1HNMR spectroscopy of the crude product indicated the
presenceofsomebyproducts,possiblyformedbycondensationreactions.
Similar to the MeCBS reductions, a loss in ee for the products bearing electron
withdrawing substituents was experienced for all of the ATH reaction systems. These
typesofeffectshavebeenshownnottoberelatedsolelytoelectronicpropertiesbutalso
tochangesininteractions,solvationeffectsanddispersioninteractions.146

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Table3.1:Isolatedyields,enantiomericexcessandabsoluteconfigurationofthealcohols12ahafterasymmetric
reductionofthe
fluoroacetophenones1ahusing(R)MeCBSboranecomplex((R)14),and[RuCl(mesitylene)(R,R)
TsDPEN](19)inwaterandformicacid/triethylamine(5/2).
    Asymmetrictransferhydrogenation
Substrate (R)MeCBS((R)14)   Cat.19(water)   Cat.19(HCOOH:Et3N5:2)
 Yielda[%]
(min)
ee[%]   Conv.b[%]
(h)
ee[%]   Yielda[%]
(h)
ee[%]
1a OMe 88(30) 99.5(R)   >99(5) 95.0(S)   76(4)c 96.0(R)
1b OBn 88(15) 97.0(R)   71(20) 90.0(S)   61(5)c 99.5(R)
1c H 84(20) 96.5(R)   >99(2) 95.5(S)   86(6)c 98.0(R)
1d F 76(20) 99.0(R)   >99(5) 91.0(S)   79(4)c 93.0(R)
1e Br 82(20) 98.5(R)   >99(5) 90.5(S)   79(4)c 91.0(R)
1f CF3 84(20) 93.0(R)   52(10)
a,c 92.5(R)   >99(2)b 90.5(S)
1g CN 74(20) 91.5(R)   45(20) 84.0(S)   85(4)c 87.0(R)
1h NO2 80(20) 92.5(R)   99(20) 76.5(S)   91(4)
c 85.0(R)
a)Isolatedyield.
b)DeterminedbyHPLC(254nm).
c)[RuCl(mesitylene)(S,S)TsDPEN](19)usedascatalyst.

3.2.3 Summary
As can be seen from the overall results shown in Table 3.1, the alcohols 12ae were
obtainedinexcellentenantiomericexcess(99.598.0%)usingeithertheMeCBSreduction
system or asymmetric transfer hydrogenation. Although decent enantioselectivity was
achieved also for the alcohols containing more electron withdrawing aromatic
substituents (12fh) (93.091.5% ee), they are not satisfactory when high enantiomeric
purityisthetarget.Itseems,therefore,thatthetestedreductionsystemsarenotsuitable
methodswhenreducing1aryl2fluoroethanonesbearingelectronwithdrawingaromatic
substituents.Recently,however,adiphenylprolinolderivedcatalysthasbeenreportedto
reduce1(4nitrophenyl)ethanone(7h)withexcellentselectivity.147Thismayindicatethat
improvedresultsforthe1aryl2fluoroethanones12fhcanbeachievedusingstructural
analoguesofMeCBS(13).
Whencomparingthetworeductionsystems,thebestoverallresultswereobtainedwith
(R)MeCBS ((R)14) as catalyst. These reactions were fast and gave the products in
generallygoodyieldsandhighenantiomericexcess.Theexperimental setupof theATH
reactionswas, however, considerably simpler as the reactionswere performedwithout
inertatmosphereprotectionat40°C.Thelattermethodisalsohighlytunableasanumber
of both ligands andmetal complexes are available for adjusting the catalyst reactivity.
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From an environmental point of view, ATH is also the better choice, an important
argumentwhenconsideringindustrialprocesses.

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4. Enantiomericallyenriched1aryl2fluoroethylamines

ThischaptersummarisessomeoftheresultspresentedinPaperV.MasterofScienceThor
Håkon Krane Tvedt is acknowledged for the work with the reductive amination/kinetic
resolutionpathwaywhichisapartofhiscurrentlyongoingPhDstudies.MasterofScience
Svein Jacob Kaspersen is acknowledged for performing the experiments related to the
potentialtyrosinekinaseinhibitors.ThisprojectisapartofhisongoingPhDstudies.
4.1 Introduction
During the work with the 1aryl2fluoroethanols it was realised that similar structural
elements had been used in chiral bioactive compounds targeting tyrosine kinases in
cancer therapy.148,149 Two promising drug candidates, patented by Novartis,150,151 were
particularlyinterestingastheyconsistofapyrrolopyrimidineskeletonlinkedtoabenzylic
amine(Figure4.1).Toinvestigatetheusefulnessofourpreparedalcohols12ahaschiral
building blocks, we wanted to synthesise structural analogues of these tyrosine kinase
inhibitors.Theintroductionofafluorineatomclosetothebenzylicaminewouldlowerits
basicityandthiscouldpotentiallyhaveapositiveeffectonthebioavailabilityofthedrugs.

Figure4.1:Examplesofcompoundswithhighinhibitingactivityagainsttyrosinekinases.148,149
Reacting the enantiomerically enriched 1aryl2fluoroethanols 12ah directly with the
pyrrolopyrimidinemoietywas considered at the early stages of theproject. Thiswould
have provided the ether analogues of the drug candidates. However, as all reported
similar tyrosine kinase inhibitors contained the amine functionality, it was considered
important to keep this structural element. Two retrosynthetic approaches toward the
drug analogues (I) are shown in Scheme 4.1. In path a, the bond between the
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pyrrolopyrimidinemoietyandtheaminogroupisdisconnected.Thisbondcanbeformed
by a nucleophilic aromatic substitution reaction between the halogenated
pyrrolopyrimidine II and the benzylic amines (S)21ah. The latter compounds can be
made by performing a Mitsunobu inversion on the 1aryl2fluoroethanols (R)12ah.
Anotherpossibilityisdisconnectingthebenzylicaminebond(pathb).Thiswouldgivethe
aminogroupbearingpyrrolopyrimidine IVwhich can react via anSN2 reactionwith, for
instance,themesylatedalcoholsV.

Scheme4.1
PKI166 (Figure 4.1) has previously been synthesised in good yield by the nucleophilic
aromatic substitution pathway (path a).152,153 The analogue of 21d, 1(4
fluorophenyl)ethylamine, has also been successfully employed as substrate in the same
strategy.152Althoughthefluorinatedamines21ahwillhavelowerbasicitythanthenon
fluorinatedanalogues, theirnucleophilicitywillnotbe influenced to the sameextent.154
They should, therefore, be suitable as substrates in nucleophilic aromatic substitution
reactions.Whilepathaemployspreviouslyreportedpyrrolopyrimidines,152,155 this isnot
the case for pathb. Based on this, path a was selected as the preferred approach for
synthesisingthefluorinateddruganalogues.
When startingwith the alcohols (R)12ah, aMitsunobu inversionwas seen as thebest
strategytomaketheamines(S)21.Parallelwiththeworkonthisstrategy,however,the
researchgroupalso investigated thepossibilityofmaking theenantiomericallyenriched
aminesbyperformingakineticresolutionoftheracemicamines21ah.Thisapproachwas
investigatedbyMasterofScienceThorHåkonKraneThvedtasapartofhisongoingPhD
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project. The results from thisworkwill, therefore, only be briefly summarised and not
discussedindetailherein.
4.1.1 TheMitsunobureactioninaminesynthesis
Since its discovery in 1967,156 the Mitsunobu reaction has become one of the classic
reactionsinsyntheticorganicchemistry.Themainreasonsforitspopularityareattributed
to the mild reaction conditions, the wide range of possible substrates and the
stereospecifity which is observed. The Mitsunobu reaction is often used in the
modification of primary and secondary alcohols with different nucleophiles. For chiral
alcohols, the reaction normally proceedswith inversion of stereochemistry.157 Although
thereactionwasdiscoveredwellover40yearsago,thedetailsofthereactionmechanism
arestillheavilydebated.158160For that reason,Scheme4.2presents justanoverviewof
themechanism,showingonlyintermediateswhichhavebeenconfirmedbyexperimental
data.161Thefirststepofthereactionisthenucleophilicattackofaphosphine(mostoften
triphenylphosphine) on an azodicarboxylate (usually diethyl azodicarboxylate (22)
(DEAD)). This results in the formation of the betain 23 which then deprotonates the
pronucleophile (NuH). The resulting ionic species24 then reactswith the alcohol (ROH)
and generates the key alkoxyphosphonium salt 25. Depending on the pKa of the
pronucleophile and on the polarity of the solvent, the different phosphorous
intermediates 2628 are present in variable amounts. The only pathway leading to the
desiredproduct29,however,isanucleophilicattack(SN2)ofthenucleophile(Nu
)onthe
alkoxyphosphoniumion25,liberatingtriphenylphosphineoxide.

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Scheme4.2161
Byutilisingnucleophilessuchasamidesorazides,theMitsunobuprotocolcanbeauseful
toolfortransformingalcoholsintoamines.Amongtheamides,theactivatedphthalimide
(30)isoftenused.157TheresultingNsubstitutedphthalimidescaneasilybeconvertedinto
thecorrespondingaminesbyhydrazinolysis.162Moreover,phthalimideischeapandeasy
tohandle.
Even thoughmuchwork has been done on transforming alcohols to the corresponding
amines, very few examples of the Mitsunobu inversion of 1arylethanols to 1
arylethylamineshavebeenreported.Themajorityofthefewreportsthatdoexist,utilise
phthalimide (30) as pronucleophileand standardMitsunobu conditions,withDEAD (22)
andtriphenylphosphineintetrahydrofuran(THF).Afterhydrazinolysiswithhydrazine,the
corresponding amines could be obtained in decent yields.163165 Other pronucleophiles
suchashydrogenazide166andaptoluenesulfonamide167havealsobeenusedwithgood
results. By replacing triphenylphosphine with a chiral phosphorous reagent, an
enantioselectiveMitsunobu reactionofa seriesof racemic1arylethanolshasalsobeen
reported.Unfortunately,onlymoderateeevalueswereexperienced.168

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4.2 Mitsunobuinversionofenantioenriched(R)1aryl2fluoroethanols
Standard Mitsunobu reaction conditions using triphenylphosphine, DEAD (22) and THF
werechosenforthefirststepinthetransformationofthe1aryl2fluoroethanols(R)12a
htothe1aryl2fluoroethylamines(S)21ah(Scheme4.3).Phthalimide(30)wasusedas
pronucleophile. The reactions were performed by dissolving triphenylphosphine,
phthalimide(30)andthesubstratealcohols(R)12ah inTHFunderaninertatmosphere.
DEAD(22)wasthenaddedandthereactionmixturewasstirredatroomtemperatureover
night.

Scheme4.3
AsTable4.1shows,theMitsunobureactionsgavetheNsubstitutedphthalimides(S)31c
fingoodyieldsandwithacleaninversionofstereochemistry.Thecompoundscontaining
electron donating groups at the aromatic ring, (S)31a and (S)31b, were, however,
troubledbyracemisationandpooryields.Thisphenomenonhasbeenobservedpreviously
whensimilarcompoundshavebeensubjectedtoMitsunobureactionconditions.167,169,170
Hillierandcoworkershaveexplainedthelossinenantiomericexcessbytheformationof
the intermediateVI, shown inScheme4.4.170This compoundcan form intermediateVII
viaanSN1typepathwayandthenreactwitheitherthenucleophiletoformtheracemic
product,orTHFtoformVIII.Thelowyieldsexperiencedindicatethatthesepathwaysmay
alsoberesponsiblefortheformationofotherbyproducts.
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Scheme4.4
TheNsubstitutedphthalimideswiththemostelectronwithdrawingsubstituents,(S)31g
and(S)31h,werealsoobtainedinpooryields,thoughwithoutracemisation. It isknown
thathydroxyl compoundswithanacidichydrogenatomadjacent to thehydroxyl group
may undergo intramolecular dehydrations or elimination reactions under Mitsunobu
reaction conditions.157,158 Numerous examples of such byproducts have been reported
butnoneresultingfrom1arylethanols.171173
Table4.1:EnantiomericexcessandisolatedyieldsoftheNsubstitutedphthalimides(S)31ahandtheamines(S)21ah
followingtheMitsunobuinversionofthealcohols(R)12ah.
Substrate  Phthalimide (S)31 Amine(S)21
 R ee[%] Yield[%] ee[%] Yield[%] ee[%]
(R)12a OMe 96.0  32 53.0 73 53.5 
(R)12b OBn 99.5  37 60.0 72 60.0 
(R)12c H 98.0  77 99.0 66 98.5 
(R)12d F 93.0  77 a 75 92.5 
(R)12e Br 91.0  83 90.0 66 90.5 
(R)12f CF3 92.5  78 92.0 71 91.5 
(R)12g CN 87.0  66 87.5 75 87.5 
(R)12h NO2 85.0  34 84.0 80 84.0 
a)Notdetermined
Themainreasonforthelowyieldsobtainedinthesynthesisof(S)31gand(S)31hproved
to be the formation of the corresponding acetophenones,7g and7h. In an attempt to
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determine how these byproducts were formed, some additional experiments were
conducted.
The initial experiments showed that, in the absence phthalimide (30), the Mitsunobu
inversionof the fluoroalcohols12gh yielded themethylketones7gh as theonlymajor
products.Mixing the fluoroalcohols12g or12hwitheither triphenylphosphineorDEAD
(22) alone did not give any reactions, so both reagents had to be present for the by
products to be formed. In an attempt to identify possible reaction intermediates, the
reactionwiththefluoroalcohol12hwasperformedinTHFd8andcontinuouslymonitored
by1HNMRspectroscopy.Spectrawererecordedeachminuteduringthereactionbutno
distinct intermediatescouldbedetected.Asshortlived intermediatescanbedifficult to
observe by 1H NMR spectroscopy, the formation of reaction intermediates could,
however,notberuledoutbythisexperiment.
Thefluoroketones1gh,themethylalcohols15ghandtheepoxides32ghwereallseenas
possiblereactionintermediates.Itwas,therefore,investigatedifthesecompoundscould
betransformedintothemethylketones7ghunderthegivenreactionconditions(Scheme
4.5).

Scheme4.5
DEAD(22) isanoxidisingagentandcouldpossiblyconvertthe fluoroalcohols12gh into
the fluoroketones1gh.174 However,when the fluoroketone1h was subjected to DEAD
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(22)andtriphenylphosphine,theacetophenone7hwasnotformed,thus,RouteAcould
be excluded. Another possible route to the acetophenones 7gh was the formation of
epoxides ((R)32gh) followed by a subsequent rearrangement (Route C). This could,
however, also be excluded since an experiment using 2(4nitrophenyl)oxirane (32h) as
substrate failed to yield detectable amounts of 7h. To test if the fluoroalcohols 12gh
somehow could react via the methylalcohols 15gh (Route B), 1(4nitrophenyl)ethanol
(15h) was subjected to the Mitsunobu conditions. This also resulted in no observable
amountsofthebyproductbeingformed.
Thepresenceofanelectronwithdrawingsubstituentonthearomaticring,alongwiththe
adjacentfluorineatom,will lowerthepKaoftheprotonatthestereogeniccentreofthe
alcohols 12g and 12h, thereby making them susceptible to elimination reactions. This,
alongwiththeobservationsdiscussedabove,makestheconcertedmechanismshownin
Scheme4.6apossibleexplanationfortheformationoftheacetophenones7gand7h.This
mechanistic proposal is further strengthened by the fact that triphenylphosphine
previouslyhasbeenusedasadefluorinatingagent.175

Scheme4.6
FollowingtheMitsunobuinversion,theenantioenrichedamines(S)21ahwereobtained
byperformingahydrazinolysisoftheNsubstitutedphthalimides(S)31ah(Scheme4.7).
Thiswasachievedbystirringthesubstrates(S)31ahtogetherwithhydrazineinmethanol
at room temperature until the starting material had been consumed. Aqueous
hydrochloricacidwasthenaddedand,afterstirringovernight,theamines(S)21ahwere
isolated in decent yieldswithout alteration of the enantiomeric excess (Table 4.1). The
absoluteconfigurationof theproductswasdeterminedbyCD.Thiswork isdescribed in
ChapterV.
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Scheme4.7
4.3 Kineticresolutionofracemic1aryl2fluoroethylamines
To synthesise the racemic 1aryl2fluoroethylamines21ah, the 
fluoroacetophenones
1ahwere treatedwith ammonia and titanium(IV) isopropoxide in ethanol, followedby
sodiumborohydride(Scheme4.8).Thisproducedtheamines21ahin9568%yield(Table
4.2).
O
F
R
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EtO
O
OMe HN
F
R
NH2
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R
+
(S)-33a-h (R)-21a-h
1) NH3 in EtOH
Ti(Oi-Pr)4
2) NaBH4
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NH2
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R
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O
OMe
Novozym 435
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
Scheme4.8
The racemic amines 21ah were then resolved by a lipase catalysed kinetic resolution
(Scheme4.8).Afterconductinganumberofsmall scalescreeningexperiments, thebest
resultswereachievedwithimmobilisedlipaseBfromCandidaantarctica (Novozym435)
inhexaneat60°Cusingequimolaramountsofethylmethoxyacetateasacyldonor.The
mainresultsaresummarisedinTable4.2.


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Table4.2:Isolatedyieldsoftheracemicamines21ahafterthereductiveaminationofthe
fluoroacetophenones1ah.
Isolatedyields,eeandabsoluteconfigurationofthemethoxyacetamides(S)33ahandamines(R)21ahafterkinetic
resolution.
 Red.amination  Kineticresolution
R Amine21  Methoxyacetamide (S)33 Amine (R)21
 Yield[%]  Yield[%] ee[%] Yield[%] ee[%]
OMe 89  35 >99.5 (S) 43 97.0(R)
OBn 84  31 >99.5(S) 34 96.0(R)
H 93  32 >99.5(S) 36 >99.5(R)
F 95  40 >99.5(S) 43 >99.5(R)
Br 71  42 >99.5(S) 39 >99.5(R)
CF 68  35 >99.5(S) 38 >99.5(R)
CN 81  42 >99.5(S) 37 99.0(R)
NO2 79  36 >99.5(S) 43 >99.5(R)

As Table4.2 shows, the kinetic resolutions producedboth themethoxy acetamides (S)
33ahandtheamines(R)21ahingoodyieldsandinexcellentenantiomericexcess.
4.4 Synthesisofpotentialtyrosinekinaseinhibitors
Toutilisethesynthesisedamines(S)21ahinthepreparationofpotentialtyrosinekinase
inhibitors,attemptsweremadetoreact(S)21aand(S)21cwiththepyrrolopyrimidine34
as shown in Scheme 4.9. Based on reports on successful syntheses using several non
fluorinated 1arylethylamines,176 two different methods were investigated. The first
approachwasanucleophilicaromaticsubstitutionperformedinrefluxing1butanolusing
theaminesinathreefoldexcess.177Thesecondmethodtestedwasapalladiumcatalysed
BuchwaldHartwig cross coupling reaction performed in tertbutyl alcohol. The catalyst
wasmade insitubymixingPd(OAc)2 (5mol%)with thedialkylbiarylphosphine ligand35
(10mol%)andwater(4mol%)intertbutylalcoholat110°C.Thereactionswerecarried
outat60°Cand110°C.178
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Scheme4.9
Unfortunately, none of the methods yielded the desired products. The nucleophilic
aromaticsubstitutionapproachwastroubledby lowreactionratesandtheformationof
an unidentified byproduct. This indicated that the adjacent fluorine atomhad reduced
the nucleophilic character of the amino group, thereby, preventing the reaction from
taking place. The BuchwaldHartwig cross coupling reactions also failed to afford the
target compounds. In contrast to the aromatic substitution reactions, however, these
reactions were fast (100% conversion within 15 minutes) and yielded two major by
products.The identityof thebyproductshasnotbeenestablishedbut 1Hand 13CNMR
spectroscopy revealed that none of the compounds contained fluorine atoms. Further
investigationsarecurrentlyunderwaytosolvetheencounteredproblems.
4.5 Summary
Whencomparingtheresultsofthetwotestedroutestotheenantiomericallyenriched1
aryl2fluoroethylamines21ah,anobviousadvantageofthekineticresolutionapproach
was the excellent enantioselectivity observed. The asymmetric transfer hydrogenations
reducedtheketones1acinalmostmatchingselectivitybuttheinversionsof(R)12aand
(R)12bwerehamperedby racemisationunder theMitsunobu reaction. Therefore,only
amine(S)21cwasproducedinsimilarenantiomericexcessbytheMitsunobuapproach.
Thekineticresolutionapproachrequiresonlytwostepstoproducethetargetcompounds,
compared with three steps for the Mitsunobu approach. The drawback of a kinetic
resolution is, however, the limitation of amaximum 50% yield of one enantiomer. The
consequenceofthiscanbeseenwhentheoverallyieldsoftheamines21ahfromthe1
aryl2fluoroethanones 1ah are compared (Table 4.3). Despite the extra step, all the
Enantiomericallyenriched1aryl2fluoroethylamines
43

aminesexcepttheonescontainingelectrondonatingsubstituents(21ab)wereproduced
inslightlyhigheryieldsbytheMitsunoburoute.
Table4.3:Overallyields,enantiomericexcessandabsoluteconfigurationoftheenantioenrichedamines21ah,starting
fromthe1aryl2fluoroethanones1ah.
  Amine21
Substrate  Mitsunobuapproach Kineticresolution
  Yield[%] ee[%] Yield[%] ee[%]
1a (OMe) 18 53.5(S) 38 97.0 (R)
1b (OBn)  16 60.0 (S) 29 96.0 (R)
1c (H)  44 98.5 (S) 33 >99.5(R)
1d (F)  46 92.5(S) 41 >99.5 (R)
1e (Br)  43 90.5 (S) 28 >99.5(R)
1f (CF3)  29 91.5(S) 26 >99.5(R)
1g (CN)  42 87.5(S) 29 99.0 (R)
1h (NO2)  25 84.0(S) 34 >99.5(R)

It should be mentioned that kinetic resolutions, unlike asymmetric transfer
hydrogenations,donotofferthepossibilityofchoosingwhichenantiomerthatshouldbe
synthesised.Themethoxyacetamides(S)33ah,prepared inthiscase,canbeconverted
into the amines (S)21ah but this will further diminish the yields. If the desired
enantiomerisnottheonebeingproduced,thiscanbeasignificantdrawback.
Seen from an environmental point of view, the Mitsunobu reaction route has serious
disadvantages.AlthoughATHisconsideredtobeanenvironmentalfriendlyreaction,the
Mitsunobureaction isnot. Inaddition tousing the toxicandpotentiallyexplosiveDEAD
(22), the reaction generates two moles of waste for each mole of product formed.
Hydrazine, used in the final hydrazinolysis step, is also an environmentally harmful and
toxiccompound.Whenconsideringthekineticresolutionroute,theonlyseriousdrawback
istheuseoftwoequivalentsoftitanium(IV)isopropoxideinthereductiveaminationstep.
Thisproblemcan,however,becircumventedbyemployinganothermethodtowardsthe
racemicamines21ah.
In total, theresultsobtained fromthekinetic resolutionapproacharesuperior to those
achieved with the Mitsunobu route. Despite the lower yields experienced for some
substrates,theenantioselectivityforallthereactionswasbetter.Thisisakeyfactorwhich
outweighstheslightlyreducedyields.Anotherargumentforthisapproachisthefactthat
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both stepswere performed using a very simple experimental setup. Due to the higher
yieldsachievedfortheamine21c,theMitsunobuapproachcouldbechosenifveryhigh
enantiomericpurityisnotcrucial.

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5. Determinationofabsoluteconfigurationbycirculardichroism

ThischaptersummarisessomeoftheresultspresentedinPaperIIIandV.
5.1 Introduction
Thedeterminationoftheabsoluteconfigurationofanenantioenrichedcompoundcanbe
achievedbyseveraldifferentmethods.179ThemostcommonlyusedapproachesincludeX
raycrystallography,180theuseofchiralshiftreagentsinNMRspectroscopy181andcircular
dichroism.182,183 Provided no racemisation takes place, synthesising a compound from
chiralprecursorswithknownabsoluteconfigurationisalsoaviableapproach.184
Electronic circular dichroism (ECD)measurements have been performed routinely since
around 1960.185 The technique has been widely used for determining the absolute
configuration of organic molecules and relies on the ability of enantiomers to rotate
circularly polarised light in opposite directions. The early work was based on empirical
rulesassociatedwithrelativelysimplemolecules185but ithasnowbeenestablishedasa
nonempiricalmethod,widelyused forstructural investigationsoforganicand inorganic
compounds,polymersandbiomacromolecules.182,186
One of the simplest and most versatile ECDtechniques is the “exciton chirality
method”.187 Thismethod relies on the spatial interaction between two ormore strong
chromophoricelectricdipoletransitionswhicharechirallyarrangedandclose inenergy.
The dipoleswill interact and give rise to an exciton split CD spectrum, known as a CD
couplet, consisting of two Cotton effects of opposite signs. The sign of the CD couplet,
defined by the longer wavelength component, reflects the absolute sense of twist
between the two interacting chromophores. This sense of twist can be predicted by
viewing the twochromophoresalong thedirection connecting their centres.Anegative
signisdefinedwhenananticlockwiserotationmakesthedipoleinthefrontsuperimpose
thedipole in thebackandviceversa (Figure5.1). Provided that the relativeorientation
between the interacting dipoles and their spectroscopic properties are known, exciton
coupledCDenablestheunambiguousdeterminationofabsoluteconfiguration.186188The
method is limited to compounds with at least two chromophores located at suitable
positions in themolecule.Derivatisation is, therefore,oftenrequiredbefore thedesired
informationcanbeobtained.
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Figure5.1:Illustrationoftheexcitonchiralitymethod,showing(A)clockwiseand(B)counterclockwiseorientationof
twoidenticalchromophoresandthetworesultingCDspectra.(ReprintedwithkindpermissionfromSpringerScience
andBusinessMedia.)189

5.2 Determination of the absolute configuration of enantioenriched
1aryl2fluorethanols
Among the synthesised 1aryl2fluoroethanols 12ah, only 12c and 12e had previously
been characterised in enantiomerically enriched form.61,77 Therefore, the absolute
configurationoftheremainingalcoholshadtobedetermined.AstheCDexcitonchirality
method had previously been used for assigning the absolute configuration of similar
compounds,190itwasdecidedtoinvestigatethisapproach.
SincetheCDexcitonchiralitymethodrequiresthepresenceofatleasttwochromophores
in a molecule, an additional chromophore had to be introduced in the 1aryl2
fluoroalcohols12ah.Thebenzoategrouphasbeenfrequentlyusedformakingsecondary
alcoholsandprimaryamineseligibleforCDmeasurementsandwas,therefore,selectedas
theadditionalchromophore.189191
ThebenzoylderivatisationwasconductedbyaNovozym435catalysedkineticresolution
of the racemic alcohols 12ah, using vinyl benzoate as acyl donor (Scheme 5.1). These
robustreactionsuseasimpleexperimentalsetupandareperformedundermildreaction
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conditions, thus minimising the risk of racemisation. The benzoates (S)36ah were
isolatedingoodtoexcellentenantiomericexcess(Table5.1)butprolongedreactiontime
(12weeks)wasanobviousdisadvantageforthisapproach.

Scheme5.1
ResultsfromCDmeasurementscanonlybeinterpretedcorrectlywhenthemostfavoured
conformationof thecompound isknown.Therefore,anenergyminimisationcalculation
(MM2) of the benzoates (S)36ah was performed. In accordance with calculations
previously performed on related compounds,190 this showed that all the benzoates (S)
36ahhadsimilarpreferredconformations,with thehydrogenat thestereogeniccentre
arranged in the sameplane as the disubstituted aromatic ring. Figure 5.2(A) shows the
mostfavouredconformationfor(S)36h.
Determinationofabsoluteconfigurationbycirculardichroism
48


Figure5.2:(A)Themostfavouredconformationfor(S)36hand(B)theCDandUVspectrumof(S)36e.
As illustrated in Figure 5.2(A) for (S)36h, an anticlockwise rotation of the disubstituted
phenylringbringsitontothebenzoatedipole.Accordingtotheexcitonchiralityrule,this
predicts a negative first Cotton effect. This was confirmed by the CD measurements
performed and the absolute configuration of the prepared benzoates 36ah could be
assignedas(S).TheCDandUVspectrumof(S)36eisshowninFigure5.2(B).Thesecond
Cotton effect was not observed because the CD spectrum was perturbed by other
electronic transitions and effects caused by solvents. Based on the results from the
benzoates, the 1aryl2fluoroethanols 12ah left unreacted in the resolution reactions
wereassignedas(R).Themolarextinctionvalues()andmaxofthebenzoates(S)36ah
aresummarisedinTable5.1.
Table5.1:Enantiomericexcess(ee),molarextinction()andmaxoffirstCottoneffectfor(S)36ah.
Compound ee[%]  max [nm]
(S)36a (OMe) 73 5.9 233
(S)36b (OBn) 99 14.2 234
(S)36c (H) 88 9.0 228
(S)36d (F) 79 7.1 228
(S)36e (Br) 94 22.3 232
(S)36f (CF3) 96 6.0 227
(S)36g (CN) 90 19.6 237
(S)36h (NO2) 94 9.0 265
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5.3 Determination of the absolute configuration of enantioenriched
1aryl2fluoroethylamines
Among the prepared 1aryl2fluoroethylamines 21ah, only 21a192 and 21c192194 had
previously been characterised in enantiomerically enriched form. As for the 1aryl2
fluoroethanols12ah,theabsoluteconfigurationoftheamines21ahwasdeterminedby
usingtheCDexcitonchiralitymethod.
ThephthalimidegroupchromophorehaspreviouslybeenusedforCDmeasurements195,196
and,astheNsubstitutedphthalimides(S)31ahwerealreadyavailable,theywereutilised
for determining the absolute configuration of the corresponding 1aryl2
fluoroethylamines(S)21ah.
The most favoured conformation of the Nsubstituted phthalimides (S)31ah was
predictedbyenergyminimisation calculations.All the compoundshad similar preferred
conformations,with thehydrogenatomattached to the stereogenic centre arranged in
the same plane as the phenyl ring. Figure 5.3(A) illustrates the most favoured
conformationfor(S)31f.

Figure5.3:(A)Themostfavouredconformationfor(S)31fand(B)theCDandUVspectrumof(S)31f.
Based on the conformation shown for (S)31f in Figure 5.3(A), a negative negative first
Cotton effect was expected for the Nsubstituted phthalimides (S)31ah. This was
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confirmedbytheCDmeasurementsas illustratedfor(S)31f inFigure5.3(B).Theresults
foralltheNsubstitutedphthalimides(S)31aharesummarisedinTable5.2.
Table5.2:Enantiomericexcess(ee),molarextinction()andmaxoffirstCottoneffectfor(S)31ah.
Compound ee[%]  max [nm]
(S)31a (OMe) 53.0 1.3 232
(S)31b (OBn) 60.0 3.8 234
(S)31c (H) 99.0 3.5 223
(S)31d (F) a 1.6 223
(S)31e (Br) 90.0 3.9 230
(S)31f (CF3) 92.0 4.8 225
(S)31g (CN) 87.5 2.7 237
(S)31h (NO2) 84.0 1.4 228
a)Notdetermined
5.4 Summary
ByapplyingtheCDexcitonchiralitymethod,theabsoluteconfigurationofthebenzoates
(S)36ahandNsubstitutedphthalimides(S)31ahhasbeenunambiguouslydetermined.
Based on these results, the absolute configuration of the alcohols (R)12ah and the
amines(S)21ahcouldalsobeassigned.
AscanbeseenfromTable5.1andTable5.2,themolarextinctionvalues()fortheN
substituted phthalimides (S)31ah were considerably lower than the values for the
benzoates (S)36ah. This was expected, as the exciton coupling between two equal
chromophoreswill giveahighervalue.182Even though lowermolarextinctionvalues
were experienced, they were still large enough to provide reliable and reproducible
results.Asanticipated,thephthalimidegroupandthebenzoategroupwereconfirmedas
goodalternativesasanextrachromophorewhentheabsoluteconfigurationof1aryl2
fluoroethanols and 1aryl2fluoroethylamines is to be determined by the CD exciton
chiralitymethod.

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6. ChiralderivativesofButenafineandTerbinafine

ThischaptersummarisestheresultspresentedinPaperVI.MasterofTechnologyHanne
Høgmoen is acknowledged for the work with the di and trifluorinated compounds.
MasterofScienceEliOtterholtandAssociateProfessorColinCharnockareacknowledged
fortheworkrelatedtothebiologicalactivityscreens.
6.1 Introduction
Butenafine (37) and Terbinafine (38) (Figure 6.1) are part of awell established class of
antimycotic agents referred to as allylamines. They are used among others in topical
treatmentofdermatocytesinvadingskinandnailsandactbypreventingthesynthesisof
ergosterol in fungal cells. Ergosterol is anessentialmembranecomponentanda lackof
this compound causes the fungal cells to lyse. In the biosynthesis of ergosterol, the
allylamines inhibit the enzyme squalene epoxidase responsible for converting squalene
into squalene 2,3epoxide. In addition to the lack of ergosterol, the accumulation of
squalenealsoplaysaroleinthefungicidalactionofthesepharmaceuticals.197

Figure6.1:ThestructureoftheantimycoticagentsButenafine(37)andTerbinafine(38).
As can be seen from Figure 6.1, both Butenafine (37) and Terbinafine (38) are achiral
compounds consistingof a tertiary amine located in thebenzylic positionof anaphthyl
group.Theantifungalactivityofanumberofachiralderivativesofthesecompoundshave
previouslybeen investigated.198204However,derivatives containingastereogeniccentre
adjacent to the central nitrogen atomhavebeen substantially less studied. Both the 1
acetonaphthone derived compounds 39a and 40a (Figure 6.2) have previously been
showntohaveantifungalactivity,205207whiletheusefulnessof(R)40bhasbeenindicated
bycomparativemolecularfieldanalysis.208
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Elderly and immunocompromised patients are an increasing part of the world’s
population and, as a result of this, an increased use of antimycotics for treatment of
fungalinfectionshasoccurred.Followingthisincrease,pathogenicfungalstrainsshowing
resistanceagainsttheavailableantifungalagentsareemergingasaseriousproblem.209211
Althoughmanyfungalinfectionsareeitherharmlessorgiveonlyminorsymptoms,some
fungalstrainscancausepotentiallylethalinfections.TheCryptococcusneoformansspecies
is, for instance, known to cause the potentially fatal infection cryptococcosis in a large
numberofAIDSpatients.212214Thesamespecies isalsoresponsibleforcausingasevere
form of meningitis, especially frequent in the developing world.215,216 Cryptococcus
diffluens is from the same genus as Cryptococcus neoformans and, although being less
pathogenic, it is a common cause of the eczema atopic dermatitis.217 Trichosporon
cutaneum (syn.T.Beigelii)218 isa fungal strainwhich isnormally found in soilbut it can
alsoinhabithumans.Tohealthyhumanbeingsitisharmless,althoughinsomecasesitcan
cause the hair infection white piedra. To immunocompromised patients, however, it
represents a potential life threatening pathogen and responds poorly to antifungal
agents.219
6.2 SynthesisofchiralderivativesofButenafineandTerbinafine
A simple retrosynthetic analysis shows that chiral derivatives of Butenafine (37) and
Terbinafine (38) could potentially be made starting from 1naphthylethanones (XII)
(Scheme6.1).BydisconnectingoneoftheaminebondsofthetargetcompoundsIXandX,
the shown routeutilises the resulting secondarymethylaminesXI as key intermediates.
These intermediates can be accessed by a number of routes, one being the reductive
aminationofthecorresponding1naphthylethanonesXII.
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
Scheme6.1
By employing 1naphthyl2fluoroethanones as starting compounds, fluorinated amines
couldbeproduced.Theaminogroupofthesecompoundswouldhavelowerbasicitythan
the nonfluorinated analogues and, to investigate if this would affect the antifungal
activity,theButenafineandTerbinafineanalogues39afand40afweretargeted(Figure
6.2).

Figure6.2:Potentialbioactivetargetcompounds.
Themono,diandtrifluorinatedanalogues39ceand40cewouldhavelowerpKavalues
thantheexistingdrugs,whilethemethylandethylsubstitutedderivatives39aband40a
b would be slightly more basic (Table 6.1). To separate a possible size effect from an
electroniceffect,thecyanosubstitutedcompounds39fand40fwerealsoincludedinthe
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study.ThecyanogroupisclosetoCHF2andCF3inrespectofelectronicpropertiesbutitis
smallerthanamethylgroupinsize(Table6.1).
Table6.1:CalculatedpKavaluesof37,38,39afand40afandtherelativesizesofthedifferentRgroups.
  

R Rel.sizea Compound Calcd.pKa
b  Compound Calcd.pKa
b 
H 0 37 9.2  38 8.9 
Me 0.52 39a 9.5  40a 9.2 
Et 0.56 39b 9.5  40b 9.5 
CH2F 0.62 39c 9.5  40c 7.6 
CHF2 0.68 39d 9.8  40d 5.8 
CF3 0.91 39e 7.9  40e 2.9 
CN 0.40 39f 6.1 40f 5.1 
a)Chartonvolumefromtabulatedvalues.208,220
b)ThepKavalueswerecalculatedusingtheMarvinprogramsuite.

6.2.1 Synthesisofsecondarymethylamineintermediates
Thesecondarymethylamines41aeweresynthesisedasshowninScheme6.2.Thecyano
derivative 41f was considered made via the Strecker synthesis221 but as it was
commerciallyavailableitwasinsteadpurchased.
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Scheme6.2
Thesecondarymethylamine41awasobtainedingoodyieldafterthereductiveamination
of1acetonaphtone(7j)usingmethylamine,aceticacidandsodiumcyanoborohydride.A
Grignard reaction between 1cyanonaphthalene (42) and ethylmagnesium bromide
followed by hydrolysis of the imine intermediate yielded the ketone 43b which, by a
reductive amination, gave the ethyl substituted secondarymethylamine41b. To obtain
the monofluorinated methylamine 41c, electrophilic fluorination of the crude
trimethylsilylenolether8jusingSelectfluor®wasemployed.Thisreactionsufferedfrom
the formation of ring fluorinated byproducts, resulting in a poor 29% yield of the 

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fluoroketone 1j. The subsequent reductive amination provided the secondary
methylamine41c inamediocre53%yield.Thedifluorinatedmethylamine41dwasmost
conveniently synthesised from 1acetonaphthone (7j) via the imine 44. This was
difluorinatedwithNFSItoprovidetheimine45d,whichthenwasreduceddirectlytothe
methylamine41d inadecent65%overallyield.Finally, the trifluorinatedderivative41e
was synthesised by transforming 1bromonaphthalene (46) to 1lithiumnaphthalene
whichsubsequentlywastreatedwithethyltrifluoroacetate.Thetrifluorinatedketone47
wasconvertedtotheimine45ewhichthenwasreducedtothetargetcompound41e in
decentyield.
6.2.2 Nalkylationofsecondarymethylamines
Tosynthesisethefinaldruganalogues39afand40af,thesecondarymethylamines41af
werealkylatedwiththecommerciallyavailable1(bromomethyl)4tertbutylbenzene(48)
and (E)1chloro6,6dimethylhept2en4yne (49) (Scheme 6.3). The reactions were
performedinrefluxingacetonitrile,withN,Ndiisopropylethylamineasthebase.

Scheme6.3
The yield of the reactions depended both on the nature of the Rgroups and on the
alkylating agent. As Table 6.2 shows, the Butenafine analogues 39af were isolated in
generally higher yields than the Terbinafine analogues 40af. In addition to the better
leavinggroupabilityofthebromidecomparedtothechlorideanion,theobservedtrend
couldalsobeattributed to the fact that thealkylating agent49 contained4%of theZ
isomer.Thisresultedinmorecomplexreactionmixturesandtroublesomepurificationsfor
theTerbinafineanalogues40af.Wheninspectingthesummarisedresults,atrendcould
alsobeseenbetweenthenatureofRgroupsand the reaction times.As thenumberof
fluorine atoms increased, the reaction timewas extended from a few hours to several
days.Thiseffectwasexpectedandcanbeexplainedbythedecreasingnucleophilicityof
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the amine moiety of 39de and 40de. For the synthesis of the cyano substituted
analogues39fand40f,1HNMRspectroscopyindicatedthatthenitrilegrouphadpartially
hydrolysed into the carboxylic acid and this probably explains the lower yields
experiencedforthesereactions.
Table6.2:Isolatedyieldsandreactiontimesof39afand40affollowingtheNalkylationof41afusing48and49as
alkylatingagents.


R Compound Reaction
time[h]
Isolated
yield[%]
 Compound Reaction
time[h]
Isolated
yield[%]

Me 39a 2 81  40a 2 61 
Et 39b 2 82  40b 2 55 
CH2F 39c 4 86  40c 2 41 
CHF2 39d 48 90 40d 144 63
CF3 39e 120 82  40e 240 44 
CN 39f 4 75  40f 120 45 

Startingwithenantiomericallypure(R)41a(99.5%ee)and(S)41a(98.5%ee),(R)39aand
(S)39a were also synthesised according to the same procedure as described for the
racemicanalogue39a.
6.3 Antifungalactivity
TheantifungalactivitytestingwasperformedattheOsloUniversityCollegebyMasterof
Science Eli Otterholt as a part of her PhD project. The results from this work will,
therefore,onlybebrieflydiscussedandsummarisedinthischapter.
Initially, the antifungal activity of the drug analogues 39af and 40af towards the
microorganism C. neoformans was evaluated. For comparison, Butenafine (37) and
Terbinafine (38) were also included in the test. The evaluation was performed by
employing the semisolid agar antifungal susceptibility (SAAS)method and the resulting
minimuminhibitoryconcentration(MIC)valuesareshowninTable6.3.


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Table6.3:Antifungalactivity(MICvalues)of37,38,39af,40aftowardsC.neoformans,determinedbytheSAAS
method.

 
R Compound MIC50
[g/mL]
MIC75
[g/mL]
 Compound MIC50
[g/mL]
MIC75
[g/mL]
H Butenafine(37) 0.125 0.25  Tebinafine(38) 0.25 0.5 
Me 39a 0.125 0.25  40a 0.5 1.0 
Me (R)39a <0.031 0.031     
Me (S)39a 0.5a 18a     
Et 39b 0.254a 8 40b 28a 16 
CH2F 39c >16 >16  40c >16 >16 
CHF2 39d >16 >16  40d >16 >16 
CF3 39e >16 >16  40e >16 >16 
CN 39f >16 >16  40f >16 >16 
a)TrailinggrowthcomplicatedassignmentofMICvalues.
The testing revealed that the racemicmethyl substitutedButenafinederivative39a had
higheractivitythanTerbinafine (38)andthesameactivityasButenafine(37).Bytesting
both theenantiomers (R)39a and (S)39a separately, the activitywasprovedmainly to
originate from the (R)enantiomer, as this was significantly more potent than both
Butenafine (37) and the (S)enantiomer. The racemic methyl substituted Terbinafine
derivative 40a was less efficient than the parent compound 38. When the methyl
substituent was replaced by an ethyl substituent, the antifungal activity of both the
Butenafineanalogue39b and theTerbinafineanalogue40bdropped.For theanalogues
containing fluorineor a cyanogroup (39cf and40cf), noantifungal activity towardsC.
neoformanswasobserved.
Although less fungal growth inhibitionwas observedwhen the size of the Rgroupwas
increased frommethyl, via ethyl to the fluorinated substituents, theobservations could
not solelybeexplainedbystericeffects.The lackofantifungalactivityobserved for the
cyanosubstituted39fand40findicatedthatelectroniceffectswereofequalimportance
as steric effects. As no structural information currently is available for the squalene
epoxidasesofthetestedorganisms,itisdifficulttoexplaintheresultsatamolecularlevel.
To verify the main results from the SAAS testing, Butenafine (37) and the methyl
substituted derivatives 39a, (R)39a and (S)39a were also evaluated using the broth
microdilution method.222 To further investigate the usefulness of the compounds as
antifungal agents, two additional fungal species (C. diffluens and T. cutaneum) were
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included in the investigation.The resultsare summarised inTable6.4andshowthatall
the compounds tested inhibited fungal growth.Although theMIC valuesobtained from
thebrothmicrodilutionmethodofC.neoformansvariedslightlyfromtheSAASvalues,the
relativeactivitieswerethesame.ThetestingagainstC.diffluenswastroubledbytrailing
growthbut(R)39awasidentifiedasthemostactivederivative,withaMIC50valuehalfof
thatforButenafine(37).AgainsttheT.cutaneumstrain,Butenafine(37)andtheanalogues
39aand(R)39awereequallyefficient.Althoughstillbeingtheleastefficientcompound,
therelativeactivityof(S)39awashigheragainstT.cutaneumwhencomparedtotheother
organisms.Thiscouldindicateamoreflexibleinhibitorbindingsite.
Table6.4:Antifungalactivityof37,39a,(R)39aand(S)39atowardsC.neoformans,C.diffluensandT.cutaneum,
determinedbythebrothmicrodilutionmethod.
Compound C.neoformans  C.diffluens  T.cutaneum
 MIC50
[g/mL]
MIC75
[g/mL]
 MIC50
[g/mL]
MIC75
[g/mL]
 MIC50
[g/mL]
MIC75
[g/mL]
37 0.5 1.0  0.5a 4.0a  0.5 1.0
39a 0.25 0.5  0.5a 2.0a  0.5 1.0
(R)39a 0.125 0.25  0.25a 1.0a  0.5 1.0
(S)39a 1.0a 2.0a  4.0a >16a  1.0a 2.0a
a)TrailinggrowthcomplicatedassignmentofMICvalues.
6.4 Summary
Thecompounds39afand40af,structurallyrelatedtotheantimycoticagentsButenafine
(37) andTerbinafine (38), havebeen synthesisedand their antifungal activity againstC.
neoformans have been evaluated. The compound displaying the highest activity was
found to be 39a, being equally as efficient as Butenafine (37). By testing each of the
enantiomers (R)39a and (S)39a separately, it was revealed that the main activity
originatedfromthe(R)enantiomer,whichwassignificantlymoreactivethanButenafine.
When themethyl substituent at the stereogenic centrewas replaced bymore electron
withdrawing substituents, the antifungal activity towardsC. neoformans droppedbelow
detectable limits.Thismay indicate that thebasicityof thenearbyaminogroupplaysa
crucial role in the antifungal action of these compounds. By applying the broth
microdilution method, it was confirmed that the enantiomerically enriched methyl
derivative(R)39ahadsimilarorbetterantifungalactivitythanButenafine(37)againstC.
neoformans,C.diffluensandT.cutaneum.Theseresultssuggestthatantimycoticagents
based on this compound can potentially offer improvements of the existing Butenafine
basedformulationsusedtoday.
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Electrophilic ﬂuorination
1-Chloromethyl-4-ﬂuoro-1,4-
diazoniabicyclo[2.2.2]octane bis-
(tetraﬂuoroborate)
Tetrabutylammonium hydrogen biﬂuoride
a-Fluoroacetophenone
a b s t r a c t
para-Substituted a-ﬂuoroacetophenones have been synthesised by three different routes. Electrophilic
ﬂuorination of trimethylsilyl enol ethers of acetophenones using Selectﬂuor (F–TEDA–BF4, 1-chloro-
methyl-4-ﬂuoro-1,4-diazoniabicyclo[2.2.2]octane bis-(tetraﬂuoroborate)) gave high to moderate yield
depending on the electronic properties of the substituents. F–TEDA–BF4 mediated ﬂuorination of
acetophenones in methanol resulted in a mixture of a-ﬂuoroacetophenones and the corresponding 2-
ﬂuoro-1,1-dimethyl acetals. The dimethyl acetals were hydrolysed using triﬂuoroacetic acid in water to
maximise the yield of the product. Nucleophilic ﬂuorination of a-bromoacetophenones using tetrabu-
tylammonium hydrogen biﬂuoride (TBABF) led to moderate yield when having electron-donating
substituents, whereas low yields were experienced when more electron-withdrawing substituents were
introduced.
 2008 Elsevier Ltd. All rights reserved.
1. Introduction
The importance of ﬂuorinated compounds in pharmaceuticals,
agrochemicals and material sciences has been thoroughly recog-
nised.1–5 As a consequence ﬂuorinated building blocks are required.
a-Fluoroacetophenones can give access to a number of interesting
molecules by reaction at the keto-group, the a-carbon or the aro-
matic ring. Examples include synthesis of ﬂuorinated tetralones,6
pyrozoles7 and thiadiazoles.8 a-Fluoroacetophenones are also
suitable starting materials for ﬂuorochemicals such as 1,1,2-tri-
ﬂuoroethyl aryl ethers,9 1,2-diﬂuoroethylaryls10 and 1,1,2-
triﬂuoroethylaryls.11
Various methods can be used for synthesis of a-ﬂuo-
roacetophenones, including nucleophilic displacement,11–16 elec-
trophilic ﬂuorination,7,17–21 Friedel–Crafts chemistry,22,23 coupling
chemistry24 and reaction via diazo ketones.25,26 Some of these
methods have drawbacks due to the use of hazardous and toxic
chemicals.
Being in need of a series of a-ﬂuoroacetophenones, it was rec-
ognised that the literature mainly covers reactions towards the
parent compound 2-ﬂuoro-1-phenylethanone, and no systematic
study on the effect of substrate structure on yield had been per-
formed. Therefore, the aim of the work was to compare the use-
fulness of two electrophilic and one nucleophilic strategies for the
preparation of eight different para-substituted a-ﬂuoro-
acetophenones. Targeting nonhazardous procedures, Selectﬂuor
(F–TEDA–BF4) and tetrabutylammonium hydrogen biﬂuoride
(TBABF) were selected as ﬂuorination reagents. F–TEDA–BF4 is
a stable crystalline solid with low hydroscopicity and toxicity,
suited for safe ﬂuorination.27 TBABF is a nucleophilic ﬂuorine
source, claimed to be noncorrosive, possessing good solubility
properties, and having a high thermal stability.12
2. Results and discussion
2.1. Comparison of the routes
The three routes investigated for the synthesis of a-ﬂuo-
roacetophenones, 1a–h, are shown in Scheme 1.
O
R
2a-h
O
R
F
1a-h
O
R
3a-h
BrRoute C
Route B
Route A
Scheme 1. Route A: (1) Base/TMSCl, (2) F–TEDA–BF4. Route B: (1) F–TEDA–BF4, (2) TFA.
Route C: TBABF. R¼OMe (a), OBn (b), H (c), F (d), Br (e), CF3 (f), CN (g) and NO2 (h).
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In route A, acetophenones were converted to the corresponding
trimethylsilyl enol ethers, and reacted with F–TEDA–BF4. The
ﬂuorination was performed in acetonitrile at room temperature. In
route B,7,17 electrophilic ﬂuorination of the acetophenones, 2a–h,
was performed using 2 equiv of F–TEDA–BF4 in reﬂuxingmethanol.
The reaction yielded the ﬂuorinated ketones 1a–h and their cor-
responding 2-ﬂuoro-1,1-dimethyl acetals. Hydrolysis under acidic
conditions was required to convert the acetals to the a-ﬂuo-
roacetophenones, 1a–h. For the nucleophilic approach (route C),
the a-bromoacetophenones, 3a–h, were reacted with 2 equiv of
TBABF in reﬂuxing THF. The isolated yields for the three strategies
are summarised in Table 1.
Electrophilic ﬂuorination via the trimethylsilyl enol ethers
(route A) provided on average the highest yield. The process was
especially suited for substrates bearing electron-donating sub-
stituents. A decrease in yield was observed as more electron-
withdrawing groups were introduced, and only a moderate 44%
yield was obtained for the 4-nitro derivative, 1h.
Fluorination of acetophenones in methanol (route B) gave yields
in the range of 25–77%. Fluorination of 2a–b also led to ring ﬂuo-
rinated by-products, which complicated the puriﬁcation step. Of
the methods tested, route B gave the highest yields of 1e–h.
Nucleophilic ﬂuorination of 3a–h using TBABF (route C) gave
moderate to low yield, depending on substrate structure. The best
yields for route C were obtained when reacting a-bromoaceto-
phenones having electron-donating substituents, whereas for
substrates bearing electron-withdrawing substituents low yields
were experienced.
2.2. Electrophilic ﬂuorination via trimethylsilyl enol ethers
(route A)
In the ﬁrst step, the acetophenones (2a–h) were converted to
the trimethylsilyl enol ethers 4a–h, Scheme 2. For preparation of
4a–g, lithium hexamethyldisilazane (LiHMDS) and trimethylsilyl
chloride (TMSCl) were used, giving a conversion of >98%. Com-
pound 4h proved to be more difﬁcult to prepare in decent purity by
this method. Changing the base to DBU improved the synthesis, and
a conversion of 95% could be obtained.
The crude trimethylsilyl enol ethers, 4a–h, were treated with F–
TEDA–BF4 at room temperature in acetonitrile. The reaction prog-
ress was monitored by 1H NMR spectroscopy. Some reactions failed
to go to completion, but addition of 0.1–0.3 additional equivalents
of F–TEDA–BF4 allowed for full conversion (>98%). Of the substrates
tested, only ﬂuorination of 4h failed to reach full conversion after
additional F–TEDA–BF4 had been added. The highest conversion
obtained for 1h via route A was 91%.
2.3. Electrophilic ﬂuorination in methanol (route B)
Treating the acetophenones, 2a–h, with 2 equiv of F–TEDA–BF4
in reﬂuxing methanol7 gave the products 1a–h and the corre-
sponding 2-ﬂuoro-1,1-dimethyl acetals, 6a–h, Scheme 3. For sub-
strates bearing electron-donating substituents, the ring ﬂuorinated
ketones, 5a–b, and their 2-ﬂuoro-1,1-dimethyl acetals, 7a–b, were
also formed. The chemoselectivity (aliphatic/aromatic) was found
to be dependent on the degree of conversion, with higher conver-
sion leading to increased levels of 5a–b and 7a–b.
Table 2 summarises the reaction time, degree of conversion and
product distribution for the reactions prior to acetal cleavage. The
reaction time varied from 48 h for 2a to 11 days for 2h.
The ketone to dimethyl acetal product ratio depended on
substrate structure, the dimethyl acetal form being favoured by
electron-withdrawing groups. This is in agreement with ketone–
dimethyl acetal equilibrium constants found for acetophenones.28
1H NMR spectroscopy also indicated trace amounts of a,a-
diﬂuoroacetophenones and a-chloroacetophenones being present
at high conversions. The formation of the latter is most likely due to
electrophilic chlorine impurities in the commercial reagent.
Treating the ketone/dimethyl acetal mixture under acidic con-
ditions, converted 6a–h and 7a–b to the corresponding a-ﬂuo-
roacetophenones,1a–h and 5a–b. The yield of 1a–h varied between
25 and 77%. The low yield in the case of 1d is explained by the
volatility of the intermediate 2-ﬂuoro-1,1-dimethyl acetal, 6d. A
test distillation performed at atmospheric pressure, revealed that
both 6d and 1d co-distilled with methanol at 66–67 C.
The hydrolytic stability of the dimethyl acetals was also de-
pendent on the aromatic substituents. Electron-withdrawing
Table 1
Isolated yields for the routes A–C
R Product Isolated yield (%)
Route A Route B Route C
OMe 1a 91 67 48
OBn 1b 89 58 51
H 1c 76 66 42
F 1d 74 25 36
Br 1e 69 77 33
CF3 1f 69 73 26
CN 1g 55 64 20
NO2 1h 44 70 20
Table 2
Reaction time, conversion and product distribution (1H NMR spectroscopy) for
ﬂuorination of acetophenones, 2a–h, using F–TEDA–BF4 in methanol
Substrate Reaction time (h) Conv. (%) Product distribution (%)
1 5 6 7
2a 48 98 67 13 11 7
2b 72 96 57 6 24 9
2c 96 98 36 0 62 0
2d 96 99 38 0 61 0
2e 125 98 26 0 72 0
2f 144 99 7 0 92 0
2g 192 99 13 0 86 0
2h 261 99 7 0 92 0
O
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2a-h
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R
F
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R
F
MeOH
R
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F
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R
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F
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F F
Scheme 3. Products formed in ﬂuorination of acetophenones using F–TEDA–BF4 in
methanol.
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Scheme 2. Synthesis of 1a–h via the trimethylsilyl enol ethers,4a–h, using F–TEDA–BF4.
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groups increased the stability. Compound 6h proved to be particu-
larly stable and could not be cleaved by several protocols.29–31
However, reﬂuxing with 10% aqueous hydrochloric acid in THF, or
triﬂuoroacetic acid/water/chloroform,32 provided full conversion
within 20 h. The use of HCl had the drawback of formation of small
amounts of the corresponding a-chloroacetophenone. The mecha-
nistic rational behind this transformation has not been investigated.
2.4. Nucleophilic displacement (route C)
The yield of the nucleophilic displacement reaction using TBABF
depended on the aromatic ring substituents. Moderate outcome
was observed for substrates having electron-donating groups,
whereas only 20% isolated yield was obtained for 1g–h. The de-
crease in reaction yield through the series parallels the increasing
electron-withdrawing property and acidity of the acetophenones.33
The main by-products in these reactions were trans-1,2,3-tri-
(benzoyl)cyclopropanes, 8a–h, Scheme 4.
In thecaseof3c–e, ca. 20%of thesubstrateswere consumed in this
side reaction. Compounds 8c–ewere isolated and characterised. The
stereochemistryof8c–ewasevident fromthe 1HNMRspectra,which
contained a one proton triplet at ca. 4.2 ppm and a two proton dou-
blet at ca. 3.7 ppm, bothwith a coupling constant of ca. 5.6 Hz. These
compounds are most likely formed via the trans-1,2-dibenzoyl-
ethylenes, by a cycloaddition reaction of ionic character.34,35 1H NMR
spectroscopy also indicated compounds 9a–h, products of Darzen-
type condensations,36–38 to be formed under these conditions.
Pyridine and triethylamine have previously been used in ﬂuori-
nationsofa-bromoacetophenonesusingTBABF.15,39Themethodwas
tested in ﬂuorination of 3b using both pyridine and triethylamine,
and in reaction of 3c using pyridine. However, this led to further loss
in yield due to formation of compounds 10b,11b and 10c, Scheme 5.
R
O
N+
R
O
N+ CH3
CH3
CH3
11b
Br- Br-
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Scheme 5. By-products caused by pyridine or triethylamine.
3. Conclusion
Using three different methods, eight a-ﬂuoroacetophenones
have been prepared. Three of these have previously not been char-
acterised (1b,1f and 1g). In general, electrophilic ﬂuorination via the
trimethylsilyl enol ethers, 4a–h, using F–TEDA–BF4, gave higher
yields than that for the othermethods tested. The yield depended on
the aromatic ring substituents, with substrates bearing electron-
donatinggroupsgivinghigher yield. In contrast tomolecularﬂuorine
and triﬂuoromethyl hypoﬂuorite,18,20 theuseof F–TEDA–BF4 enables
the ﬂuorination to take place at room temperature in conventional
media. Fluorinationof acetophenoneswithF–TEDA–BF4 inmethanol
gave the a-ﬂuoroacetophenones, 1a–h, and the corresponding 2-
ﬂuoro-1,1-dimethyl acetals, 6a–h. The dimethyl acetals were
hydrolysed to 1a–h using triﬂuoroacetic acid. The method is
experimentally simple, and the yields were independent of the
electronic properties of the aromatic substituents. The protocol
suffers from low chemoselectivity for substrates bearing electron-
donating groups, prolonged reaction times and the requirement of
2 equivof F–TEDA–BF4. However, themethodgave thehighest yields
for compounds 1e–h. Nucleophilic displacement of a-bromoaceto-
phenones containing electron-donating substituents gavemoderate
yields. For substrates bearing electron-withdrawing groups, con-
densation reactions led to complex mixtures and low yields. Com-
pared to the electrophilic ﬂuorinations, this method is of less value.
4. Experimental
4.1. General
The acetophenones 2a, 2c and 2f–h, the a-bromoacetophenones
3a and 3c and tetrabutylammonium hydrogen biﬂuoride (50% so-
lution) were purchased from Fluka. LiHMDS, Selectﬂuor (F–TEDA–
BF4) and trimethylsilyl chloride were purchased from Aldrich.
Column chromatography was performed using silica gel 60A from
Fluka, pore size 40–63 mm. 1-(4-Benzyloxyphenyl)ethanone (2b)
was prepared from 4-hydroxyacetophenone using benzyl chloride
and potassium carbonate in N,N-dimethylformamide as solvent. 1-
(4-Fluorophenyl)ethanone (2d) was prepared as described by Olah
et al.40 The a-bromoacetophenones 3b and 3d–hwere prepared by
bromination of the corresponding acetophenones using molecular
bromine. NMR spectra and high resolution mass spectra were in
accordance with proposed structures. Compounds 6b, 6e–h and 7b
were isolated by column chromatography after synthesis according
to route B (4.41 mmol scale), omitting the hydrolytic step.
4.2. Analyses
NMR spectra were recorded with Bruker Avance DPX 400
operating at 400 MHz for 1H, 375 MHz for 19F and 100 MHz for 13C.
For 1H and 13C NMR chemical shifts are in parts per million relative
to TMS, while for 19F NMR the shift values are relative to hexa-
ﬂuorobenzene. Coupling constants are in hertz. NMR resonance
assignment was aided by the HMBC technique.41 MS (EI/70 eV):
Finnigan MAT 95 XL, MS (ESI): Waters QTOF II and MS (CI): Waters
Prospec Q. FTIR spectra were recorded on a Thermo Nicolet Avatar
330 infrared spectrophotometer. All melting points are uncorrected
and measured by a Bu¨chi melting point instrument.
4.3. Electrophilic ﬂuorination via trimethylsilyl enol ethers
(route A)
The trimethylsilyl enol ethers, 4a–g, were prepared as described
by Wiles et al.42 starting with 20 mmol of the acetophenones.
Compound 4h was prepared according to Schumacher and Reis-
sig.43 1H NMR spectra were in accordance with that reported pre-
viously: 4a,44 4b,44 4c,45 4d,18 4f,43 4g46 and 4h.43 Compound 4e:
1H NMR (CDCl3) d: 0.26 (s, 9H), 4.44 (d, J¼1.9 Hz, 1H), 4.89 (d,
J¼1.9 Hz, 1H) and 7.44 (m, 4H).
The crude trimethylsilyl enol ether 4 (20 mmol) dissolved in dry
acetonitrile (50 mL) was added to a suspension of F–TEDA–BF4
(20 mmol) in dry acetonitrile (150 mL). The reaction mixture was
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stirred at room temperature and monitored by 1H NMR spectros-
copy until complete consumption of the trimethylsilyl enol ether.
Additional F–TEDA–BF4 (0.1–0.2 equiv) was added in cases where
complete conversion was not obtained. A solvent switch from
acetonitrile to EtOAc (100 mL) was performed. The organic phase
was washed with water (2100 mL) and brine (100 mL), and dried
over Na2SO4 before the solvent was evaporated under reduced
pressure. The crude products were puriﬁed as follows: 1a, silica gel
chromatography (pentane/EtOAc, 5:2); 1b, crystallisation (i-PrOH);
1c, bulb to bulb distillation (94–96 C at 1.5102 mbar); 1d, silica
gel chromatography (cyclohexane/acetone, 5:1); 1e, silica gel
chromatography (pentane/acetone, 10:1); 1f, bulb to bulb distilla-
tion (83–85 C at 7.5102 mbar); 1g, crystallisation (EtOH) and 1h,
silica gel chromatography (CHCl3).
4.4. Electrophilic ﬂuorination in methanol (route B)
The acetophenone (8.84 mmol) and F–TEDA–BF4 (2 equiv) were
mixed in methanol (64 mL) and stirred at reﬂux for 2–11 days. The
reaction mixture was cooled to room temperature, and the meth-
anol was removed under reduced pressure. The residue was diluted
with dichloromethane (150 mL). The organic fraction was washed
with water (230 mL) and brine (30 mL), dried over Na2SO4 and
concentrated under reduced pressure. The crude product was
mixed with chloroform (15 mL), triﬂuoroacetic acid (3 mL) and
water (3 mL). The acetals 6a–e were cleaved at room temperature,
whereas compounds 6f–h were hydrolysed by reﬂuxing for 20 h.
Triﬂuoroacetic acid was neutralised by addition of saturated
aqueous NaHCO3. The mixture was extracted with chloroform
(325 mL), dried over Na2SO4 and concentrated under reduced
pressure. Compounds were puriﬁed as follows 1a: silica gel chro-
matography (pentane/EtOAc, 5:2), 1b: crystallisation (i-PrOH), 1c:
silica gel chromatography (CH2Cl2), 1d: silica gel chromatography
(cyclohexane/acetone, 5:1), 1e: silica gel chromatography (pen-
tane/acetone, 10:1), 1f: silica gel chromatography (CH2Cl2), 1g:
crystallisation (EtOH), 1h: crystallisation (i-PrOH).
4.5. Nucleophilic displacement (route C)
Tetrabutylammonium hydrogen biﬂuoride (10 mmol in aceto-
nitrile) was treated under a stream of nitrogen gas to remove
acetonitrile prior to dilution with freshly distilled THF (25 mL). The
a-bromoacetophenone (5 mmol) was dissolved in THF (25 mL) and
added drop wise to the TBABF solution under a nitrogen atmo-
sphere. The mixture was reﬂuxed until TLC analysis indicated
complete conversion. The reaction mixture was then diluted with
diethyl ether (50 mL) and washed with dilute HCl (0.1 M, 320 mL)
and water (230 mL). The water phase was back extracted twice
with diethyl ether. The combined organic fractions were dried over
MgSO4, concentrated, and then subjected to puriﬁcation by silica
gel column chromatography (CH2Cl2/MeOH, 100:1).
4.6. Analytical data for a-ﬂuoroacetophenones
4.6.1. 2-Fluoro-1-(4-methoxyphenyl)ethanone (1a)47
White solid, mp 79–80 C (78–79 C).7 1H, 13C and 19F NMRwere
in accordance with that reported by Funabiki et al.48 IR was in ac-
cordancewith Barkakaty et al.47 MS (EI,m/z, %): 168 (Mþ, 6), 127 (8),
71 (6) and 43 (100). HRMS (EI): 168.0580 (calcd 168.0587).
4.6.2. 1-(4-Benzyloxyphenyl)-2-ﬂuoroethanone (1b)
White solid, mp 110–111 C. 1H NMR (CDCl3) d: 5.14 (s, 2H), 5.46
(d, J¼47.0 Hz, 2H), 7.02–4.04 (m, 2H), 7.36–7.43 (m, 5H) and 7.87–
7.89 (m, 2H). 13C NMR (CDCl3) d: 70.2, 83.5 (d, J¼181.1 Hz), 115.0
(2C), 127.0, 127.5 (2C), 128.4, 128.8 (2C), 130.3 (d, J¼2.9 Hz, 2C),
135.9, 163.4 and 191.9 (d, J¼15.5 Hz). 19F NMR (CDCl3) d: 230.4 (t,
J¼47.0 Hz). IR (KBr, cm1): 2940, 1700, 1599, 1242, 1174, 1082, 1007,
975, 834 and 755. MS (EI, m/z, %): 244 (Mþ, 3), 91 (100) and 65 (7).
HRMS (EI): 244.0895 (calcd 244.0990).
4.6.3. 2-Fluoro-1-phenylethanone (1c)14
Clear oil, which solidiﬁed upon storage, mp 25–26 C (26 C).49
NMR14,50 and IR-spectra21 were in accordance with that reported
previously. MS (EI, m/z, %): 138 (Mþ, 9), 105 (100) and 77 (64).
HRMS (EI): 138.0483 (calcd 138.0481).
4.6.4. 2-Fluoro-1-(4-ﬂuorophenyl)ethanone (1d)19
White solid, mp 49–51 C (48–50 C).19 1H NMR (CDCl3) d: 5.49
(d, J¼46.9 Hz, 2H), 7.15–7.21 (m, 2H) and 7.83–7.98 (m, 2H). 13C
NMR (CDCl3) d: 83.5 (d, J¼186.7 Hz), 116.1 (d, J¼22.0 Hz, 2C), 130.2
(dd, J¼4.2 and 1.1 Hz), 130.7 (dd, J¼12.1 and 3.1 Hz, 2C), 166.2 (d,
J¼255.0 Hz) and 192.0 (d, J¼15.8 Hz). 19F NMR (CDCl3) d: 103.3
(m) and 230.0 (t, J¼47.0 Hz). IR (KBr, cm1): 2951, 1686, 1600,
1236, 1161, 1083, 976 and 835. MS (EI,m/z, %): 156 (Mþ, 1), 123 (42),
95 (27) and 75 (10). HRMS (EI): 156.0379 (calcd 156.0387).
4.6.5. 1-(4-Bromophenyl)-2-ﬂuoroethanone (1e)25
White solid, mp 72–73 C (71–72 C).25 1H NMR was in agree-
ment with Ying et al.51 13C and 19F NMR corresponded with that
reported by Bridge et al.25 IR was in accordance with Barkakaty
et al.47 MS (EI,m/z, %): 216/218 (Mþ, 7), 183/185 (100), 155/157 (50)
and 104 (40). HRMS (EI): 215.9585 (calcd 215.9586).
4.6.6. 2-Fluoro-1-(4-triﬂuoromethylphenyl)ethanone (1f)
White solid, mp 35–36 C. 1H NMR (CDCl3) d: 5.52 (d, J¼46.8 Hz,
2H), 7.76–7.79 (m, 2H) and 8.02–8.04 (m, 2H). 13C NMR (CDCl3) d:
83.8 (d, J¼184.3 Hz), 123.4 (q, J¼273 Hz), 126.0 (q, J¼3.8 Hz, 2C),
128.6 (d, J¼3.1 Hz, 2C), 135.4 (q, J¼32.9 Hz), 136.5 (m) and 192.9 (d,
J¼16.4 Hz). 19F NMR (CDCl3) d: 63.9 (s, 3F) and 230.2 (t,
J¼47.0 Hz). IR (KBr, cm1): 2937, 1707, 1418, 1330, 1175, 1066, 976
and 836. MS (EI,m/z, %): 206 (Mþ, 0.1), 173 (35), 145 (100), 125 (29),
95 (17) and 75 (9). HRMS (EI): 206.0360 (calcd 206.0355).
4.6.7. 1-(4-Cyanophenyl)-2-ﬂuoroethanone (1g)
White solid, mp 104–105 C. 1H NMR (CDCl3) d: 5.51 (d,
J¼46.8 Hz, 2H), 7.81 (m. 2H) and 8.02 (m, 2H). 13C NMR (CHCl3) d:
83.8 (d, J¼183.5 Hz), 117.4, 117.6, 128.6 (d, J¼3.3 Hz, 2C), 132.7 (2C),
136.7 (d, J¼1.1 Hz) and 192.7 (d, J¼16.9 Hz). 19F NMR (CDCl3) d:
229.6 (t, J¼47.0 Hz). IR (KBr, cm1): 3095, 2932, 2231, 1709, 1437,
1232, 1083, 979 and 839. MS (EI,m/z, %): 163 (Mþ, 2), 130 (100), 102
(56), 76 (11) and 75 (17). HRMS (EI): 163.0437 (calcd 163.0433).
4.6.8. 2-Fluoro-1-(4-nitrophenyl)ethanone (1h)25
Off-white solid, mp 96–97 C (90–92 C).25 1H, 13C and 19F NMR
corresponds with that of Bridge et al.,25 except the C–F coupling
constant for the carbonyl: 192.8 (d, J¼17.0 Hz). IR (KBr, cm1): 3119,
2934, 1709, 1607, 1526, 1346, 1227, 1091, 973, 857 and 799. MS (EI,
m/z, %): 183 (Mþ, 1), 150 (100), 104 (33), 92 (15) and 76 (20). HRMS
(EI): 183.0339 (calcd 183.0332).
4.7. Analytical data for impurities and intermediates
4.7.1. 2-Fluoro-1-(3-ﬂuoro-4-methoxyphenyl)ethanone (5a)7
Synthesis according to route B. Compound 5a was isolated by
silica gel chromatography (pentane/EtOAc, 5:2) as a white solid mp
84–85 C (82–84 C).7 1H NMR was in accordance with that
reported previously.7 13C NMR (CDCl3) d: 56.5, 83.8 (dd, J¼182.9 and
0.7 Hz), 112.8 (d, J¼2.0 Hz), 115.9 (dd, J¼19.3 and 3.2 Hz), 125.7 (t,
J¼3.5 Hz), 127.1 (dd, J¼5.3 and 1.2 Hz), 152.3 (dd, J¼249.0 and
0.5 Hz), 153.0 (d, J¼10.8 Hz) and 191.5 (dd, J¼16.0 and 2.0 Hz). 19F
NMR (CDCl3) d: 133.3 (m) and 230.0 (t, J¼46.9 Hz). IR (KBr,
cm1): 2925, 2852, 1697, 1612, 1519, 1280, 1084, 1012 and 995. MS
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(EI, m/z, %): 186 (Mþ, 45), 153 (100), 125 (37), 110 (48), 95 (63) and
82 (47). HRMS (EI): 186.0497 (calcd 186.0492).
4.7.2. 1-(4-(Benzyloxy)-3-ﬂuorophenyl)-2-ﬂuoroethanone (5b)
Synthesis according to route B. The mother liquor after crys-
tallisation of 1b was concentrated, and compound 5b was isolated
by silica gel chromatography (CH2Cl2) yielding a white solid, mp
90–92 C. 1H NMR (CDCl3) d: 5.22 (s, 2H), 5.42 (d, J¼47.0 Hz, 2H),
7.05 (m, 1H), 7.33–7.44 (m, 5H), 7.64 (m, 1H) and 7.68 (dd, J¼11.5
and 2.1 Hz, 1H). 13C NMR (CDCl3) d: 71.4, 83.7 (dd, J¼183.0 and
0.7 Hz), 114.6 (d, J¼1.9 Hz), 116.2 (dd, J¼19.5 and 3.2 Hz), 125.6 (t,
J¼3.4 Hz), 127.6 (2C), 128.7, 129.0 (2C), 130.5 (d, J¼5.2 Hz), 135.6,
152.0 (d, J¼10.8 Hz), 152.6 (dd, J¼249.4 and 0.5 Hz) and 191.5 (dd,
J¼16.0 and 2.0 Hz). 19F NMR (CDCl3) d: 132.7 (m) and 230.0 (t,
J¼46.9 Hz). IR (KBr, cm1): 2933, 1707, 1687, 1608, 1517, 1275, 1081
and 994. MS (EI, m/z, %): 262 (Mþ, 2), 139 (7), 91 (100) and 65 (8).
HRMS (EI): 262.0804 (calcd 262.0805).
4.7.3. 1-(2-Fluoro-1,1-dimethoxyethyl)-4-methoxybenzene (6a)
Compound 6a was synthesised from 1a according to Ranu
et al.30 Compound hydrolysed during work-up yielding only 4 mg
(5%) after silica gel chromatography (hexane/EtOAc, 7:3). 1H NMR
(CDCl3) d: 3.27 (s, 6H), 3.82 (s, 3H), 4.48 (d, J¼47.2 Hz, 2H), 6.91
(m, 2H) and 7.45 (m, 2H). 13C NMR (CDCl3) d: 49.1 (2C), 55.3, 83.5
(d, J¼178.1 Hz), 100.4 (d, J¼20.1 Hz), 113.6 (2C), 128.5 (d, J¼0.9 Hz,
2C), 130.2 (d, J¼0.9 Hz) and 159.7. 19F NMR (CDCl3) d: 228.7 (t,
J¼47.4 Hz). IR (KBr, cm1): 2942, 2837, 1612, 1513, 1250, 1071 and
1038. MS (EI, m/z, %): 214 (Mþ, 6), 183 (62), 181 (100), 149 (40),
135 (88), 121 (25) and 107 (41). HRMS (EI): 214.1000 (calcd
214.1005).
4.7.4. 1-(Benzyloxy)-4-(2-ﬂuoro-1,1-dimethoxyethyl)benzene (6b)
Compound 6b was puriﬁed by silica gel chromatography (pen-
tane/EtOAc, 9:1) yielding a white sold, mp 64.5–66.5 C. 1H NMR
(CDCl3) d: 3.30 (s, 6H), 4.51 (d, J¼47.3 Hz, 2H), 5.10 (s, 2H), 7.02 (m,
2H), 7.36 (m, 2H) and 7.40–7.42 (m, 5H). 13C NMR (CDCl3) d: 49.3
(2C), 70.2, 83.7 (d, J¼178.2 Hz), 100.6 (d, J¼20.0 Hz), 114.6 (2C),
127.7 (2C), 128.2, 128.8 (2C), 128.8 (2C), 130.6, 137.1 and 159.1. 19F
NMR (CDCl3) d: 228.7 (t, J¼46.9 Hz). IR (KBr, cm1): 2935, 2830,
1610, 1514, 1454, 1247, 1098 and 1038. MS (EI, m/z, %): 291 (Mþþ1,
4), 260 (24), 259 (50), 258 (73),169 (5),167 (5), 92 (34), 91 (100) and
65 (26). HRMS (EI): 290.1305 (calcd 290.1318).
4.7.5. 1-Bromo-4-(2-ﬂuoro-1,1-dimethoxyethyl)benzene (6e)
The dimethyl acetal 6e was puriﬁed by silica gel chromatogra-
phy (CH2Cl2) yielding a colourless oil.
1H NMR (CDCl3) d: 3.27 (s,
6H), 4.47 (d, J¼47.1 Hz, 2H), 7.40 (m, 2H) and 7.52 (m, 2H). 13C NMR
(CDCl3) d: 49.3 (2C), 83.2 (d, J¼178.2 Hz),100.4 (d, J¼20.4 Hz),123.0,
129.3 (d, J¼0.9 Hz, 2C), 131.6 (2C) and 137.5 (d, J¼0.5 Hz). 19F NMR
(CDCl3) d: 229.8 (t, J¼46.9 Hz). IR (KBr, cm1): 2944, 2836, 1592,
1485, 1394, 1290, 1071, 826 and 743. MS (EI, m/z, %): 264 (35), 262
(36), 245 (36), 243 (32), 234 (64), 233 (86), 232 (82), 231 (100), 230
(78), 229 (93), 216 (31), 201 (7), 199 (9), 105 (10) and 91 (17). HRMS
(EI): 262.0006 (calcd 262.0005).
4.7.6. 1-(2-Fluoro-1,1-dimethoxyethyl)-4-(triﬂuoromethyl)-
benzene (6f)
The dimethyl acetal 6fwas puriﬁed by silica gel chromatography
(pentane/acetone, 7:1) yielding a clear oil. 1HNMR (CDCl3) d: 3.30 (s,
6H), 4.51 (d, J¼47.0 Hz, 2H) and 7.66 (m, 4H). 13CNMR (CDCl3) d: 49.2
(2C), 82.9 (d, J¼178.2 Hz),100.2 (d, J¼20.6 Hz),124.1 (q, J¼272.3 Hz),
125.2 (q, J¼3.8 Hz, 2C), 127.8 (d, J¼0.9 Hz, 2C), 130.7 (q, J¼32.4 Hz)
and142.3 (m).19FNMR(CDCl3) d:63.2 (s) and230.3 (t, J¼47.0 Hz).
IR (KBr, cm1): 2949, 2839, 1620, 1411, 1327, 1166 and 845. MS (EI,
m/z, %):Mþdmissing, 221 (32), 219 (100),173 (47),159 (17),145 (31)
and 109 (24). HRMS (EI): not obtained, molecular ion unstable.
4.7.7. 4-(2-Fluoro-1,1-dimethoxyethyl)benzonitrile (6g)
The dimethyl acetal 6gwas puriﬁed by silica gel chromatography
(CHCl3) yielding colourless oil.
1H NMR (CDCl3): 3.27 (s, 6H), 4.48 (d,
J¼47.0 Hz, 2H) and7.67 (m, 4H).13CNMR(CDCl3) d: 49.4 (2C), 82.6 (d,
J¼178.2 Hz),100.2 (d, J¼19.8 Hz),112.6,118.8,128.4 (d, J¼1.0 Hz, 2C),
132.2 (2C) and 143.7. 19F NMR (CDCl3) d: 230.7 (t, J¼46.9 Hz). IR
(KBr, cm1): 2943, 2843, 2232, 1610, 1294, 1067 and 1034. MS (EI,
m/z, %): 209 (Mþ, 6),179 (43),178 (95),177 (76),176 (100),146 (8),130
(64) and 104 (5). HRMS (EI): 209.0855 (calcd 209.0852).
4.7.8. 1-(Fluoro-1,1-dimethoxyethyl)-4-nitrobenzene (6h)
The dimethyl acetal 6h was puriﬁed by silica gel chromatogra-
phy (CHCl3), yielding a with solid, mp 45–46 C. 1H NMR (CDCl3) d:
3.29 (s, 6H), 4.50 (d, J¼47.0 Hz, 2H), 7.72 (m, 2H) and 8.24 (m, 2H).
13C NMR (CDCl3) d: 49.4, 82.6 (d, J¼178.1 Hz), 100.2 (d, J¼20.8 Hz),
123.5 (2C), 128.7 (2C), 145.6 (d, J¼3.5 Hz) and 148.2. 19F NMR
(CDCl3) d: 230.8 (t, J¼46.9 Hz). IR (KBr, cm1): 3001, 2941, 1609,
1522, 1354, 1288, 1090 and 1071. MS (CI, CH4–Cl, m/z, %): 231
(Mþþ2, 11) and 230 (Mþþ1, 100). HRMS (CI, CH4–Cl): 230.0821
(calcd for C10H13FNO4
þ 230.0823).
4.7.9. 1-(Benzyloxy)-2-ﬂuoro-4-(2-ﬂuoro-1,1-
dimethoxyethyl)benzene (7b)
Compound 7b was isolated by silica gel chromatography (pen-
tane/EtOAc, 9:1) yielding a yellowish oil. 1H NMR (CDCl3) d: 3.29 (s,
6H), 4.47 (d, J¼47.4 Hz, 2H), 5.16 (s, 2H), 7.20 (m,1H), 7.29 (dd, J¼12.5
and 2.0 Hz, 1H) and 7.32–7.49 (m, 6H). 13C NMR (CDCl3) d: 49.4 (2C),
71.5, 83.3 (d, J¼178.2 Hz), 100.1 (dd, J¼20.8 and 1.7 Hz), 115.2 (d,
J¼2.0 Hz), 115.8 (d, J¼20.4 Hz), 123.3 (d, J¼2.9 Hz), 127.6 (2C), 128.4,
128.9 (2C),132.0 (d, J¼5.4 Hz),136.7,147.0 (d, J¼10.8 Hz) and 152.8 (d,
J¼245.9 Hz).19FNMR(CDCl3) d:134.3 (m)and229.3 (t, J¼46.9 Hz).
IR (KBr, cm1): 2943, 2836, 1601, 1515, 1276, 1072 and 1036. MS (EI,
m/z, %): 308 (Mþ, 31), 277 (58), 276 (53), 275 (88), 257 (53), 186 (27),
183 (18) and 91 (100). HRMS (EI): 308.1218 (calcd 308.1224).
4.7.10. trans-1,2,3-Tribenzoylcyclopropane (8c)35
Compound 8c was isolated after synthesis according to route C
by silica gel chromatography (CH2Cl2/MeOH, 100:1) and re-crys-
tallised from EtOAc yielding a white solid, mp 216–217 C (216–
217 C).52 1H NMR corresponds with that of Fuhrmann et al.36 13C
NMR (CDCl3) d: 30.4, 36.4 (2C), 128.5 (4C), 128.7 (4C), 128.8 (2C),
128.9 (2C), 133.6 (2C), 134.0, 136.5 (3C), 193.0 (2C) and 196.0. IR
(KBr, cm1): 3066, 3042, 2999, 1685, 1672, 1596, 1447, 1330, 1220
and 715. MS (EI, m/z, %): 354 (Mþ, 1), 249 (32), 233 (9), 105 (100)
and 77 (38). HRMS (EI): 354.1262 (calcd 354.1256).
4.7.11. trans-1,2,3-Tri(4-ﬂuorobenzoyl)cyclopropane (8d)
trans-1,2,3-Tri(4-ﬂuorobenzoyl)cyclopropane (8d) was isolated
after synthesis according to route C by silica gel chromatography
(CH2Cl2). White solid, mp 200–202 C. 1H NMR (CDCl3) d: 3.69 (d,
J¼5.6 Hz, 2H), 4.15 (t, J¼5.6 Hz, 1H), 7.09–7.13 (m, 4H), 7.18–7.22 (m,
2H), 8.01–8.03 (m, 4H) and 8.21–8.24 (m, 2H). 13C NMR (CDCl3) d:
30.3, 36.0 (2C), 116.0 (d, J¼22.0 Hz, 4C), 116.1 (d, J¼22 Hz, 2C), 131.4
(d, J¼9.5 Hz, 4C), 131.5 (d, J¼9.6 Hz, 2C), 132.8 (d, J¼2.7 Hz, 2C),
132.8 (d, J¼2.7 Hz), 166.1 (d, J¼256.1 Hz, 2C), 166.4 (d, J¼256.8 Hz),
191.3 (2C) and 194.1. IR (KBr, cm1): 3068, 3018, 1684, 1665, 1597,
1506, 1227, 1156 and 849. MS (EI, m/z, %): 408 (Mþ, 7), 409 (2), 286
(55), 285 (92), 269 (57), 124 (65), 123 (100) and 95 (90). HRMS (EI):
408.0977 (calcd 408.0973).
4.7.12. trans-1,2,3-Tri(4-bromobenzoyl)cyclopropane (8e)53
trans-1,2,3-Tri(4-bromobenzoyl)cyclopropane (8e) was isolated
after synthesis according to route C by silica gel chromatography
(CH2Cl2/MeOH,100:1). White solid, mp 198–200 C. 1H NMR (CDCl3)
d: 3.69 (d, J¼5.6 Hz, 2H), 4.13 (t, J¼5.6 Hz,1H), 7.59–7.61 (m,4H), 7.67–
7.70 (m, 2H), 7.85–7.87 (m, 4H) and 8.03–8.06 (m, 2H). 13C NMR
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(CDCl3) d: 30.3, 36.1 (2C),129.1 (2C),129.6,129.9 (4C),130.2 (2C),132.1
(4C),132.3 (2C),135.0 (3C),191.8 (2C) and194.6. IR (KBr, cm1): 3052,
1693,1670,1397,1317,1296,1204,1072and1008.MS (EI,m/z, %): 589/
591 (Mþ, 1), 406 (17), 185 (59), 183 (58), 157 (14), 155 (14) and 28
(100). HRMS (EI): 589.8529 (calcd for C24H15O3
79Br81Br2: 589.8551).
4.7.13. (3-(Bromomethyl)-3-(4-ﬂuorophenyl)oxiran-2-yl)(4-
ﬂuorophenyl)methanone (9d)
Compound9dwas isolated after synthesis according to routeCby
column chromatography (CH2Cl2) starting with 3d.
1H NMR (CDCl3)
d: 3.67 (d, J¼11.1 Hz,1H), 3.80 (d, J¼11.1 Hz,1H), 4.38 (s,1H), 7.11–7.23
(m, 4H), 7.55–7.60 (m, 2H) and 8.04–8.09 (m, 2H). 13CNMR (CDCl3) d:
31.4, 64.8, 116.0 (d, J¼21.8 Hz, 2C), 116.4 (d, J¼22.1 Hz, 2C), 128.3 (d,
J¼8.4 Hz, 2C), 131.4 (d, J¼9.6 Hz, 2C), 132.2 (d, J¼3.1 Hz), 132.4 (d,
J¼3.3 Hz), 163.1 (d, J¼248.8 Hz), 166.5 (d, J¼257.3 Hz) and 190.2.
4.7.14. 1-(2-(4-(Benzyloxy)phenyl)-2-oxoethyl)pyridinium
bromide (10b)
1-(2-(4-(Benzyloxy)phenyl)-2-oxoethyl)pyridinium bromide
precipitated from the reactionmixture uponﬂuorinationof3busing
TBABF in the presence of pyridine. It was also synthesised from 3b.
1-(4-Benzyloxyphenyl)-2-bromoethanone (3b) (1.5 g, 4.9 mmol)
dissolved inTHF (25 mL)was treatedwithpyridine (0.93 g,12 mmol)
and stirred at 45 C for 5 h. THFwas removed and the residuewas re-
crystallised from ethanol utilising diethyl ether as anti solvent,
yielding 1.2 g (64%) of a slight yellowish solid, mp 198–200 C. 1H
NMR(DMSO) d: 5.29 (s, 2H), 6.44 (s, 2H), 7.26–7.28 (m, 2H), 7.36–7.50
(m, 5H), 8.03–8.05 (m, 2H), 8.27 (t, 2H), 8.73 (t, 1H) and 8.99 (d, 2H).
13C NMR (CDCl3) d: 66.5, 70.3,115.9 (2C),127.1 (2C),128.4 (2C),128.7,
129.1 (2C), 131.3 (2C), 136.8, 146.9 (2C), 163.9 and 189.5. IR (KBr,
cm1): 3028, 2939,1690,1670,1636,1599,1492,1240,1173, 990, 834,
752 and 686. HRMS (ESI): 304.1331 (calcd for C20H18NO2
þ: 304.1332).
4.7.15. 1-(2-Oxo-2-phenylethyl)pyridinium bromide (10c)54
Compound 10c was isolated as described for 10b. 1H and 13C
NMR were in accordance with Szwajca et al.54
4.7.16. 2-(4-(Benzyloxy)phenyl)-N,N,N-triethyl-2-
oxoethanaminium bromide (11b)
The identity of 11b was conﬁrmed by synthesis of a reference
sample. 1-(4-Benzyloxyphenyl)-2-bromoethanone (3b) (1.5 g,
4.9 mmol) in THF (25 mL) was mixed with triethylamine (1.0 g,
10 mmol) and heated at 50 C. After 5 h the reaction mixture was
cooled to room temperature and diethyl ether (25 mL) was added.
The solid material obtained after ﬁltration was re-crystallised from
isopropanol, yielding 1.51 g (75%) of a white solid, mp 162–164 C.
1H NMR (CDCl3) d: 1.41 (t, J¼7.3 Hz, 9H), 3.87 (q, J¼7.3 Hz, 6H), 5.13
(s, 2H), 5.45 (s, 2H), 7.05–7.07 (m, 2H), 7.35–7.40 (m, 5H) and 8.34–
8.36 (m, 2H). 13C NMR (CDCl3) d: 8.4 (3C), 54.6 (3C), 59.9, 70.2, 115.2
(2C), 126.7, 127.4 (2C), 128.2, 128.6 (2C), 131.6 (2C), 135.7, 164.2 and
189.5. IR (KBr, cm1): 2974, 2913, 1687, 1601, 1576, 1456, 1237, 1006,
833 and 755. HRMS (ESI): 326.2116 (calcd for C21H28NO2
þ 326.2115).
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diazoniabicyclo[2.2.2]octane bis-
(tetraﬂuoroborate)
a-Fluoroacetophenone
Dimethyl acetal
a b s t r a c t
A two-step, one-pot microwave (MW) assisted ﬂuorination of 1-arylethanones to their corresponding
1-aryl-2-ﬂuoroethanones has been developed. The ﬁrst step utilises Selectﬂuor as a ﬂuorinating agent in
methanol forming 1-aryl-2-ﬂuoroethanones and their corresponding dimethyl acetals. In the second step,
water is added and Selectﬂuor acts as a Lewis acid in the hydrolytic cleavage of the dimethyl acetals.
Compared to the thermal synthesis, the MWassisted method leads to a reduction in reaction time both in
theﬂuorination and for the dimethyl acetal cleavage.Moreover, the one-pot procedure reduces reagent and
solvent consumption. Themethod is best suited for the preparation of 1-aryl-2-ﬂuoroethanones containing
substituents that deactivates electrophilic aromatic substitution, however highly electron deﬁcient ke-
tones such as 1-(3,5-dinitrophenyl)ethanone reacts more slowly. Reactions using electron rich aromatic
ketones had a low regioselectivity, and also produced ﬂuoroaromatic products.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Microwave irradiation (MW) is a powerful and easily control-
lable heating source. For a number of reactions, especially those
involving polar transition states, signiﬁcant rate acceleration can be
achieved compared to conventional heating.1–4
The use of microwaves has also been applied in various forms of
ﬂuorination.5–13 Selectﬂuor (F-TEDA-BF4) is a relatively stable
electrophilic ﬂuorinating agent,14 andmicrowave assisted reactions
on 1,3-dicarbonyl compounds,13 aromatic compounds,5 and 1-aryl-
1-nitromethanes,11 have been reported. Moreover, F-TEDA-BF4 has
also been applied as a Lewis acid in MW assisted synthesis.15
a-Fluoroacetophenones can be synthesised by nucleophilic
displacement,16–21 electrophilic ﬂuorination of ketones, imines or
enamines,22–30 Friedel/Crafts acylation,31,32 coupling chemistry,33
and reaction via diazo ketones.34,35 However, some of these
methods have drawbacks due to the use of hazardous and toxic
chemicals or the involvement of unstable intermediate compounds.
We have recently compared three methods using conventional
heating for the preparation of a-ﬂuoroacetophenones.36 A simple
method using only F-TEDA-BF4 in methanol enabled acetophe-
nones to be ﬂuorinated in decent yields. The method consists of
two steps; ﬂuorination yielding the target a-ﬂuoroketone, 3, its
dimethyl acetal, 2, and subsequent hydrolysis to convert 2 into 3,
Scheme 1.
Although being very simple, an obvious drawback of the ther-
mal method was the prolonged reaction times, especially for sub-
strates containing electron withdrawing substituents. Moreover,
several of the dimethyl acetals, 2, required heating to reﬂux in the
presence of triﬂuoroacetic acid for several hours for complete
conversion to 3.
To improve the usefulness of the method, we have investigated
the use of microwaves to increase the reaction rates and yields in
conversion of 1-arylethanones, 1 to the corresponding 1-aryl-2-
ﬂuoroethanones, 3.
O
R
O
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OMeMeOF-TEDA-BF4
MEOH
D
H+
1 2 3
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Scheme 1. Fluorination of acetophenones using F-TEDA-BF4 in methanol.
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2. Results and discussion
2.1. MW assisted ﬂuorination: solvent, effect (W) and
reaction time
The reaction rate in the thermal ﬂuorination of acetophenones
using F-TEDA-BF4 in MeOH was very dependant on the electronic
properties of the substituents.36 Therefore, initial experiments
using MW as a heating source were performed using 1-(4-bromo-
phenyl)ethanone (1e), which was intermediate with respect to
electronic character. An Anton Paar 3000 microwave instrument
equipped with a magnetic stirrer device was used. The reactions
were performed in sealed Teﬂon tubes.
Running the reaction at 120 Wusing two equivalents of F-TEDA-
BF4 in methanol revealed that ﬂuorination took place. However,
several other ﬂuorinated compounds and undeﬁned substances
were present in the discoloured reaction mixture. 1H NMR spec-
troscopywas used for the identiﬁcation of reaction components. The
1H NMR chemical shifts of 1–3e (Scheme 2) were known from
a previous study.36 The presence of 1-(4-bromophenyl)-2,2-
diﬂuoroethanone (4e) could be conﬁrmed by the characteristic
triplet at 6.24 ppm (JHF¼53.5 Hz). In addition, a triplet with com-
parable coupling constant was observed at 5.82 ppm (JHF¼55.3 Hz).
Analysis after hydrolytic treatment revealed that this substancewas
converted to 4e, and was therefore assigned as the dimethyl acetal,
5e. Trace amounts of 1-(4-bromophenyl)-2-chloroethanone (6e),37
was also observed. It is currently unclear if formation of 6e is due to
impurities in F-TEDA-BF4 or decomposition reactions leading to
electrophilic chlorine sources. A chlorinated by-product has pre-
viously been reported inﬂuorinationof thiazoleusing F-TEDA-BF4.
38
O
Br
1e
F-TEDA-BF4 O
Br
F
3e
Br
F
MeOH
Br
OMeMeO
O
Br
OMeMeO
4e
2e 5e
F F
F
F
O
Br
Cl
6e
MW
Scheme 2. Reaction products after ﬂuorination of 1e in methanol using F-TEDA-BF4.
Follow-up experiments revealed a positive effect both on con-
version andcolourof the reactionmixturewhen the effectwas in the
range of 80–100 W. Having found a suitable effect (W), the choice of
reactionmediumwas reevaluated. If possible, it would be beneﬁcial
to avoid the formation of the intermediate dimethyl acetal, 2e.
Moreover, a change in solvent might affect conversion rates due to
temperature effects. The ﬂuorinationwas performed in six different
solvents and reacted for 60 min at 80 W. The degree of conversion
and product distribution after ﬂuorination are given in Table 1.
The degree of conversion was highly dependant on the solvent
used. No ﬂuorination was observed in t-BuOH or i-PrOH, while
reactions in water and ethanol gave 8 and 12% conversion re-
spectively. The reaction in acetonitrile gave a 36% conversion,
whereas 97% was obtained using methanol as reaction solvent. In
addition to the a-ﬂuoroketone, 3e, and its dimethyl acetal, 2e, the
diﬂuoro-compounds 4e and 5e were observed. Although, aliphatic
diﬂuorination appeared in methanol, the reaction proceeded much
faster than in any of the other solvents tested. One could speculate
that methanol shifts the keto/enol equilibrium more to the enol
side and that this is the reason for the solvent dependant rate
acceleration.
Further experiments were undertaken to study how the effect
and reaction time inﬂuenced the degree of conversion and product
distribution using 1e as substrate. The effect was varied between 60
and 100W, and the reaction time was varied between 60 and
100 min. The results are summarised in Table 2.
The degree of conversion measured by amount of residual 1-(4-
bromophenyl)ethanone (1e) versus ﬂuorinated products depended
on both effect (W) and reaction time. Full conversion was not
obtained at 60 W (Entries 1 and 2), due to insufﬁcient reaction time.
The incomplete conversion at 100 Wwas probably due to a thermal
decomposition of F-TEDA-BF4 as it was noted that the reaction
mixture turned black. At 80 W, full conversion was obtained
without discolouration of the reaction mixture. As full conversion
and the absence of coloured by-products allowed for easier product
puriﬁcation, 80 Wwas selected as the preferred irradiation effect in
the ﬂuorinations.
To maximise the yield of the a-ﬂuoroketone 3e, its dimethyl
acetal, 2e needed to be hydrolysed. F-TEDA-BF4 has previously
been used as a Lewis acid.15 We therefore tested if cleavage of the
dimethyl acetal 2e could be performed by simply adding water to
the crude reaction mixture followed by MW irradiation. This
proved to be the case, and 2e was readily cleaved by addition of
water and irradiating the reaction mixture at 80 W for 20 min.
This enabled the preparation of 3e using a one-pot two-step
procedure.
2.2. Scope and limitations: substrate structure
To investigate the scope and limitations of the method with
respect to substrate structure, a series of 1-arylethanones, 1a–l,
were ﬂuorinated, see Scheme 3.
Both substrates with electron donating and withdrawing sub-
stituents were investigated. Compound 1k was included in the
study to investigate if one ﬂuorine atom was sufﬁcient to reduce
ring ﬂuorination as compared to 1a. Compound 1l was used to
investigate the effects of two strong electron withdrawing groups
on the ﬂuorination and the hydrolysis steps. Both steps were per-
formed at 80 W, and the reaction time was varied to obtain high
conversions. Table 3 summarises the conversions and product
distributions after ﬂuorination, the conversions obtained in the
hydrolytic step, and the yields for 3a–l. The optimised reaction
Table 1
The conversion (conv.) and product distribution after ﬂuorination of 1e in different
solvents at 80 W for 60 min
Solvent Conv.a (%) 1e (%) 2e (%) 3e (%) 4e (%) 5e (%) 6e (%)
Acetonitrile 36 64 NA 34 0 0 2
t-BuOH 0 100 d 0 0 d 0
i-PrOH 0 100 d 0 0 d 0
EtOH 12 88 b 11 0 a 1
MeOH 97 3 30 54 11 5 1
Water 8 92 NA 6 d d 2
a Conversion was measured by 1H NMR spectroscopy.
b Ethyl acetals were not observed by 1H NMR spectroscopy.
Table 2
Conversion (conv.) and product distribution after ﬂuorination of 1e in MeOH varying
MW effect (W) and reaction time
Entry Effect (W) Time (min) Conv.a (%) 3eþ2e (%) 4eþ5e (%)
1 60 60 65 64 0
2 60 100 91 87 3
3 80 80 >99 87 11
4 100 60 97 89 7
5 100 100 98 85 14
a Conversion was measured by 1H NMR spectroscopy.
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times at 80 W for the two steps are given in Table 4 and the
structures of the by-products are shown in Figure 1.
The MW assisted ﬂuorination of the electron rich 1-aryletha-
nones 1a–b (Table 3, Entries 1–2) gave low yields of the target
products 3a–b. This was due to the formation of additional ring
ﬂuorinated by-products, 3k and 3m, high amounts of a,a-diﬂuor-
oketones, 4a–b and their corresponding dimethyl acetals, 5a–b.
Especially difﬁcult was ﬂuorination of 1-acetonaphthone (1j)
(Entry 3), which led to at least three different a-ﬂuoroketones, their
corresponding dimethyl acetals and a,a-diﬂuorides. 1H and 19F
NMR spectroscopic analysis of the crude product mixture
suggested that ring ﬂuorination had taken place. These three sub-
strates exemplify limitations of the method in general. Due to the
complexity of the reaction mixtures, puriﬁcations were not
attempted.
In terms of susceptibility towards aromatic ﬂuorination, 1-(3-
ﬂuoro-4-methoxyphenyl)ethanone (1k), (Entry 4), represents
a borderline case. As compared to ﬂuorination of 1a, the extra m-
ﬂuorine in 1k suppressed ring ﬂuorination, and only 5% of 3n and
4nwas observed. Aliphatic diﬂuorination leading to compound 4k
and 5k (19%) was however still signiﬁcant, reducing the isolated
yield to 59%.
Fluorination of 1c and 1d and subsequent hydrolysis gave 65
and 74% isolated yield of 3c and 3d respectively. In the case of 1c,
unidentiﬁed by-products were detected, explaining the lower yield.
Table 3
MW assisted ﬂuorination and hydrolysis using F-TEDA-BF4: conversion (conv.) and product distribution after ﬂuorination, conversion after hydrolysis and yields of 3a–l.
Isolated yields are reported unless otherwise stated. For reaction times see Table 4
Entry Substrate Fluorination Hydrolysis
Conv.a (%) 2 (%) 3 (%) 4þ5 (%) Others (%) Conv. (%) Yield (%) Product
1 p-MeO (1a) >99 11 44 18 27 (2kþ3k) >99 46b 3a
2 p-BnO (1b) >99 12 46 18 24 (2mþ3m) >99 46b 3b
3 1-Naphthyl (1j) 90 6 40 nd Multiplec >99 38b 3j
4 m-F, p-OMe (1k) >99 23 53 19 5 (2nþ3n) >99 59 3k
5 H (1c) >99 26 61 12 1 (6c) >99 65 3c
6 p-F (1d) >99 23 67 9 1 (6d) >99 74 3d
7 p-Br (1e) >99 24 63 11 1 (6e) >99 81 3e
8 p-CF3 (1f) >99 41 52 6 1 (6f) >99 69 3f
9 p-CN (1g) 99 30 62 6 1 (6g) >99 86 3g
10 p-NO2 (1h) >99 70 24 5 <1 (6h) >99 82 3h
11 m-NO2 (1i) 98 58 36 4 1 (6i) >99 72 3i
12 3,5-di-NO2 (1l) 94 88 3 3 3 (7l) 97 41 3l
a Conversion was measured by 1H NMR spectroscopy.
b Reaction yield of a-ﬂuoroketone as quantiﬁed by 1H NMR spectroscopy using 1-(4-methoxyphenyl)ethanone as standard.
c Not identiﬁed.
Table 4
Comparison of the MW (80 W) and thermal process for the preparation of 3a–l (reaction time and yield)
Entry Substrate MW Thermal
Rx. time
ﬂuorination (min)
Rx. time
hydrolysis (min)
Yield (%) Rx. time
ﬂuorination (h)
Rx. time
hydrolysis (h)
Yield (%)
1 p-MeO (1a) 60 15 46a 48 1 (rt) 67b
2 p-BnO (1b) 60 15 46a 72 1 (rt) 58b
3 1-Naphthyl (1j) 60 15 38a 144 1 (rt) 50a
4 m-F, p-OMe (1k) 60 15 59 96 3.5 (rt) 67
5 H (1c) 60 15 65 96 3.5 (rt) 66b
6 p-F (1d) 60 20 74 96 3.5 (rt) 25b
7 p-Br (1e) 80 15 81 125 24 (rt) 77b
8 p-CF3 (1f) 85 25 69 144 20 (reﬂux) 73
b
9 p-CN (1g) 80 30 86 192 20 (reﬂux) 64b
10 p-NO2 (1h) 50 30 82 261 20 (reﬂux) 70
b
11 m-NO2 (1i) 60 30 72 336 20 (reﬂux) 73
12 3,5-di-NO2 (1l) 120 30 41 500
c 336d (reﬂux) 39
a Reaction yield quantiﬁed by 1H NMR spectroscopy using 1-(4-methoxyphenyl)ethanone as standard.
b Results from previous study.36
c 82% conv.
d 63% conv.
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In the ﬂuorination of 1d–i (Entries 5–11), aromatic ﬂuorination
was not observed. Moreover, moving down Table 3, as the elec-
tronic withdrawing character of the substituents increases, the
level of the a,a-diﬂuorides, 4 and 5 observed was also reduced.
Higher yields were experienced, and the products could be
obtained in 69–86% isolated yield. Electron withdrawing groups on
the aromatic ring increased both the amounts and the stability of
the dimethyl acetals. As a consequence, the reaction time in the
hydrolytic step had to be increased from 15 to 30 min.
Another limitation to the presented method is exempliﬁed by
ﬂuorination of 3,5-dinitroacetophenone (1l), (Entry 12). This sub-
strate required prolonged reaction time, however, a 94% conversion
was obtained by applying 80W for 2 h.
The main product of the reaction was 2l (88%) and formation of
the dimethyl acetal 7l,39 was also noticed (Scheme 4). Such side
products were not observed in ﬂuorination of the other substrates.
The major challenge in the synthesis of 3l by this process resides in
the hydrolytic step. Somewhat surprisingly, ﬂuorination continued
during hydrolysis, resulting in the formation of three diﬂuorinated
compounds, including 4l, 5l and a unknown compound (d: 5.79,
JHF¼55.1 Hz).
The reaction progress for 1l can be rationalised by referring to
Scheme 4. When acetophenones are substituted with electron
withdrawing groups, the ketone/dimethyl acetal equilibrium po-
sition is shifted towards the dimethyl acetal side.40 This is espe-
cially pronounced in the case of 1l due to the presence of two nitro
groups. It can be assumed that ﬂuorination takes place via the enol
form of the ketone, and due to the limited amount of the ketone 1l,
and thereby its enol, a reduction in the reaction rate is experienced.
Once formed, the a-ﬂuoroketone, 3l has an even higher tendency to
react with methanol, forming 2l. As evident from Table 3, the
amount of 3l in the reaction is very low, and further ﬂuorination is
therefore difﬁcult. Whenwater is added, the equilibrium position is
shifted towards 3l and its enol form, enabling ﬂuorination to con-
tinue. The reasonwhy a,a-diﬂuorination during hydrolysis appears
only for 3l is not understood.
Attempts to ﬂuorinate 1l in water (80 W, 60 min) gave a com-
plex mixture and a conversion of approximately 30%. The domi-
nating products were 3l, 4l and the previous mentioned compound
with shift value of 5.79 ppm.
2.3. Comparison of the MW and thermal ﬂuorination
methods
A comparison of the MW and the thermal process, with respect
to reaction times and yields are shown in Table 4.
The MW assisted reactions beneﬁt from shorter reaction times;
ﬂuorination proceeds in 60–120 min, whereas hydrolysis could be
performed in 15–30 min. The corresponding thermal ﬂuorinations
required several days or weeks for complete conversion. The MW
assisted method was inferior to the thermal reaction for the se-
lective aliphatic ﬂuorination of electron rich aromatic ketones
(Entries 1–4), due to the formation of high levels of a,a-
diﬂuoroketones.
Compared to the thermal process, higher or comparable yields
were obtained in the MW assisted ﬂuorination and hydrolysis
starting with 1c–i. The largest difference in yield when comparing
the two methods is seen in preparation of 3d and 3g.
The dimethyl acetal 2d was previously found to be highly vol-
atile, and this limited the isolated yield of the reported thermal
reaction.36 The volatility is not a problem in the MW process, as the
isolation of 2d is not required. The lower yield of 3g in the thermal
process is probably due to side reactions at the cyano-group, taking
place during the prolonged reaction time.
The MW assisted ﬂuorination of 1l was hampered by a low
reaction rate, and a,a-diﬂuoride formation during hydrolysis. This
gave 41% of 3l. By comparison, the thermal process from 1l also
gave a moderate 39% isolated yield after a total of 5 weeks reaction
time.
The reaction rate in the thermal ﬂuorinationwas correlatedwith
the electronic properties of the substituents. For the MW assisted
ﬂuorination, an increase in reaction time was needed for 1e–1g,
compared to 1a–d. However, this was not seen for the nitro-de-
rivatives, 1h–i. Nitro groups are known to be efﬁcient absorbers of
MW energy, and the observation suggests that speciﬁc microwave
effects are operating.
The MW process gave a higher ketone to dimethyl acetal ratio
and higher amounts of a,a-diﬂuorinated compounds than was the
case in the thermal process. It is assumed that ﬂuorination by
F-TEDA-BF4 takes place on the enol form of the ketone, (Scheme 4).
As less a-ﬂuoroketones are trapped as dimethyl acetals in the MW
process, they are more available for further ﬂuorination. This could
explain the elevated levels of the a,a-diﬂuoroketones in the
microwave process as compared to the thermal method.
3. Conclusion
A one-pot, two-step MW assisted ﬂuorination of 1-aryletha-
nones has been developed. The main beneﬁt of the MW strategy is
a reduction of the reaction time from several days to 1.5–2 h.
Moreover, a simpliﬁcation of the dimethyl acetal cleavage step has
been developed, reducing the number of operations, chemical
consumption and time.
The method has its main advantage in the ﬂuorination of
moderately deactivated acetophenones 1c–i, leading to the pro-
duction of the 1-aryl-2-ﬂuoroethanones in 65–86% isolated yield.
Electron rich 1-arylethanones are not selectively ﬂuorinated in
the side chain, but also forms ﬂuoroaromatic derivatives. 1-(3-
Fluoro-4-methoxyphenyl)ethanone (1k) represents a borderline
case, where aromatic ﬂuorination is starting to be suppressed.
Another limitation to the ﬂuorination method is in the reaction
of 1-arylethanones having two strongly electron withdrawing
substituents. Although the ﬂuorination takes place at a reduced
rate, the hydrolysis led to the formation of aliphatic a,a-diﬂuori-
nated compounds, reducing the yield signiﬁcantly.
4. Experimental
4.1. General
The 1-arylethanones 1a, 1g–h, 1l, and 1,3-dichloro-5,5-dime-
thylhydantoin were purchased from Fluka. Selectﬂuor (F-TEDA-
BF4), 1c–f, 1j–k, and N-ﬂuorobisbenzenesulfonimide were from
Aldrich. 1-(3-Nitrophenyl)ethanone (1i) was from Acros Organics,
while 1-(4-bromophenyl)-2-chloroethanone (6e) was from Sigma–
Aldrich. Methanol was from VWR (HPLC grade, 0.03% water). Col-
umn chromatography was performed using silica gel 60A from
Fluka, pore size 40–63 mm. 1-(4-(Benzyloxy)phenyl)ethanone (1b)
was prepared from 4-hydroxyacetophenone using benzyl chloride
and potassium carbonate in N,N-dimethylformamide as solvent.
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4.2. Analyses
NMR spectra were recorded with Bruker Avance DPX 400 oper-
ating at 400 MHz for 1H, 375 MHz for 19Fand 100 MHz for 13C. For 1H
and 13CNMRchemical shifts are inppmrel toTMS,while for 19FNMR
the shift values are relative to hexaﬂuorobenzene. Coupling con-
stants are in hertz.MS (EI/70 eV) FinniganMAT95XL. Accuratemass
determination (ESI) was performed on an Agilent G1969 TOF MS
instrument equipped with a dual electrospray ion source. Samples
were injected into the MS using an Agilent 1100 series HPLC and
analysis was performed as a direct injection analysis without any
chromatography. FTIR spectra were recorded on a Thermo Nicolet
Avatar 330 infrared spectrophotometer. All melting points are un-
corrected and measured by a Bu¨chi melting point instrument. The
microwave experiments were performed using an Anton Paar 3000
instrument with a magnetic stirrer device.
4.3. General procedure MW assisted ﬂuorination
To a Teﬂon reaction tube containing a magnetic stirrer bar 1-
arylethanone (2.21 mmol), Selectﬂuor (4.42 mmol) andmethanol
(5 mL) were added. The reaction chamber was sealed and treated at
80 W for the times speciﬁed in Table 4. After cooling, water (5 mL)
was added and the mixture was hydrolysed at 80 W with the re-
action times speciﬁed in Table 4. After cooling, water (15 mL) was
added and the mixture was extracted with CH2Cl2 (415 mL). The
dichloromethane layer was then washed with brine (15 mL), dried
over Na2SO4 and evaporated to dryness. The 1-aryl-2-ﬂuo-
roethanones were puriﬁed by the methods speciﬁed for each single
compound.
4.4. Thermal ﬂuorination in methanol
Thermal ﬂuorination of the 1-arylethanones (1 equiv) in MeOH
using F-TEDA-BF4 (2 equivalents) was performed as described
previously.36
4.5. 1-Aryl-2-ﬂuoroethanones
4.5.1. 2-Fluoro-1-(4-methoxyphenyl)ethanone (3a)22,36. The iden-
tity of compound 3a was veriﬁed by comparison of 1H NMR shifts
with a previous study.36 1H NMR (CDCl3) d: 3.88 (s, 3H), 5.45 (d,
J¼47.2, 2H), 6.96 (m, 2H), 7.89 (m, 2H).
4.5.2. 1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethanone (3b)36. The iden-
tity of compound 3b was veriﬁed by comparison of 1H NMR shifts
with a previous study.36 1H NMR (CDCl3) d: 5.14 (s, 2H), 5.46 (d,
J¼47.0, 2H), 7.02–4.04 (m, 2H), 7.36–7.43 (m, 5H) and 7.87–7.89
(m, 2H).
4.5.3. 2-Fluoro-1-phenylethanone (3c)19,36. Compound 3c was pre-
pared as described in Section 4.3 starting with 1c (265 mg,
2.21 mmol). Fluorinationwas performed for 60 min, and hydrolysis
was done in 15 min. Puriﬁcation by silica gel chromatography
(pentane/EtOAc, 85/15) gave 198 mg (1.43 mmol, 65%) of 3c as
a colourless oil. 1H NMR (CDCl3) d: 5.53 (d, J¼47.0, 2H), 7.50 (m, 2H),
7.63 (m, 1H), 7.90 (m, 2H).
4.5.4. 2-Fluoro-1-(4-ﬂuorophenylethanone) (3d)25,36. Compound 3d
was prepared as described in Section 4.3 starting with 1d (305 mg,
2.21 mmol). Fluorinationwas performed for 60 min, and hydrolysis
was done in 20 min. Puriﬁcation by silica gel chromatography
(pentane/EtOAc, 85/15) gave 255 mg (1.63 mmol, 74%) of 3d as
a white solid mp 49–51 C. 1H NMR (CDCl3) d: 5.49 (d, J¼46.9, 2H),
7.15–7.21 (m, 2H) and 7.83–7.98 (m, 2H).
4.5.5. 1-(4-Bromophenyl)-2-ﬂuoroethanone (3e)34,36. Compound 3e
was prepared as described in Section 4.3 starting with 1e (440 mg,
2.21 mmol). Fluorinationwas performed for 80 min, and hydrolysis
was done in 15 min. Puriﬁcation by silica gel chromatography
(pentane/EtOAc, 85/15) gave 387 mg (1.78 mmol, 81%) of 3e as
a white solid mp 72–73 C. 1H NMR (CDCl3) d: 5.46 (d, J¼46.9, 2H),
7.64 (m, 2H) and 7.77 (m, 2H).
4.5.6. 2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethanone (3f)36. Compound
3fwas prepared as described in Section 4.3 starting with 1f (415 mg,
2.21 mmol). Fluorination was performed for 85min, and hydrolysis
wasdone in25min.Puriﬁcationbysilicagel chromatography (CH2Cl2)
gave 312 mg (1.52mmol, 69%) of 3f as a white solid mp 36–37 C. 1H
NMR (CDCl3) d: 5.52 (d, J¼46.8, 2H), 7.77 (m, 2H), 8.03 (m, 2H).
4.5.7. 4-(2-Fluoroacetyl)benzonitrile (3g)36. Compound 3g was
prepared as described in Section 4.3 starting with 1g (321 mg,
2.21 mmol), Fluorinationwas performed for 80 min, and hydrolysis
was done in 30 min. Puriﬁcation by silica gel chromatography
(pentane/acetone, 7/3) gave 312 mg (1.90 mmol, 86%) of 3g as
a white solid mp 104–105 C. 1H NMR (CDCl3) d: 5.51 (d, J¼46.8,
2H), 7.81 (m, 2H) and 8.02 (m, 2H).
4.5.8. 2-Fluoro-1-(4-nitrophenyl)ethanone (3h)36. Compound 3h
was prepared as described in Section 4.3 starting with 1h (365 mg,
2.21 mmol), Fluorinationwas performed for 50 min, and hydrolysis
was done in 30 min. Puriﬁcation by silica gel chromatography
(pentane/acetone, 7/3) gave 333 mg (1.81 mmol, 82%) of 3h as
a white solid mp 96–97 C. 1H NMR (CDCl3) d: 5.55 (d, J¼46.8, 2H),
8.11 (m, 2H) and 8.35 (m, 2H).
4.5.9. 2-Fluoro-1-(3-nitrophenyl)ethanone (3i)41. Compound 3h
was prepared as described in Section 4.3 starting with 1h (370 mg,
2.21 mmol), Fluorination was performed for 60 min, and hydrolysis
was done in 30 min. Puriﬁcation by crystallisation from ethanol gave
293 mg (1.60 mmol, 72%) of3h as awhite solidmp83–84 C.1HNMR
(CDCl3) d: 5.55 (d, J¼46.7, 2H), 7.72–7.77 (m, 1H), 8.27–8.29 (m, 1H),
8.48–8.51 (m, 1H), 8.75–8.76 (m, 1H). 13C NMR (CDCl3) d: 83.9 (d,
J¼184.7),123.1 (d, J¼3.9),128.3,130.3,133.8 (d, J¼3.5),135.0 (d, J¼1.4),
148.5,192.0 (d, J¼17.0).19FNMR (CDCl3) d:229.7 (t, J¼46.8). IR (neat,
cm1): 3101, 1712, 1630, 1537, 1438, 1239, 1080, 1021, 901, 730.
4.5.10. 2-Fluoro-1-(naphthalen-1-yl)ethanone (3j)42. For identiﬁca-
tion purpose, compound 3j was synthesised from 1j (3.64 g,
21 mmol) via the trimethylsilyl enol ether as described by Fuglseth
etal.36 Theproductwaspuriﬁedbysilica gel columnchromatography
(CH2Cl2) giving anoil. A following crystallisation fromEtOAc/pentane
yielded 1.10 g (5.83 mmol, 29%) of awhite solidmp44–45 C. The 1H,
13C and 19F NMR spectra correspondedwith that reported.42 1HNMR
(CDCl3) d: 5.60 (d, J¼47.2, 2H), 7.50–7.61 (m, 2H), 7.65 (m,1H), 7.80 (m,
1H), 7.89 (m, 1H), 8.05 (d, J¼8.3, 1H), 8.71 (m, 1H).
4.5.11. 2-Fluoro-1-(3-ﬂuoro-4-methoxyphenyl)ethanone (3k)22,36.
Compound 3k was prepared as described in Section 4.3 starting
with 1k (370 mg, 2.21 mmol). Fluorination was performed
for 60 min, and hydrolysis was done in 15 min. Puriﬁcation by
silica gel column chromatography (pentane/EtOAc, 5/2) gave
241 mg (1.30 mmol, 59%) of 3k as a white solid mp 84–85 C. 1H
NMR (CDCl3) d: 3.97 (s, 3H), 5.44 (d, J¼47.0, 2H), 7.04 (m, 1H), 7.70
(m, 2H).
4.5.12. 1-(3,5-Dinitrophenyl)-2-ﬂuoroethanone (3l). Compound 3l
was prepared as described in Section 4.3 starting with 1l (464 mg,
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2.21 mmol). Fluorination was performed for 120 min, and hydro-
lysis was done in 30 min. Compound 3l was puriﬁed by crystal-
lisation from chloroform giving 204 mg (0.89 mmol, 41%) of awhite
solid, mp 111–112 C. 1H NMR (CDCl3) d: 5.55 (d, J¼47.0, 2H), 9.04–
9.05 (m, 2H), 9.28–9.30 (m, 1H). 13C NMR (CDCl3) d: 84.3 (d,
J¼186.9), 123.0, 128.3 (d, J¼4.9, 2C), 136.5 (d, J¼2.0), 149.0 (2C),
190.7 (d, J¼18.4). 19F NMR (CDCl3) d:227.3 (t, J¼46.9). HRMS (ESI):
227.0106 (calcd 227.0110, MHþ). IR (neat, cm1): 3116, 3084, 2942,
1709, 1612, 1525, 1349, 1230, 1074, 975, 805, 736.
4.5.13. 1-(3,5-Diﬂuoro-4-methoxyphenyl)-2-ﬂuoroethanone
(3n). Compound 3n was isolated after a thermal ﬂuorination pro-
tocol as described previously,36 starting with 1k (1.49 mg,
8.84 mmol). Fluorination was performed for 96 h., while hydrolysis
in TFA/water/CHCl3 was performed for 3.5 h. The by-product, 3n,
was isolated by silica gel chromatography (pentane/EtOAc, 7/3)
giving 14 mg (0.07 mmol, 1%) of a colourless oil. 1H NMR (CDCl3) d:
4.14 (t, J¼1.8, 3H), 5.40 (d, J¼46.9, 2H), 7.47–7.52 (m, 2H). 13C NMR
(CDCl3) d: 61.7 (t, J¼4.2), 83.6 (d, J¼184.4), 112.6 (ddd, J¼3.9, 7.4,
16.6, 2C), 117.2 (d, J¼1.4), 141.6, 154.9 (dd, J¼5.7, 256.4, 2C), 190.7 (d,
J¼16.0). 19F NMR (CDCl3) d: 127.2 (d, J¼8.0), 229.2 (t, J¼46.9).
HRMS (ESI): 205.0473 (calcd 205.0471, MþHþ). IR (neat, cm1):
2946, 2847, 1708, 1517, 1432, 1330, 1081, 1040, 992, 707.
4.6. 1-Aryl-1,1-dimethoxyethylﬂuorids (2)
Seven 1-aryl-2,2-dimethoxyethylﬂuorides were characterised in
the previous study.36 The identity of the dimethyl acetals 2d and 2n
was assumed from their 1H NMR shifts and coupling constants, and
their conversion to the corresponding 1-aryl-2-ﬂuoroethanones by
hydrolysis.
4.6.1. 1-(2-Fluoro-1,1-dimethoxyethyl)-3-nitrobenzene (2i). Compound
2i was synthesised from 1i (370 mg, 2.21 mmol) by MW ﬂuorina-
tion at 80 W for 60 min, omitting the hydrolytic step. Puriﬁcation
by silica gel chromatography (pentane/acetone, 7/3), gave 137 mg
(0.60 mmol, 27%) of a slightly yellowish solid, mp 57–59 C. 1H NMR
(CDCl3) d: 3.30 (s, 6H), 4.52 (d, J¼47.0, 2H), 7.58 (m, 1H), 7.86 (m,
1H), 8.22 (m, 1H) and 8.42 (m, 1H). 13C NMR (CDCl3) d: 49.3 (2C),
82.5 (d, J¼178.4), 99.9 (d, J¼20.8),122.8 (d, J¼1.1),123.6,129.3,133.5
(d, J¼1.1), 140.8, 148.5. 19F NMR (CDCl3) d: 231.7 (t, J¼47.0). HRMS
(ESI): 252.0643 (calcd 252.0648, MþNaþ). IR (neat, cm1): 3097,
1543, 1348, 1070, 730, 695.
4.6.2. 1-(2-Fluoro-1,1-dimethoxyethyl)-3,5-dinitrobenzene (2l).
Compound 2lwas synthesised from 1l (464 mg, 2.21 mmol) byMW
ﬂuorination at 80 W for 120 min, omitting the hydrolytic step.
Puriﬁcation by silica gel chromatography (pentane/acetone, 7/3),
gave 157 mg (0.57 mmol, 26%) of a slightly yellowish solid, mp 87–
91 C. 1H NMR (CDCl3) d: 3.34 (s, 6H), 4.56 (d, J¼46.8, 2H), 8.72 (d,
J¼2.1, 2H) and 9.05 (t, J¼2.1, 1H). 13C NMR (CDCl3) d: 49.5 (2C), 81.7
(d, J¼178.7), 99.6 (d, J¼21.2), 119.0, 127.9 (d, J¼1.1, 2C), 143.5, 148.6
(2C). 19F NMR (CDCl3) d: 232.2 (t, J¼46.9). IR (neat, cm1): 3086,
1528, 1347, 1064, 703.
4.7. 1-Aryl-2,2-diﬂuoroketones (4)
The 1H NMR chemical shift and the coupling constants of the
diﬂuoromethylene groups in the a,a-diﬂuoroketones were com-
pared by that reported previously for 4a,29,43 4c,29 4e,43 and 4h.28
Selected compounds were isolated or synthesised. The compounds
4i and 4j could not be isolated in a sufﬁciently pure form for
characterisation.
4.7.1. 2,2-Diﬂuoro-1-phenylethanone (4c)29. Compound 4c was
prepared as described for 3c using MW heating. Puriﬁcation by
silica gel chromatography (pentane/acetone, 85/15) gave 41 mg
(0.26 mmol, 12%) of 4c as an oil. 1H NMR data corresponded with
that reported previously.29 1H NMR (CDCl3) d: 6.29 (t, J¼53.6, 1H),
7.54 (m, 2H), 7.68 (m, 1H), 8.08 (m, 2H).
4.7.2. 2,2-Diﬂuoro-1-(4-ﬂuorophenyl)ethanone (4d)44. Compound
4dwas prepared as described for 3d usingMWheating. Puriﬁcation
by silica gel chromatography (pentane/acetone, 85/15) gave 63 mg
(0.36 mmol, 16%) of 4d as an oil. 1H NMR (CDCl3) d: 6.24 (t, J¼53.6,
1H), 7.21 (m, 2H) and 8.13 (m, 2H).
4.7.3. 1-(4-Bromophenyl)-2,2-diﬂuoroethanone (4e)43. Compound
4ewas prepared as described for 3e usingMWheating. Puriﬁcation
by silica gel chromatography (pentane/acetone, 85/15) gave 85 mg
(0.36 mmol, 16%) of 4e as an oil. 1H NMR data corresponded with
that reported previously.43 1H NMR (CDCl3) d: 6.24 (t, J¼53.5, 1H),
7.69 (m, 2H), 7.95 (m, 2H).
4.7.4. 2,2-Diﬂuoro-1-(4-triﬂuoromethylphenyl)ethanone (4f). Compound
4fwas prepared as described for 3f using MW heating. Puriﬁcation
by silica gel chromatography (CH2Cl2) gave 87 mg (0.38 mmol, 17%)
of 4f as an oil. 1H NMR (CDCl3) d: 6.27 (t, J¼53.4, 1H), 7.81 (m, 2H)
and 8.21 (m, 2H).
4.7.5. 2,2-Diﬂuoro-1-(4-nitrophenyl)ethanone (4h)28. Compound
4h was synthesised as described by Peng et al.28 starting with 1h
(2.07 g, 12.53 mmol). The crude product obtained (1.65 g, contam-
inated with 3h) had an 1H NMR spectra, which corresponded well
with that reported. 1H NMR (CDCl3) d: 6.28 (t, J¼53.3, 1H), 8.27 (m,
2H), 8.39 (m, 2H).
4.7.6. 2,2-Diﬂuoro-1-(naphthalen-1-yl)ethanone (4j)42. Compound
4j was synthesised based on the method reported by Verniest
et al.30 starting with 1j (2.30 g. 13.54 mmol). Compound 1jwas ﬁrst
converted to its corresponding methyl imine, followed by ﬂuori-
nation using N-ﬂuorobisbenzenesulfonimide. The diﬂuorinated
imine formedwas hydrolysed using HCl. This gave after puriﬁcation
by silica gel column chromatography (CH2Cl2) 1.34 g, (6.50 mmol,
48%) of a pale yellow oil. The 1H, 13C and 19F NMR spectra corre-
sponded with that reported.42 1H NMR (CDCl3) d: 6.42 (t, J¼53.9,
1H), 7.54–7.63 (m, 3H), 7.68 (m, 1H), 7.91 (d, J¼8.0, 1H), 8.14 (d,
J¼8.0, 1H), 8.19 (m, 1H), 8.85 (d, J¼8.0, 1H).
4.8. 1-Aryl-2-chloroethanones (6)
Trace impurities of 1-aryl-2-chloroethanoes were observed af-
ter most ﬂuorinations. The identity of selected compounds was
veriﬁed by isolation or synthesis.
4.8.1. 1-(4-(Benzyloxy)phenyl)-2-chloroethanone (6b)45. 1-(4-Ben-
zyloxyphenyl)ethanone (1b) (5.49 g, 19.0 mmol) and p-TsOH
(2.31 g, 12.1 mmol) were suspended in methanol (500 mL) at 40 C.
Then 1,3-dichloro-5,5-dimethylhydantoin (3.59 g, 18.2 mmol) was
added in portions over 1 h, followed by agitation of the reaction
mixture at 40 C for 22 h. Methanol was then distilled off until
crystallisation started, followed by slow addition of water (200 mL).
The suspension formed was then stirred for 45 min followed by
isolation of the solid material. The crude product was recrystallised
from EtOAc/ethanol. This gave 4.03 g (63%) of a white solid, mp
111–112 C (Lit.45 109–110 C). 1H and 13C NMR spectra corre-
sponded with that reported.45 1H NMR (CHCl3) d: 4.62 (s, 2H), 5.13
(s, 2H), 7.01 (m, 2H), 7.30–7.42 (m, 5H), 7.92 (m, 2H).
4.8.2. 1-(4-Bromophenyl)-2-chloroethanone (6e)37. The identity of
6e was veriﬁed by HPLC co-eluation with a commercial sample of
6e. Column: Symmetry C8 3.5 mm, 4.6150 mm, (Waters Corp.,
T.H. Krane Thvedt et al. / Tetrahedron 65 (2009) 9550–9556 9555
Massachusetts, USA); gradient elution starting with H2O/acetoni-
trile/diethylamine (98/2/0.1, vol %), to H2O/acetonitrile/diethyl-
amine (30/70/0.1, vol%) after 70 min; ﬂow rate: 1.0 mL/min;
detection at 220 nm, retention time 6e: 57.3 min.
4.8.3. 2-Chloro-1-(triﬂuoromethylphenyl)ethanone (6f)46. Following
a thermal ﬂuorination of 1f (1.58 g, 8.84 mmol) in methanol using
F-TEDA-BF4, and acetal cleavage using triﬂuoroacetic acid as de-
scribed previously,36 9 mg (0.04 mmole, 0.5%) of 6f as an oil was
isolated by silica gel column chromatography (CH2Cl2).
1H NMR
data in DMSO-d6 corresponded with that reported.
46 1H NMR
(DMSO-d6) d: 5.28 (s, 2H), 7.94 (m, 2H), 8.17 (m, 2H).
4.8.4. 2-Chloro-1-(4-nitrophenyl)ethanone (6h)37. Compound 6h
were obtained after a thermal ﬂuorination a of 1h (2.92 g,
17.68 mmol) in methanol for 11 days, followed by acetal cleavage
using hydrochloric acid (10%, 20 mL) in THF (80 mL) at 65 C over-
night. Afterwork-up, the resulting solidwas crystallised fromCHCl3.
The resulting mother liquor was then puriﬁed by silica gel chro-
matography (CHCl3) yielding 30 mg (0.02 mmol, 1%) of an off-white
solid, mp 87–91 C. 1H and 13C NMR data corresponded with that
reported.47 1HNMR (CDCl3) d: 4.72 (s, 2H), 8.15 (m, 2H), 8.36 (m, 2H).
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a b s t r a c t
The asymmetric reduction of eight a-ﬂuoroacetophenones has been investigated using (R)-MeCBS as a
catalyst in various media. Based on a solvent screen, 1,2-dimethoxyethane, diethyl ether and dichloro-
methane were used in reductions of the a-ﬂuoroacetophenones. The enantiomeric excess of the products
depended on the solvent and the electronic character of the aromatic substituents. Higher enantioselec-
tivity and less solvent dependency were observed in the reduction of substrates bearing electron donat-
ing substituents, whereas the opposite was the case for reduction of the substrates with electron
withdrawing substituents. The (R)-2-ﬂuoro-1-arylethanols were obtained with enantiomeric excesses
in the range of 91–99% using 1,2-dimethoxyethane as a solvent. Six of the alcohols produced are new
chemical entities. The absolute conﬁgurations of the (R)-2-ﬂuoro-1-arylethanols were determined by
circular dichroism using the exciton chirality method of the (S)-benzoate esters of the alcohols. The
(S)-benzoate esters were obtained by lipase-catalysed resolution using Novozym 435.
 2008 Elsevier Ltd. All rights reserved.
1. Introduction
The importance of ﬂuorinated compounds has been well
documented and there is a fast growing demand of optically active
ﬂuorinated building blocks, for example, in medicinal chemistry,
biochemistry and material science.1–4 Approximately 20% of drugs
on the market contain ﬂuorine, a number expected to grow.5 The
1-arylethanol-skeleton is a frequently encountered structural
element in bioactive molecules.6–9 However, applications of
1-aryl-2-ﬂuoroethanols are not numerous.
Enantioenriched (R)- and (S)-2-ﬂuoro-1-phenylethanol are well
known and have been prepared by microbial reductions,10–13
reduction using DIP-Chlorine and Alpine-borane,14 asymmetric
epoxide opening15,16 and hydrolase catalysed resolutions.17–19
Also, (R)-1-(4-bromophenyl)-2-ﬂuoroethanol has been prepared
by Baker’s yeast reduction.10
Chiral oxazaborolidine-catalysed borane reduction of prochiral
ketones to chiral secondary alcohols is one of the most important
methods in asymmetric synthesis. The present work deals with
the asymmetric reduction and solvent selection for a series a-ﬂuo-
roacetophenones using (R)-MeCBS.20 The MeCBS catalyst had pre-
viously been used for the reduction of structurally related
acetophenones, giving the corresponding alcohols in high enantio-
meric excess (ee).21,22 Mathre et al.,21 compared the effect of three
solvents on ee in reductions of a series of para-substituted aceto-
phenones. Solvent effects have also been investigated experimen-
tally by Gilmore et al.,23 Xu et al.24 and Corey et al.25 whilst Xu
et al.,26 have investigated substrate electronic effects on the
enantioselectivity in oxazaborolidine-catalysed reductions. Several
theoretical studies of the catalyst have also been performed.27–30
2. Result and discussion
2.1. Asymmetric reduction
In order to ﬁnd suitable conditions for the asymmetric
reduction of a series of a-ﬂuoroacetophenones, 2a–h (Scheme 1),
a solvent screen was performed. The investigation was carried
out using nine different solvents, 2a as the model substrate and
0957-4166/$ - see front matter  2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetasy.2008.07.019
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Scheme 1. Asymmetric reduction of 2a–h using (R)-MeCBS in various solvents.
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(R)-MeCBS as the catalyst (Table 1). The catalyst was prepared
from (R)-a,a-diphenyl-2-pyrrolidinemethanol,21 and was used as
the borane complex in equimolar amounts.
The enantioselectivity of the reductions depended on the sol-
vent. The product (R)-1awas obtained in high ee when the reaction
was performed in diethyl ether, tert-butyl methyl ether (t-BuOMe)
and 1,2-dimethoxyethane (DME). Acyclic ethers had previously
been found to be suitable solvents for the asymmetric reduction
of structurally related ketones.31,32 The reductions of 2a in dichlo-
romethane and THF also gave acceptable ee-values, whereas the
reductions in the other solvents resulted in moderate enantioselec-
tivity. Surprisingly, reductions in diisopropyl ether gave low selec-
tivity. The reason for this is not clear; however, both the catalyst
and the substrate had a low solubility in the reaction medium.
To investigate the effect of solvents on the enantioselectivity
further, the whole series of substrates, 2a–2h, were reduced in
diethyl ether, dichloromethane and DME. t-BuOMe was not
included due to the low solubility of the catalyst in this medium.
Dichloromethane was included to ensure a larger variability in sol-
vent properties. The reductions of 2a–h in the three solvents were
performed using (R)-MeCBS at 25 C. The results are summarised in
Table 2.
The effect of the solvent on the enantioselectivity varied be-
tween the substrates. For the whole series, reductions in DME on
average gave the highest ee-values, whilst reactions in dichloro-
methane gave the lowest enantioselectivity. Only minor effects of
the solvent on the ee were observed in the reduction of 2a–b,
whereas for the reduction of 2c–2h the choice of solvent was very
important.
Solvent effects on enantioselectivity in similar reaction systems
had previously been explained by changes in the equilibrium
between the monomer and dimer species of the catalyst,23 reduc-
tion caused by free borane,21,24 and stabilisation of the reactive
intermediates.27,28 The solvent effect observed in this study is
likely to be caused by a combination of all the above-mentioned
mechanisms.
Clearly, the substrate structure has an effect on the outcome of
the reaction. In all solvents, there was a decrease in ee going from
1a to 1h. Such effects have also been observed in similar
systems.25,26
The enantioselectivity of (R)-MeCBS-catalysed asymmetric
reductions has been observed to be dependant on the reaction
temperature24 and the addition time of the substrate. The effects
of these two parameters were investigated in the reduction of 2a.
The reaction temperature was varied between –20 C and +40 C,
and the substrate addition time was varied from 0 to 4 h. The re-
sults are given in Table 3.
The ee of the product, (R)-1a, depended on the reaction temper-
ature. Lower enantioselectivity was experienced at 40 C. The sub-
strate addition time seemed to be less important, but a minor
effect was observed at a higher reaction temperature.
Based on the above ﬁndings, all the substrates were reduced on
a 1 mmol scale using (R)-MeCBS at 20 C in DME. The addition of
the substrates was carried out over 20 min; the results are given in
Table 4.
All the products were obtained in good to excellent ee, but a
slight decrease in enantioselectivity was observed going from
(R)-1a to (R)-1h. Comparing the reactions in DME performed at
20 C with those at +25 C, only minor changes in enantioselec-
tivity were observed for most substrates. However, the enantio-
selectivity in the reduction of 2e increased from 93.5% to 98.5%.
This effect was not investigated, but might be due to either a tem-
perature effect, addition time or a scale effect.
2.2. Determination of the absolute conﬁguration
Optical rotation data had previously only been reported for (R)-
1c,10,18 and (R)-1e.10 The absolute conﬁguration of the remaining
alcohols was determined by circular dichroism spectroscopy (CD)
of the benzoates (S)-3a–h, (Scheme 2). The CD exciton chirality
method,33,34 had previously been used for assigning the absolute
conﬁguration of similar compounds.35
The stereopreference of lipase B from Candida antarctica is well
documented.36,37 Therefore, this lipase (Novozym 435) was used to
obtain the benzoates, (S)-3a–h, from the racemic alcohols, rac-1a–
h, by kinetic resolution via a 0.1 mmol scale. Vinyl benzoate was
used as acyl donor and t-BuOMe as a solvent (Scheme 2).
The remaining substrate from the resolution had the same con-
ﬁguration as the alcohols, (R)-1a–h, obtained by the asymmetric
reduction using (R)-MeCBS. Thus, the benzoates obtained, (S)-3a–
h, had the opposite conﬁguration.
Table 1
Effect of solvent on ee (%) in reduction of 2a at 25 C
Solvent ee (%) Absolute conﬁguration
Diethyl ether 98.0 (R)
t-BuOMe 97.0 (R)
DME 97.0 (R)
THF 96.0 (R)
CH2Cl2 94.5 (R)
Toluene 86.5 (R)
i-Pr ether 86.0 (R)
Hexane 81.0 (R)
MeCN 74.5 (R)
Table 2
Effect of solvent on ee in reduction of 2a–h at 25 oC
Product ee (%)
Diethyl ether CH2Cl2 DME
(R)-1a 98.0 94.5 97.0
(R)-1b 98.0 98.0 97.0
(R)-1c 91.5 78.0 96.5
(R)-1d 94.5 92.0 97.5
(R)-1e 90.0 81.5 93.5
(R)-1f 85.5 65.0 90.0
(R)-1g a 74.0 89.0
(R)-1h 75.0 68.0 93.5
a Low solubility of substrate resulted in slow conversion.
Table 3
Effect of reaction temperature and addition time on ee in reduction of 2a
Reaction temperature (C) Addition time (h) ee (%)
40 0 92.5
40 4 93.5
10 2 98.0
10 2 98.5
20 0 98.5
20 4 98.5
Table 4
Asymmetric reduction of 2a–h at 20 C using (R)-MeCBS in DME
Product Reaction time (min) ee (%) Isolated yield (%)
(R)-1a 30 99.5 88
(R)-1b 15 97.0 88
(R)-1c 20 96.5 84
(R)-1d 20 99.0 76
(R)-1e 20 98.5 82
(R)-1f 20 93.0 84
(R)-1g 20 91.5 74
(R)-1h 20 92.5 80
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The exciton chirality method depends on the conformation of
the molecule. Therefore, an energy minimisation using Molecular
Modelling Pro (MM2) was performed. The benzoates, (S)-3a–h,
had similar preferred conformations, with the hydrogen atom at
the stereogenic centre arranged in the same plane as the disubsti-
tuted aromatic ring, see Figure 1.
The CD chirality exciton method predicts that upon looking
through the centres of the two interacting dipoles, a negative sign
is deﬁned when an anticlockwise rotation brings the dipole in the
front onto that in the back, and vice-versa.38
For the benzoates, (S)-3a–h, an anticlockwise rotation of the
disubstituted phenyl ring brings it onto the benzoate dipole, thus
a negative ﬁrst Cotton effect was predicted. This was conﬁrmed
by CD measurements. The ee of the benzoates, (S)-3a–h, the molar
extinction (De) and UV absorption maximum (kmax) are summa-
rised in Table 5.
The second Cotton effect at lower wavelength was not observed
because the CD spectrum is perturbed by other electronic transi-
tions and effects caused by solvents, see Figure 2.
3. Conclusion
Eight a-ﬂuoroacetophenones have been reduced with good to
excellent enantioselectivity, using the (R)-MeCBS borane complex
as catalyst. The enantiomeric excess of the products depended on
the choice of solvent, DME being the preferred reaction medium.
The enantioselectivity of the reactions was also affected by sub-
strate structure. High enantioselectivity was obtained in the reduc-
tion of substrates having electron donating substituents, whereas a
slight decrease in ee of the products were observed in reductions of
substrates having electron withdrawing substituents.
Six of the prepared 2-ﬂuoro-1-arylethanols had not previously
been described. The absolute conﬁguration of the alcohols, (R)-
1a–h, was determined by CD spectroscopy using the exciton chiral-
ity method.
4. Experimental
4.1. General
The a-ﬂuoroacetophenones were prepared as described previ-
ously.39 The (R)-MeCBS borane complex was prepared according
toMathre et al.21 startingwith (R)-a,a-diphenyl-2-pyrolidinemeth-
anol. Trimethylboroxine, borane dimethyl sulﬁde complex, vinyl
benzoate and NaBH4 were purchased from Aldrich. (R)-a,a-Diphe-
nyl-2-pyrrolidinemethanol was a gift from Borregaard (Norway).
Novozym 435 was from Novozymes A/S (Denmark). Column chro-
matography was performed using Silica Gel 60A from Fluka, pore
size 40–63 lm. Preparative TLC plates were made by known proce-
dures. Solvents were dried by standard procedures before use.
4.2. Analyses
NMR spectra were recorded with Bruker Avance DPX 400 oper-
ating at 400 MHz for 1H, 375 MHz for 19F and 100 MHz for 13C. 1H
and 13C NMR chemical shifts are in ppm relative to TMS, whilst for
19F NMR, the shift values are relative to hexaﬂuorobenzene. Cou-
pling constants are in Hertz. Mass spectroscopy (EI): Finnigan
MAT 95 XL Mass Spectrometer (EI/70 eV). Accurate mass determi-
nation (ESI) was performed on an Agilent 6520 QTOF MS instru-
ment equipped with a dual electrospray ion source. Samples
OH
F
R
1a-h
Ph
O
O+
OH
F
R
O
F
R
O
Ph
+
(R)-1a-h (S)-3a-h
Novozym 435
t-BuOMe
Scheme 2. Kinetic resolution of racemic 1a–h using Novozym 435 and vinyl benzoate as acyl donor.
Figure 1. Favoured conformation of (S)-3h.
Table 5
Enantiomeric excess, De and k for (S)-3a–h
Compound R ee (%) De ka (nm)
(S)-3a OMe 73 5.9 233
(S)-3b OBn 99 14.2 234
(S)-3c H 88 9.0 228
(S)-3d F 79 7.1 228
(S)-3e Br 94 22.3 232
(S)-3f CF3 96 6.0 227
(S)-3g CN 90 19.6 237
(S)-3h NO2 94 9.0 265
a Maximum of ﬁrst Cotton effect.
Figure 2. CD and UV spectra of (S)-3e.
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were injected into the MS using an Agilent 1200 series HPLC, and
analysis was performed as a ﬂow injection analysis without any
chromatographic steps. All melting points are uncorrected and
measured by a Büchi melting point instrument. FTIR spectra were
recorded on a Thermo Nicolet Avatar 330 infrared spectrophotom-
eter. CD spectra were recorded on an OLIS DSM 1000 spectropho-
tometer in a 1 cm cuvette, using acetonitrile as a solvent. Optical
rotations were measured using sodium D line at 589 nm on a Per-
kin–Elmer 243 B polarimeter. The ee of the alcohols was deter-
mined by HPLC using an Agilent 1100 series system equipped
with a Bruker DAD detector and a Chiracel OD column
(0.46 cm  25 cm), mobile phase: hexane/2-propanol, 98:2, ﬂow
rate 1.0 mL/min. Retention times for the enantiomers: (S)-1a
24.7 min, (R)-1a 30.0 min, (S)-1b 46.7 min, (R)-1b 49.6 min, (S)-
1c 16.2 min, (R)-1c 21.4 min, (R)-1d 15.2 min, (S)-1d 16.2 min,
(R)-1e 17.8 min, (S)-1e 20.4 min, (R)-1f 16.3 min, (S)-1f 18.3 min,
(R)-1g 47.3 min, (S)-1g 52.7 min, (R)-1h 42.5 min, (S)-1h 47.3 min.
4.3. Screening scale (R)-MeCBS reductions
Under anhydrous conditions, (R)-MeCBS (29 mg, 0.1 mmol) was
dissolved in the given solvent (0.5 mL) and added to a solution of
the a-ﬂuoroacetophenone (0.1 mmol, 0.10 M) in the same solvent.
The reaction mixture was then stirred at the given temperature un-
til full conversion as monitored by HPLC.
4.4. Preparative scale (R)-MeCBS reductions
The a-ﬂuoroacetophenone (1.5 mmol) was dissolved in DME
(10 mL) and cooled to 20 C. Through an addition funnel was
added a solution of (R)-MeCBS (437 mg, 1.5 mmol) dissolved in
DME (5 mL) over 20 min. The mixture was kept at 20 C and stir-
red until complete consumption of the ketone as analysed by HPLC.
The reaction mixture was then quenched with MeOH (5 mL) at
20 C and acidiﬁed with HCl (1%) at 0 C. Water (10 mL) was
added before the reaction mixture was extracted with CH2Cl2
(3  15 mL). The organic phase was washed with water
(2  20 mL) and dried over Na2SO4 before the solvent was evapo-
rated under reduced pressure. The crude product was puriﬁed by
column chromatography (CH2Cl2/MeOH, 100:1).
4.5. Lipase-catalysed resolution
The racemic 2-ﬂuoro-1-arylethanols, rac-1a–h, (0.1 mmol), ob-
tained by NaBH4 reduction of the a-ﬂuoroacetophenones, 2a–h,
were dissolved in t-BuOMe (3 mL). Vinyl benzoate (74 mg,
0.5 mmol) and Novozym 435 (60 mg) were added. The reaction
mixture was agitated at 45 C and monitored by HPLC. The enzyme
was ﬁltered off, and the solvent was removed under reduced pres-
sure. The benzoate esters, (S)-3a–h, and alcohols, (R)-1a–h, were
separated by preparative TLC. Degree of conversions (c) was deter-
mined by 1H NMR spectroscopy, whilst enantiomeric excess of the
substrate alcohols (ees) was determined as described in Section
4.2. The ee of the benzoates (eep) was calculated by the formula
eep = (ees/c)  ees.40
4.6. Analytical data for (R)-2-ﬂuorophenylethanols
4.6.1. (R)-2-Fluoro-1-(4-methoxyphenyl)ethanol (R)-1a
Colourless oil (224 mg, 88%), ee = 99.5%, ½a25D ¼ 38:5 (c 0.70,
CHCl3). 1H NMR (CDCl3) d: 2.41 (br, 1H), 3.81 (s, 3H), 4.38 (ddd,
J = 8.3, 9.5, 48.5, 1H), 4.49 (ddd, J = 3.4, 9.5, 46.8, 1H), 4.97 (ddd,
J = 3.4, 8.3, 13.2, 1H), 6.89–6.93 (m, 2 H), 7.29–7.33 (m, 2H). 13C
NMR (CDCl3) d: 55.3, 72.5 (d, J = 19.8), 87.1 (d, J = 174.5), 114.0 (2
C), 127.6 (2 C), 130.2 (d, J = 8.1) and 159.7. 19F NMR (CDCl3, C6F6)
d: 220.8 (dt, J = 13.4, 47.4). IR (neat, cm1): 3420, 2955, 2839,
1612, 1514, 1250, 1177 and 1089. MS (EI, m/z, %): 170 (M+, 14),
153 (29), 137 (100), 109 (27) and 77 (37). HRMS (EI): 170.0744
(calcd 170.0743).
4.6.2. (R)-1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethanol (R)-1b
White solid (216 mg, 88%), mp 71–73 C, ee = 97.0%,
½a25D ¼ 19:9 (c 0.60, CHCl3). 1H NMR (CDCl3) d: 2.39 (dd, J = 1.1,
2.9, 1H), 4.40 (ddd, J = 8.4, 9.5, 48.5, 1H), 4.48 (ddd, J = 3.4, 9.5,
46.8, 1H), 4.97 (m, 1H), 5.07 (s, 2H), 6.95–7.01 (m, 2H), 7.28–7.45
(m, 7H). 13C NMR (CDCl3) d: 70.3, 72.8 (d, J = 19.8), 87.4 (d,
J = 175.2), 115.3 (2C), 127.7 (2C), 127.9 (2C), 128.2, 128.8 (2C),
130.7 (d, J = 8.4), 137.0 and 159.1 19F NMR (CDCl3, C6F6) d:
220.8 (dt, J = 13.4, 47.9). IR (KBr, cm1): 3427, 2948, 2860,
1612, 1512, 1248, 1170, 1078 and 1007. MS (EI, m/z, %): 246 (M+,
3), 91 (100), 65 (11), 43 (12). HRMS (EI): 246.1056 (calcd
246.1056).
4.6.3. (R)-2-Fluoro-1-phenylethanol (R)-1c10,18
Colourless oil (174 mg, 84%), ee = 96.5%, ½a25D ¼ 64:4 (c 1.20,
CHCl3), Ref. ½a25D ¼ 49:9 (c 1.2, CHCl3).10 1H NMR (CDCl3) d: 2.51
(br, 1H), 4.41 (ddd, J = 8.3, 9.6, 48.5, 1H), 4.51 (ddd, J = 3.3, 9.6,
46.7, 1H), 5.01 (ddd, J = 3.3, 8.3, 14.0, 1H), 7.33–7.36 (m, 5H). 13C
NMR (CDCl3) d: 73.0 (d, J = 19.8), 87.2 (d, J = 174.1), 126.3 (d,
J = 0.7, 2C), 128.5, 128.7 (2C) and 138.1 (d, J = 8.1). 19F NMR (CDCl3,
C6F6) d: 221.2 (dt, J = 13.9, 48.5). IR (neat, cm1): 3564, 3387,
2950, 1604, 1454, 1311, 1198, 1064 and 1009. MS (EI, m/z, %):
140 (M+, 61), 123 (14), 107 (100), 105 (46), 91 (52), 79 (93) and
77 (88). HRMS (EI): 140.0639 (calcd 140.0637).
4.6.4. (R)-2-Fluoro-1-(4-ﬂuorophenyl)ethanol (R)-1d
Colourless oil (180 mg, 76%), ee = 99.0%, ½a25D ¼ 36:5 (c 0.60,
CHCl3). 1H NMR (CDCl3) d: 2.63 (br, 1H), 4.39 (ddd, J = 8.2, 9.6,
48.3, 1H), 4.48 (ddd, J = 3.3, 9.6, 46.7, 1H), 5.00 (ddd, J = 3.3, 8.3,
13.9, 1H), 7.00–7.08 (m, 2H), 7.32–7.36 (m, 2H). 13C NMR (CDCl3)
d: 72.3 (d, J = 19.6), 87.0 (d, J = 175.7), 115.5 (d, J = 21.6, 2C),
128.0 (d, J = 8.2, 2C), 134.7 (dd, J = 3.2, 11.3) and 162.7 (d,
J = 245.3). 19F NMR (CDCl3, C6F6) d: 114.2 (m), 221.4 (dt,
J = 13.8, 48.2). IR (neat, cm1): 3588, 3385, 2952, 2892, 1606,
1510, 1223, 1197, 1088 and 1010. MS (EI, m/z, %): M+ 158 (M+, 5)
125 (72), 109 (10), 97 (52), 95 (23). HRMS (ESI): 157.0470, (calcd
157.0471 [MH+]).
4.6.5. (R)-1-(4-Bromophenyl)-2-ﬂuoroethanol (R)-1e10
White solid (273 mg, 82%), mp 40–41 C, ee = 98.5%.
½a25D ¼ 32:3 (c 0.90, CHCl3), Ref. ½a25D ¼ 25:9 (c 0.9 CHCl3).10 1H
NMR (CDCl3) d: 2.45 (dd, J = 1.1, 3.1, 1H), 4.38 (ddd, J = 8.2, 9.6,
48.3, 1H), 4.48 (ddd, J = 3.3, 9.6, 46.6, 1H), 4.97 (m, 1H), 7.27–
7.30 (m, 2H), 7.45–7.53 (m, 2H). 13C NMR (CDCl3) d: 72.3 (d,
J = 20.2), 86.9 (d, J = 174.7), 122.4, 128.0 (2C), 131.8 (2C) and
137.1 (d, J = 8.3). 19F NMR (CDCl3, C6F6) d: 221.9 (dt, J = 13.4,
47.4). IR (KBr, cm1): 3360, 2953, 2896, 1592, 1489, 1327, 1195,
1091 and 1008. MS (EI, m/z, %): 220/218 (M+, 6) 187 (47), 185
(52), 78 (50), 77 (100). HRMS (EI): 217.9737 (calcd 217.9743).
4.6.6. (R)-2-Fluoro-1-(4-(triﬂuoromethyl)phenyl) ethanol (R)-1f
Colourless oil (265 mg, 84%), ee = 93.0%, ½a25D ¼ 20:0 (c 0.70,
CHCl3). 1H NMR (CDCl3) d: 2.54 (d, J = 3.1, 1H), 4.41 (ddd J = 8.1,
9.6, 48.0, 1H), 4.54 (ddd, J = 3.3, 9.6, 46.7, 1H), 5.10 (m, 1H),
7.51–7.53 (m, 2H), 7.63–7.69 (m, 2H). 13C NMR (CDCl3) d: 72.4
(d, J = 20.5), 86.8 (d, J = 174.7), 124.0 (q, J = 272.3), 125.6 (q,
J = 3.9, 2C), 126.7 (d, J = 0.7, 2C), 130.7 (q, J = 32.5) and 142.1 (dq,
J = 1.4, 7.8). 19F NMR (CDCl3, C6F6) d: 63.2 (s, 3F), 222.4 (dt,
J = 13.8, 47.0). IR (neat, cm1): 3581, 3386, 2954, 2895, 1621,
1418, 1327, 1166, 1068 and 1016. MS (EI, m/z, %): M+ 208 (M+,
2), 189 (8), 175 (100), 145 (14), 127 (88), 95 (4). HRMS (EI):
208.0503 (calcd 208.0511).
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4.6.7. 4-((R)-2-Fluoro-1-hydroxyethyl)benzonitrile (R)-1g
White solid (183 mg, 74%), mp 59–61 C, ee = 91.5%.
½a25D ¼ 27:1 (c 0.70, CHCl3). 1H NMR (CDCl3) d: 2.63 (d, J = 3.1,
1H), 4.40 (ddd, J = 8.0, 9.5, 48.0, 1H), 4.54 (ddd, J = 3.4, 9.5, 46.7,
1H), 5.07 (m, 1H), 7.46–7.56 (m, 2H), 7.65–7.71 (m, 2H). 13C
NMR (CDCl3) d: 72.2 (d, J = 20.3), 86.5 (d, J = 173.3), 112.5, 118.5,
127.0 (2C), 132.4 (2C) and 143.3 (d, J = 7.6). 19F NMR (CDCl3,
C6F6) d: 222.9 (dt, J = 13.8, 47.0). IR (KBr, cm1): 3456, 2947,
2239, 1609, 1454, 1323, 1202, 1096, and 1009. MS (EI, m/z, %):
M+ 165 (M+, 5), 132 (100), 104 (50), 102 (14), 77 (29). HRMS (EI):
165.0589 (calcd 165.0590).
4.6.8. (R)-2-Fluoro-1-(4-nitrophenyl)ethanol (R)-1h
White solid (223 mg, 80%), mp 97–99 C, ee = 92.5%,
½a25D ¼ 17:7 (c 0.70, CHCl3). 1H NMR (CDCl3) d: 2.65 (br, 1H),
4.43 (ddd J = 7.8, 9.6, 47.9, 1H), 4.57 (ddd, J = 3.4, 9.6, 46.5, 1H),
5.16 (ddd, J = 3.4, 7.8, 14.5, 1H), 7.57–7.63 (m, 2H), 8.22–8.27 (m,
2H). 13C NMR (CDCl3) d: 72.1 (d, J = 20.5), 86.5 (d, J = 175.6),
123.8 (2C), 127.2 (2C), 145.2 (d, J = 7.4) and 147.9. 19F NMR (CDCl3,
C6F6) d: 223.2 (dt, J = 14.4, 47.4). IR (KBr, cm1): 3482, 3116,
2943, 2889, 1604, 1560, 1521, 1349, 1197, 1092, and 1002. MS
(EI, m/z, %): M+ 185(M+, 4), 152 (42), 102 (19), 83 (20). HRMS
(EI): 185.0488 (calcd 185.0488).
4.7. Analytical data for the benzoates
4.7.1. (S)-2-Fluoro-1-(4-methoxyphenyl)ethyl benzoate (S)-3a
Colourless oil (11.5 mg, 43%), ee = 73%, ½a25D ¼ 15:0 (c 0.60,
CHCl3). CD (acetonitrile): De = 5.9 (233 nm). 1H NMR (CDCl3) d:
3.80 (s, 3H), 4.65 (ddd, J = 3.5, 10.1, 46.7, 1H), 4.75 (ddd, J = 7.6,
10.1, 47.8, 1H), 6.23 (ddd, J = 3.5, 7.6, 16.2, 1H), 6.89–6.93 (m,
2H), 7.37–7.48 (m, 4H), 7.55–7.59 (m, 1H), 8.09–8.13 (m, 2H). 13C
NMR (CDCl3) d: 55.3, 74.4 (d, J = 19.9), 84.2 (d, J = 179.3), 114.2
(2C), 127.6 (d, J = 6.8), 128.3 (2C), 128.4 (2C), 129.8 (2C), 130.0,
133.2, 160.0 and 165.7. 19F NMR (CDCl3, C6F6) d: 221.6 (dt,
J = 16.1, 47.0). HRMS (ESI): 297.0895 (calcd 297.0897 [M+Na+]).
4.7.2. (S)-1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethyl benzoate (S)-
3b
White solid (13.5 mg, 39%), mp 91–92 C, ee = 99%,
½a25D ¼ 13:9 (c 1.00, CHCl3) CD (acetonitrile): De = 14.2
(234 nm). 1H NMR (CDCl3) d: 4.64 (ddd, J = 3.5, 10.1, 46.5, 1H),
4.74 (ddd, J = 7.6, 10.1, 48.0, 1H), 5.05 (s, 2H), 6.23 (ddd, J = 3.5,
7.6, 16.2, 1H), 6.97–6.99 (m, 2H), 7.25–7.47 (m, 9H), 7.55–7.59
(m, 1H), 8.09–8.11 (m, 2H). 13C NMR (CDCl3) d: 70.1, 74.3 (d,
J = 20.2), 84.2 (d, J = 179.3), 115.1 (2C), 127.4 (2C), 127.8 (d,
J = 6.7), 128.1, 128.3 (2C), 128.4 (2C), 128.6 (2C), 129.8 (2C),
130.0, 133.2, 136.7, 159.2 and 165.7. 19F NMR (CDCl3, C6F6) d:
222.7 (dt, J = 16.1, 47.0). HRMS (ESI): 373.1207 (calcd 373.1210
[M+Na+]).
4.7.3. (S)-2-Fluoro-1-phenylethyl benzoate (S)-3c
Colourless oil (12.0 mg, 50%), ee = 88%, ½a25D ¼ 42:2 (c 0.70,
CHCl3). CD (acetonitrile): De = 9.0 (228 nm). 1H NMR (CDCl3) d:
4.68 (ddd, J = 3.4, 10.1, 46.7, 1H), 4.76 (ddd, J = 7.3, 10.1, 47.7,
1H), 6.28 (ddd, J = 3.4, 7.3, 16.7, 1H), 7.33–7.48 (m, 7H), 7.56–
7.60 (m, 1H), 8.11–8.13 (m, 2H). 13C NMR (CDCl3) d: 74.7 (d,
J = 19.8), 84.2 (d, J = 179.8), 126.8 (2C), 128.5 (2C), 128.8 (2C),
128.9, 129.8 (2C), 129.9, 133.3, 135.5 (d, J = 6.7) and 165.6. 19F
NMR (CDCl3, C6F6) d: 223.0 (dt, J = 16.1, 47.0). HRMS (ESI):
267.0791 (calcd 267.0792 [M+Na+]).
4.7.4. (S)-2-Fluoro-1-(4-ﬂuorophenyl)ethyl benzoate (S)-3d
Colourless oil (9.0 mg, 37%), ee = 79%, ½a25D ¼ 23:3 (c 0.60,
CHCl3). CD (acetonitrile): De = 7.1 (228 nm). 1H NMR (CDCl3) d:
4.67 (ddd, J = 3.5, 10.1, 46.7, 1H), 4.74 (ddd, J = 7.1, 10.1, 47.5,
1H), 6.24 (ddd, J = 3.5, 7.1, 16.9, 1H), 7.06–7.10 (m, 2H), 7.43–
7.48 (m, 4H), 7.57–7.61 (m, 1H), 8.10–8.12 (m, 2H). 13C NMR
(CDCl3) d: 74.0 (d, J = 20.1), 84.0 (dd, J = 1.1, 179.4), 115.8 (d,
J = 21.6, 2C), 128.5 (2C), 128.8 (d, J = 8.5, 2C), 129.69, 129.81 (2C),
131.4 (dd, J = 2.8, 3.5), 133.4, 162.9 (d, J = 248.0) and 165.5. 19F
NMR (CDCl3, C6F6) d: 113.3 (m), 223.8 (dt, J = 17.2, 47.0). HRMS
(ESI): 285.0696 (calcd 285.0698 [M+Na+]).
4.7.5. (S)-1-(4-Bromophenyl)-2-ﬂuoroethyl benzoate (S)-3e
White solid (12.0 mg, 38%), mp 52–53 C, ee = 94%,
½a25D ¼ 49:5 (c 0.90, CHCl3). CD (acetonitrile): De = 22.3
(232 nm). 1H NMR (CDCl3) d: 4.67 (ddd, J = 3.5, 10.1, 46.7, 1H),
4.73 (ddd, J = 6.8, 10.1, 47.5, 1H), 6.20 (ddd, J = 3.5, 6.8, 17.4, 1H),
7.32–7.35 (m, 2H), 7.45–7.53 (m, 4H), 7.58–7.61 (m, 1H), 8.09–
8.11 (m, 2H). 13C NMR (CDCl3) d: 74.0 (d, J = 20.1), 83.9 (d,
J = 179.8), 122.9, 128.5 (2C), 128.6 (2C), 129.6, 129.8 (2C), 132.0
(2C), 133.5, 134.6 (d, J = 6.7) and 165.5. 19F NMR (CDCl3, C6F6) d:
224.2 (dt, J = 17.2, 47.0). HRMS (ESI): 344.9901 (calcd 344.9897
[M+Na+]).
4.7.6. (S)-2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethyl benzoate
(S)-3f
Colourless oil (13.5 mg, 40%), ee = 96%, ½a25D ¼ 40:3 (c 1.00,
CHCl3). CD (acetonitrile): De = 6.0 (227 nm). 1H NMR (CDCl3) d:
4.72 (ddd, J = 3.8, 10.1, 46.7, 1H), 4.76 (ddd, J = 6.3, 10.1, 47.2,
1H), 6.28 (ddd, J = 3.8, 6.3, 17.9, 1H), 7.46–7.50 (m, 2H), 7.55–
7.67 (m, 5H), 8.11–8.13 (m, 2H). 13C NMR (CDCl3) d: 74.0 (d,
J = 20.1), 83.9 (d, J = 179.8), 123.9 (d, J = 272.7), 125.8 (q, J = 3.9),
127.2 (d, J = 0.7, 2C), 128.6 (2 C), 129.4, 129.9 (2C), 131.1 (q,
J = 32.5), 133.6 (2C), 139.5–139.6 (m) and 165.5. 19F NMR (CDCl3,
C6F6) d: 63.4 (s, 3F), 226.2 (dt, J = 17.2, 47.0). HRMS (ESI):
335.0662 (calcd 335.0666 [M+Na+]).
4.7.7. (S)-1-(4-Cyanophenyl)-2-ﬂuoroethyl benzoate (S)-3g
White solid (12.0 mg, 44%), mp 70–71 C, ee = 90%,
½a25D ¼ 49:5 (c 0.90, CHCl3). CD (acetonitrile): De = 19.6
(237 nm). 1H NMR (CDCl3) d: 4.72 (ddd, J = 3.8, 10.1, 46.7, 1H),
4.76 (ddd, J = 5.8, 10.1, 47.0, 1H), 6.25 (ddd, J = 3.8, 5.8, 18.7,
1H), 7.44–7.71 (m, 7H), 8.10–8.12 (m, 2H). 13C NMR (CDCl3) d:
73.8 (d, J = 20.1), 83.6 (d, J = 179.8), 112.8, 118.3, 127.6 (d,
J = 0.7, 2C), 128.62 (2C), 129.2, 129.9 (2C), 132.6 (2C), 133.7,
140.9 (d, J = 5.6) and 165.4. 19F NMR (CDCl3, C6F6) d: 226.0 (dt,
J = 18.4, 47.0). HRMS (ESI): 292.0744 (M+Na+), (calcd 292.0744
[M+Na+]).
4.7.8. (S)-2-Fluoro-1-(4-nitrophenyl)ethyl benzoate (S)-3h
White solid (12.5 mg, 43%), mp 81–82 C, ee = 94%,
½a25D ¼ 33:4 (c 0.70, CHCl3). CD (acetonitrile): De = 9.0
(265 nm). 1H NMR (CDCl3) d: 4.75 (ddd, J = 4.3, 10.1, 47.0, 1H),
4.78 (ddd, J = 5.6, 10.1, 47.0, 1H), 6.30 (ddd, J = 4.3, 5.6, 19.0, 1H),
7.47–7.52 (m, 2H), 7.60–7.66 (m, 3H), 8.11–8.14 (m, 2H), 8.24–
8.28 (m, 2H). 13C NMR (CDCl3) d: 73.6 (d, J = 20.5), 83.6 (d,
J = 180.1), 124.0 (2C), 127.8 (d, J = 0.7, 2C), 128.7 (2C), 129.1,
129.9 (2C), 133.8, 142.8 (d, J = 5.3), 148.2 and 165.4. 19F NMR
(CDCl3, C6F6) d: 226.2 (dt, J = 19.5, 47.0). HRMS (ESI): 312.0642
(calcd 312.0643 [M+Na+]).
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1. Introduction
The importance and utilisation of optically pure secondary
alcohols has been well recognised. Due to their somewhat
troublesome preparation, ﬂuorinated secondary alcohols have
received considerably less attention. We have recently described
routes to a-ﬂuorinated ketones, rendering their corresponding
alcohols easy accessible [1]. The potential use of such optically
enriched ﬂuorinated alcoholic building blocks is vast, and includes
among others pharmaceuticals, advanced materials and agro-
chemicals [2–6].
Asymmetric transfer hydrogenation (ATH) using various metal
complexes has emerged as an excellent alternative to established
asymmetric reduction methods [7,8]. The easily available hydro-
gen sources, mild reaction conditions and simple experimental
setup have made it an area of interest for both industrial and
academic researchers [9–12]. Moreover, ATH can be performed in
water [7,9,13–16], which is the ideal solvent seen from an
environmental point of view, and potentially provides cost savings
for commercial processes. In contrast to most transition metal
catalysed reactions, asymmetric transfer hydrogenations have also
been done in presence of air [16,17], without signiﬁcant loss in
enantioselectivity.
Acetophenones are usually the benchmark substrates for
asymmetric reductions. Numerous investigations on the effects
of different catalysts, metal species, solvent systems, additives,
temperature and pH on the rate and selectivity of asymmetric
transfer hydrogenations have been reported [7,9,10,13–21].
Sterk et al. [22] has described the ATH of triﬂuoromethylk-
etones with mediocre enantioselectivity, but the ATH of mono-
ﬂuoroketones is an unexplored area. As part of our ongoing
research, we have recently investigated chiral oxazaborolidine-
catalysed borane reductions of a series of a-ﬂuoroketones to the
corresponding chiral secondary alcohols [23]. In order to develop a
more robust and environmental friendly catalytic process, we have
now turned our attention to ATH. Herein we wish to report an
improvedmethod for the preparation of enantioenriched 1-aryl-2-
ﬂuoroethanols using ruthenium catalysed asymmetric transfer
hydrogenation.
2. Result and discussion
Thea-ﬂuoroketones 4a–e (Scheme 1) weremost conveniently
prepared by ﬂuorination of the corresponding trimethylsilyl enol
ethers, 2a–e, using SelectﬂuorTM (1-chloromethyl-4-ﬂuoro-1,4-
diazoniabicyclo[2.2.2]octane bis-(tetraﬂuoroborate) [1], while
4f–h were obtained in highest yield by reacting the acetophe-
nones, 1f–h, with SelectﬂuorTM in methanol. The dimethoxyace-
tals, 3f–h formed as the major products were hydrolysed using
triﬂuoroacetic acid [1].
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The ATH of 4a–hwere studied using four different catalysts, 5–
8, whichwere prepared bymixing the rutheniumarene complexes,
[RuCl2(p-cymene)]2 and [RuCl2(mesitylene)]2 with (R,R)-TsDPEN
and (R,R)-TsCYDN, respectively. The pre-catalyst [RuCl2(mesity-
lene)]2 was synthesised from RuCl3 and 1,3,5-trimethyl-1,4-
cyclohexadiene according to literature procedures [24,25]. All
reactions were performed without solvent degassing and without
inert atmosphere protection [16].
Initially, 4a–hwere reducedwith catalysts 5–8 inwater at 40 8C
using sodium formate as hydrogen donor. The reactions were
monitored by HPLC for determination of conversion and enantio-
meric excess. The results are summarised in Table 1. All reactions
proceededwith preference of the (S)-enantiomer [23]. The ee of the
reactions depended on both catalyst and substrate structure. The
highest selectivity was obtained using catalyst 7, giving the
alcohols (S)-9a, (S)-9c and (S)-9f in 95% ee. The catalysts 5 and 8
gave comparable, but lower ee-values than was the case with 7,
while catalyst 6 gave only moderate enantioselectivity with ee-
values ranging from 77.0 to 47.5%.
The effect of the substituents on the enantioselectivity seems
complex. A general trend was that the reductions of 4c (R = H)
and 4f (R = CF3) gave some of the highest ee-values for all
catalysts, whereas the reduction of 4g (R = CN) and 4h (R = NO2)
gave the lowest selectivities. Moderate enantioselectivity
has also been the results in asymmetric transfer hydrogenation
of 4-nitroacetophenone (1h) in similar catalytic systems
[13,16,26].
The reaction rate was also dependant on both catalysts and
substrate structures. Generally, the highest rates were observed in
reductions using catalyst 5, while catalyst 6 gave the longest
reaction times. As expected, the ketones substituted with electron
donating substituents tended to react slower than their more
electron deﬁcient counterparts [18]. Observed differences in
conversion could also be due to the low solubility and crystalline
nature of several of thea-ﬂuoroacetophenones in water. Solubility
effects might therefore overshadow electronic effects caused by
the para-substituents.
A formic acid/triethylamine solvent mixture has previously
been used in reductions of acetophenone using catalysts 5 and 7
[15,27]. The reactions yielded 1-arylethanols with high enantio-
meric excess, but proceeded with a moderate reaction rate. The
introduction of a ﬂuorine atom in the a-position of the carbonyl
group increases the electrophilicity at the reaction centre, and it
was therefore considered worthwhile to investigate this solvent in
reduction of 4a–h. The reactions were performed using catalysts
5–8 at 40 8C, using S/C = 100, and a physical mixture of formic acid/
triethylamine (5:2 mol ratio). The conversions and enantiomeric
excess are summarised in Table 2.
Phase transfer limitations are less profound in the triethyla-
mine system, since the a-ﬂuoroacetophenones are soluble in the
reaction medium. Less variance in rates was also observed within
each catalytic system. The highest rates were observed in
reductions using the catalysts 5 and 7, where all starting materials
were consumed within 2 h. Using catalyst 6, the time needed to
reach full conversion was increased to 24 h, whereas the reactions
catalysed by 8 were terminated after 10 days, reaching only 20–
66% conversion.
Reductions catalysed by 5–7 in formic acid/triethylamine gave
overall higher selectivity than the reductions inwater, and only the
reduction of substrate 4f (R = CF3) resulted in lower ee-values. The
Scheme 1. Preparation and asymmetric transfer hydrogenation of the ﬂuoroketones, 4a–h, using the catalysts 5–8.
Table 1
Asymmetric transfer hydrogenation of 4a–h using catalysts 5–8 in water.a
Substrate Cat. 5 Cat. 6 Cat. 7 Cat. 8
Conv. (hours) ee (%) Conv. (hours) ee (%) Conv. (hours) ee (%) Conv. (hours) ee (%)
4a OMe >99 (2) 90.0 18 (24) 67.0 >99 (5) 95.0 88 (5)b 87.0
4b OBn >99 (10) 88.0 49 (24) 74.0 71 (20) 90.0 83 (5)b 89.0
4c H >99 (2) 91.5 >99 (24) 81.5 >99 (2) 95.5 >99 (2) 90.5
4d F >99 (2) 87.0 >99 (24) 77.0 >99 (5) 91.0 82 (5)b 87.0
4e Br >99 (2) 87.0 >99 (24) 76.5 >99 (5) 90.5 >99 (5) 87.5
4f CF3 >99 (2) 91.5 >99 (24) 77.0 >99 (5) 96.0 >99 (2) 88.0
4g CN >99 (2) 66.0 >99 (24) 51.0 45 (20) 84.0 >99 (2) 68.5
4h NO2 >99 (2) 70.0 >90 (24) 47.5 99 (20) 76.5 >99 (5) 63.0
a A suspension of [RuCl2(arene)]2 (0.001 mmol) and the ligand (0.0027 mmol) in H2O (0.5 mL) were stirred at 40 8C for 1 h. Sodium formate (34 mg, 0.5 mmol) and the
ketone (0.1 mmol) were then added and the mixture was stirred vigorously at 40 8C for the speciﬁed number of hours.
b Full conversion was obtained within 20 h reaction time.
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use of catalysts 5 and 7 yielded products with higher enantiomeric
excess than was the case with 6, and the alcohols, (S)-9a–h, could
be obtained with ee-values ranging from 97.5 to 84.5%. On the
other hand, catalyst 8, which performed reasonable well in water,
gave only moderate to low enantioselectivity in formic acid/
triethylamine.
Using catalysts 5–7 in formic acid/triethylamine, a trend
regarding the effect of substituents on the enantioselectivity could
be noticed. A drop in ee of the product alcohols were observed
going from 4a–c to substrates bearing more electron withdrawing
substituents. Fujii et al. [27] has previously reduced a series of
para-substituted acetophenones using (S,S)-7 as catalyst in formic
acid/triethylamine. At 28 8C using a catalyst/substrate ratio of
200:1, reduction of 1a (60 h), 1c (20 h) and 1g (14 h) gave the
corresponding alcohols in 97, 98 and 90% ee, respectively [27]. The
ee of the products in our study are comparable to that obtained in
reductions of the corresponding acetophenones. Substituting a
methyl- with a ﬂuoromethyl group increases the size of the
substituent, and alters the electron density at the carbonyl carbon.
It was noteworthy that the reduction ofa-ﬂuoroacetophenone (4c)
was completed in less than 2 h using catalyst 5, whereas
acetophenone (1c) under identical conditions in our hands
required 20 h to reach full conversion with 97% ee. Evidently,
the introduction of one electron withdrawing ﬂuorine increases
the reaction rate signiﬁcantly. Somewhat surprisingly the enan-
tiodiscrimination process was not affected to a large extent by this
substitution. The fact that the relative difference in activation
energy leading to the (R)- and (S)-enantiomers is almost equal in
the acetophenone and the a-ﬂuoroacetophenone series, implies
that the drop in selectivity for substrates containing electron
withdrawing aromatic substituents is not solely related to the
electronic content of the carbonyl carbon. This effect can rather be
explained by other factors such as change in p–p interactions,
solvation effects or dispersion interactions as suggested by Brandt
et al. [28].
3. Conclusion
Asymmetric transfer hydrogenation of para-substituted a-
ﬂuoroacetophenones, 4a–h, using the RuCl-(p-cymene)-(R,R)-
TsDPEN and RuCl-(mesitylene)-(R,R)-TsDPEN provides the corre-
sponding chiral 1-aryl-2-ﬂuoroethanols, 9a–h, in high tomoderate
ee. The formic acid/triethylamine system was found to give higher
enantioselectivity than for reactions in water using sodium
formate as hydrogen donor. Compared to the acetophenone series,
the introduction of a ﬂuorine atom in a-position to the ketone
increased the reaction rates signiﬁcantly without affecting
enantioselectivity. ATH of a-ﬂuoroacetophenones represent a fast,
selective, robust and environmental friendly method towards
enantioenriched 1-aryl-2-ﬂuoroethanols.
4. Experimental
4.1. General experimental procedures
Solvents and reagents were used as received from the suppliers.
[RuCl2(p-cymene]2, (R,R)-TsDPEN, (R,R)-TsCYDN and ruthenium(III)
chloride hydrate were from Aldrich, while 1,3,5-trimethyl-1,4-
cyclohxadienewas fromAlfaAesar. [RuCl2(mesitylene]2 [24,25], and
a-ﬂuoroacetophenones [1], were prepared as described previously.
Reactions were performed in an incubator shaker from Brunswic
Scientiﬁc Co. Inc. NMR spectra were recorded with Bruker Avance
DPX 400 operating at 400 MHz for 1H, 375 MHz for 19F and 100 MHz
for 13C. The ee of the alcohols were determined by HPLC using an
Agilent 1100 series system equipped with a Bruker DAD detector
andaChiracelODcolumn(0.46 cm 25 cm),mobilephase:hexane/
2-propanol, 98:2, ﬂow rate 1.0 mL/min [23].
4.2. Asymmetric transfer hydrogenation in water
A suspension of [RuCl2(arene)]2 (0.001 mmol) and the ligand
(0.0027 mmol) in H2O (0.5 mL) were stirred at 40 8C for 1 h.
Sodium formate (34 mg, 0.5 mmol) and the a-ﬂuoroacetophenone
(0.1 mmol) was then added and themixture was stirred vigorously
at 40 8C for the speciﬁed number of hours. Samples were
withdrawn from the reaction mixture, extracted with Et2O and
ﬁltered through silica before analysis by HPLC for determination of
conversion and enantiomeric excess.
4.3. Asymmetric transfer hydrogenation in formic acid/triethylamine
A suspension of the [RuCl2(arene)]2 (0.001 mmol) and ligand
(0.0027 mmol) in CH2Cl2 (0.5 mL) were stirred at 20 8C for 30 min.
After removal of CH2Cl2 by a stream of N2, the ketone (0.1 mmol) in
a physical mixture of HCO2H/Et3N (5:2 mol ratio, 0.25 mL) was
added. The reaction mixture was stirred vigorously at 40 8C for the
speciﬁed number of hours. Samples were withdrawn from the
reaction mixture and the solvent was removed under a stream of
N2. The samples were then dissolved in the HPLC-eluent, ﬁltered
through silica and analysed by HPLC for determination of
conversion and enantiomeric excess.
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a b s t r a c t
Both enantiomers of eight 1-aryl-2-ﬂuoroethylamines have been synthesised starting with 1-aryl-2-
ﬂuoroethanones. Kinetic resolution of the amines using lipase B from Candida antarctica with ethyl
methoxyacetate as the acyl donor gave the (R)-amines in 96e99% ee and the (S)-methoxyacetamides in
>99.5% ee. The resolution was robust with respect to variation in reaction temperature, acyl donor
concentration, water activity and substrate structure. Nine other lipase preparations failed to catalyse the
reaction or gave a low enantioselectivity. Secondly, a Mitsunobu inversion protocol starting with
enantioenriched 1-aryl-2-ﬂuoroethanols using phthalimide as nucleophile was employed in the syn-
thesis of the (S)-1-aryl-2-ﬂuoroethylamines. Both the inversion efﬁciency and yield depended on the
aromatic substituents. For six of the substrates, clean inversion of the stereochemistry was observed.
However, racemisation and low yields were the result when electron-donating substituents were present
at the aromatic ring. When substituted with a cyano or a nitro group, an unexpected ﬂuorine elimination
occurred, limiting the yield for these transformations. The absolute conﬁguration of the 1-aryl-2-ﬂuo-
roethylamines was determined using circular dichroism.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
1-Arylethylamines are useful building blocks for the preparation
of biological active compounds.1e4 Introduction of ﬂuorine atoms in
the a-position of amines enables tuning of the basicity of the
compounds in question.5 This can be used to modify the binding
properties, increase bioavailability, reduce toxicity or to increase
metabolic stability of a drug candidate. Recently, 1-arylethylamines
containing ﬂuoroalkyl groups have emerged as a new class of
building blocks for medicinal use.6e8
Although a vast amount of research have been devoted to the
preparationof enantioenriched1-arylethylamines, onlya fewroutes
to themonoﬂuorinated derivatives are known. Onemethod is based
on the reductive amination of a-ﬂuoroketones with enantiopure
amines.9 A stereoselective ﬂuoromethylation of enantioenriched
N-(tert-butanesulﬁnyl)imines10 and cinchona-catalysed mono-
ﬂuorination of N-Boc a-amido sulfones have also been reported.11
Enzyme-catalysed resolution is a well-known method for syn-
thesising enantiopure amines.12e14 Hydrolases are able to catalyse
the amidation of primary amines using activated esters as acyl
donors. A number of 1-arylethylamines have been resolved, often
with a high enantiomeric ratio (E-value).15,16 In the case of
ﬂuorinated analogues, a few 2,2-diﬂuoro- and 2,2,2-triﬂuoro-1-
arylethylamines have been resolved by hydrolysis of the corr-
esponding chloroacetamides using the Pseudomonas ﬂuorescens
lipase.17,18 The use of hydrolases to resolve compounds containing
a 1,2-ﬂuoroamine moiety has not been documented.
Another common route to enantioenriched amines is by con-
verting enantioenriched alcohols using the Mitsunobu inversion
with phthalimide or azide as nucleophiles.19 Although various
types of ﬂuorinated reactants have been used in the Mitsunobu
coupling,20e23 the conversion of 1,2-ﬂuorohydrins to 1,2-ﬂuoro-
amines has not been investigated.
With the aim of preparing enantiopure 1-aryl-2-ﬂuo-
roethylamines, we have studied the lipase-catalysed resolution
of 1-aryl-2-ﬂuoroethylamines and the Mitsunobu inversion of
1-aryl-2-ﬂuoroethanols.
2. Results and discussion
2.1. Lipase catalysed resolution
2.1.1. Preparation of racemic starting materials. The racemic amines
2aehwereprepared fromthe correspondinga-ﬂuoroacetophenones
1aeh. The ﬂuoroketones 1aeb were synthesised by ﬂuorination of
the corresponding trimethylsilyl enol ethers using Selectﬂuor,24* Corresponding author. E-mail address: bhoff@chem.ntnu.no (B.H. Hoff).
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while 1ceh were more conveniently prepared by a MW assisted
ﬂuorination of acetophenones.25
A reductive amination using ammonium acetate and NaBH3CN,
chosen for its simplicity, gave only mediocre conversion (33e44%).
However, the use of ammonia in EtOH in the presence of titanium
isopropoxide followed by sodium borohydride reduction,26 was
more successful and gave 68e92% yield (Scheme 1).
2.1.2. Lipase and solvent selection. Compared to their non-ﬂuori-
nated counterparts, the amines 2aeh have lower basicity and were
expected to have altered reactivity. With the aim of identifying
catalysts displaying a high activity and enantioselectivity towards
these substrates, the use of 10 different lipase preparations was
investigated. Being intermediate in both electronic character and
size, 1-(4-bromophenyl)-2-ﬂuoroethylamine (2e) was used as
model substrate, and the reactions were performed in four different
solvents. Ethyl methoxyacetate was used as acyl donor and the
reactions were monitored for 72 h. Table 1 summarises the degree
of conversion after 6 h.
Of the catalysts tested, only the two lipases from Candida ant-
arctica, showed noticeable conversionwithin 72 h. The use of lipase
B from C. antarctica (CAL-B) gave 50% conversion after 6 h in both
hexane and dodecane, whereas 24 h were needed in THF and tol-
uene. A high enantioselectivity (E>200) was experienced in all
solvents. Using lipase A from C. antarctica as catalyst, a lower rate of
reaction and a lower enantiomeric ratio (E¼4e5) was observed.
CAL-B was by far the best catalyst, and hexane was selected as
solvent for further studies.
2.1.3. Reaction temperature, water activity and amount of acyl
donor. The hydrolysis of ethyl methoxyacetate to produce
methoxyacetic acid and ethanol was a side-reaction in the resolu-
tion. It was noticed that methoxyacetic acid and the amine 2e
formed the salt pair I, a process expected to reduce the reaction rate
(see Scheme 2).
The reaction temperature, the concentration of acyl donor and
the water activity were pinpointed as important parameters in the
salt pair formation. Therefore, a two-level factorial design was
performed with these three parameters as variables. The reaction
temperature was varied from 20 to 60 C, the amount of acyl donor
from 1 to 3 equiv and the water activity (aw) fromw0 to 0.33. The
degree of conversion and enantioselectivity of the experiments are
shown in Table 2.
Within the experimental constrains, the only statistically sig-
niﬁcant variable was found to be the reaction temperature (see
Pareto chart in Fig. 1). A reaction temperature of 60 C gave the
highest rate, reaching 50% conversion in 2 h using 1 equiv of acyl
donor. However, a temperature of 40 C also offered acceptable
Table 1
The conversion of 2e to 3e after kinetic resolution (6 h) catalysed by different en-
zymes in different solvents
Enzyme Conversionb (%)
THF Toluene Hexane Dodecane
Seven lipase preparationsa 0 0 0 0
Pseudomonas cepacia 2 0 0 0
Candida antarctica lipase A (Novozym 735) 0 8 14 16
Candida antarctica lipase B (Novozym 435) 23 39 50 50
a Aspergillus niger, Aspergillus oryzae, Candida rugosa, Candida rugosa IM, Pseudo-
monas ﬂuorescens, Rhizomucor miehei, Thermomyces lanuginosa.
b The conversion was calculated by the formula conv.¼ees/(eepþees),27 where
ees and eep are the ee of the substrate and product, respectively.
Table 2
Conversion and E-value after resolution of 2e varying the reaction temperature,
water activity and equivalents of acyl donor
Temp (C) awa Equiv acyl donor Conversionb (%) E-valuec
1 h 2 h 6 h
20 0.33 1 11 16 34 >200
20 0.33 3 13 21 42 >200
20 w0 1 14 22 37 >200
20 w0 3 19 27 42 >200
40 0.12 2 32 43 50 >200
40 0.12 2 34 45 50 >200
60 0.33 1 45 49 50 >200
60 0.33 3 43 43 49 >200
60 w0 1 44 49 50 >200
60 w0 3 41 47 49 >200
a Water activity (aw) was ﬁxed by equilibration in the presence of aqueous sat-
urated salt solutions: MgCl2$7H2O (aw¼0.33), LiCl (aw¼0.12), dried over molecular
sieves 4 Å (aw¼w0).
b The conversion was calculated by the formula conv.¼ees/(eepþees), where ees
and eep are the ee of the substrate and product, respectively.27
c E-values were calculated by the method of Rakels et al. for irreversible
reactions.27
R R
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1) NH3 in EtOH,
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2) NaBH4
1a-h 2a-h
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Scheme 1. Synthesis of 2aeh from 1aeh, R¼OMe (a), OBn (b), H (c), F (d), Br (e), CF3
(f), CN (g), NO2 (h).
Br
NH2 CAL-B
EtO
O
OMe
CAL-B
HO
O
OMe
NH3
F
Br
HN
OMe
O
Br
NH2
F
2e (S)-3e (R)-2e
2e
CAL-B
O
O
OMe
Br
2e
F F
H2O
+EtOH
I
Scheme 2. The enzymatic kinetic resolution and the equilibrium involving the acyl
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Figure 1. Pareto chart of the factorial design varying the amount of acyl donor, water
activity and temperature.
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reaction times at aw¼0.11 and 2 equiv of acyl donor. The enantio-
meric ratio of the reactions was excellent under all conditions.
The amountof acyl donorwasnot a signiﬁcant variable.However,
at 20 C the conversion increased when applying higher levels of
acyl donor, whereas at 60 C the highest conversion was obtained
using 1 equiv of acyl donor. This observation could be accounted for
by the rather complex equilibrium shown in Scheme 2. The reaction
temperature is expected tohavedifferent effects on the relative rates
for the amidation reaction, the non-productive hydrolysis of the acyl
donorand theequilibriumbetween the freeamineand the salt pair I.
The effect of changing the water activity was not signiﬁcant.
However, keeping a constant water activity was still considered to
be important for the reproducibility of the resolutions.
It was further investigated if methoxyacetic acid could be used
as acyl donor in the resolution of 2e. Performing the resolution at
60 C using 1 equiv of methoxyacetic acid, a 49% conversion was
obtained after 6 h. This showed that the formation of I is reversible
and that the resolution also can be performed under such condi-
tions. Attempts to reduce the amount of acyl donor to 0.6 equiv led
to an incomplete conversion after 6 h.
2.1.4. Effect of substrate structure on conversion and selectivity.
Seven other 1-aryl-2-ﬂuoroethylamines, 2aed and 2fehwere then
submitted to lipase-catalysed resolution using CAL-B and ethyl
methoxyacetate (1 equiv) in hexane at 60 C. The small-scale re-
actions of 2beg proceeded with rate comparable to that of the
resolution of 1e and with excellent enantioselectivity. A lower rate
of reaction was observed for the resolution of 2a, and the reaction
stopped at 30% conversion. However, by adding fresh enzyme or
diluting the reaction mixture the resolution could be driven to
completion. Probably, some kind of reversible product or substrate
inhibition occurs. The nitro-derivative 2h had limited solubility in
hexane and therefore reacted slowly. An increase in rate was ob-
served when toluene was used as solvent.
Preparative kinetic resolutions were then performed on
a 2.5 mmol scale. Based on results for the resolution of 2e, a 16-fold
more concentrated reaction mixture was used in the preparative
resolutions. The ee of the product and substrate, conversions, en-
antiomeric ratio after 6 h and by completion are compiled in Table 3.
The enantiomeric ratiowas excellent in all cases (E>200) and the
product (S)-amides 3aeh could all be obtained in enantiomerically
pure form. The kinetic resolution of 2def gave full conversion and
>99%ee of the amineswithin 6 h reaction time. The other substrates
reacted slightly slower, thus, the amines 2a and 2bwere after 24 h
obtained in 97 and 96% ee, respectively. If the lower conversion is
due to inhibition, low solubility of the amines or a displacement of
the equilibrium towards the amine salt I, has not been further
investigated. However, solvent tuning as demonstrated in the small-
scale reaction of 2a and 2h is likely to bring conversion from 49 to
50% and thereby increasing the ee of the remaining substrate.
2.2. The Mitsunobu approach
The (S)-enantiomers of the ﬂuoroamines 2aeh were obtained
from the ketones 1aeh by asymmetric reduction followed by
a Mitsunobu inversion protocol as depicted in Scheme 3.
2.2.1. Preparation of enantioenriched ﬂuoroalcohols. Based on our
previous ﬁndings,28 the ﬂuoroalcohols (R)-4aeh were synthesised
from the corresponding a-ﬂuoroacetophenones 1aeh by asym-
metric transfer hydrogenation catalysed by [RuCl2(mesitylene)]2
complexed with (1S,2S)-N-p-tosyl-1,2-diphenylethylenediamine
((S,S)-TsDPEN). The alcohols (R)-4aee and (R)-4geh were syn-
thesised in a formic acid/triethylamine (5/2 mol ratio) medium,
while (R)-4f was prepared using water with sodium formate as
hydrogen donor. The yields and ee are summarised in Table 4. The
reactions performed in formic acid/triethylamine gave the product
alcohols in 61e91% yield and with good to excellent ee. However, in
the reaction performed in water, the alcohol (R)-3f was isolated in
a moderate 52% yield. The reason for this is somewhat unclear. 1H
NMR spectroscopy analysis of the distillation residue gave a spec-
trum with complex splitting pattern in the range of 4.2e5.3 ppm,
indicating the presence of several structures containing alkyl
ﬂuoride fragments.
2.2.2. Mitsunobu inversion. The alcohols (R)-4aeh were then
reacted with phthalimide in the presence of diethyl
azodicarboxylate (DEAD) and triphenylphosphine to yield the cor-
responding N-substituted phthalimides (S)-5aeh. The isolated
yields and the ee of the products are shown in Table 4.
The N-substituted phthalimides (S)-5cef were isolated in
77e83% yield and with clean inversion of the stereochemistry.
Somewhat disappointingly, the reactions leading to (S)-5aeb, were
Table 3
CAL-B catalysed kinetic resolution of 2aeh (2.5 mmol scale) at 60 C using ethyl
methoxyacetate (1 equiv) as acyl donor in hexane
R 6 h 24 h
Conversionc
(%)
2 of
ee (%)
3 of
ee (%)
Conversionc
(%)
2 of
ee (%)
3 of
ee (%)
OMe (a)a 49.5 97.0 >99.5 49.5 97.0 >99.5
OBn (b) 48.0 92.5 >99.5 49.0 96.0 >99.5
H (c) 49.5 98.5 >99.5 50.0 >99.5 >99.5
F (d) 50.0 >99.5 >99.5 d d d
Br (e) 50.0 >99.5 >99.5 d d d
CF3 (f) 50.0 >99.5 >99.5 d d d
CN (g) 47.0 87.0 >99.5 50.0 99.0 >99.5
NO2 (h)
b d d d 50.0 >99.5 >99.5
a Hexane: 24 mL, CAL-B: 2 equivwt.
b Toluene: 12 mL, CAL-B: 1 equivwt , 48 h reaction time.
c The conversion was calculated by the formula conv.¼ees/(eepþees),27 where
ees and eep are the enantiomeric excess of the substrate and product, respectively.
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Scheme 3. Synthesis of (S)-2aeh from 1aeh using asymmetric transfer hydrogenation
and Mitsunobu inversion.
Table 4
Isolated yields and ee of the alcohols (R)-4aeh, N-substituted phthalimides (S)-
5aeh, and ﬂuoroamines (S)-2aeh
R (R)-4 (S)-5 (S)-2
ee (%) Yield (%) ee (%) Yield (%) ee (%) Yield (%)
OMe (a) 96.0 76 53.0 32 53.5 73
OBn (b) 99.5 61 60.0 37 60.0 72
H (c) 98.0 86 99.0 77 98.5 66
F (d) 93.0 79 92.5a 77 92.5 75
Br (e) 91.0 79 90.0 83 90.5 66
CF3 (f) 92.5 52 92.0 78 91.5 71
CN (g) 87.0 85 87.5 66 87.5 75
NO2 (h) 85.0 91 84.0 34 84.0 80
a Analysed as 2d.
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plagued by racemisation and poor yields. Other alcohols have been
shown to partly racemise under similar conditions.29e33 The re-
actions have been found to proceed via the intermediate ROPPh3
þ
(II), which is attacked by a nucleophile in an SN2 type mechanism
(Scheme 4). However, when the substrate enables stabilisation of
a developing positive charge, II can convert to III and IV.
These intermediates might react with nucleophiles via an SN1
type mechanism to form a racemic product.29,34 The low yields
experienced indicated that other side products also might be
formed via these pathways.
The alcohols (R)-4geh reacted to (S)-5g and (S)-5h without
racemisation, but in moderate and poor yields, respectively. The
major by-product was the corresponding acetophenones 7geh.
Further experiments performed on (R)-4h and racemic 4h showed
that 7h was formed also in the absence of phthalimide. DEAD is
able to oxidise alcohols to ketones,35,36 but in this case a reaction
using only DEAD failed to give 7h. Thus, both DEAD and triphe-
nylphosphine were required for the transformation. In an attempt
to identify reaction intermediates, the reaction was run in THF-d8
and continuously monitored by 1H NMR spectroscopy. The reaction
took place, but within the time scale of NMR no distinct in-
termediates could be detected. Having no indication of the possible
mechanism, 2-ﬂuoro-1-(4-nitrophenyl)ethanone (1h), (R)-2-(4-
nitrophenyl)oxirane ((R)-8h) and 1-(4-nitrophenyl)ethanol (9h)
were reacted with DEAD and triphenylphosphine to investigate if
these compounds could be reaction intermediates. Compound 7h
was not observed in any of these experiments, excluding these
possibilities.
Alcohols have been reported to undergo dehydrations, elimi-
nations and rearrangement reactions under Mitsunobu con-
ditions.37e41 Phosphorus is known to have afﬁnity for ﬂuoride
anions, and triphenylphosphine has been used as a deﬂuorinating
agent.42,43 Based on this, and since no intermediates could be
traced, we propose a concerted mechanism to 7geh via the known
Mitsunobu intermediate II (Scheme 5). The nitro and the cyano
group increase the acidity of the benzylic proton, possibly
explaining why only 4geh reacted by this pathway in the presence
of phthalimide.
To produce the target amines (S)-2aeh, (S)-5aeh were dis-
solved in methanol and reacted with hydrazine and hydrochloric
acid. These hydrazinolysis reactions proceeded smoothly, giving
the amines (S)-2aeh in good to moderate yields without altering
the ee (Table 4).
2.3. Determination of the absolute conﬁguration
Optical rotation data have previously only been reported for the
hydrochloride salts of (S)-2a and (S)-2c.10,11 These data were in
agreement with our measurements.
The conﬁguration of the previously unknown ﬂuoroamines was
strongly indicated by the stereoselectivity of the lipase-catalysed
resolution and the Mitsunobu inversion. However, to un-
ambiguously conﬁrm this, the absolute conﬁguration of the amines
was determined by circular dichroism spectroscopy (CD) of the N-
substituted phthalimides (S)-5aeh using the exciton chirality
method.44e46 The most stable conformation of the N-substituted
phthalimides was predicted using semiempirical AM1 calculations.
All the compounds showed the same preferred conformation, with
the hydrogen attached to the stereogenic centre arranged in the
same plane as the disubstituted phenyl ring (see Fig. 2A).
For (S)-5aeh an anticlockwise rotation of the disubstituted
phenyl ring brings it onto the phthalimide dipole, thus a negative
ﬁrst Cotton effect was predicted. This was conﬁrmed by CD mea-
surements, exempliﬁed by the CD spectrum of (S)-5f in Figure 2B.
All the CD measurements are summarised in Table 5.
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Figure 2. Favoured conformation (A) and CD and UV spectrum of (S)-5f (B).
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3. Conclusions
Starting with a-ﬂuoroacetophenones, a lipase-catalysed reso-
lution and a Mitsonobu inversion have been investigated for the
preparation of enantioenriched 1-aryl-2-ﬂuoroethylamines.
Using CAL-B as catalyst and ethyl methoxyacetate as acyl donor,
the resolutions proceeded with high enantioselectivity and pro-
vided the product (R)-amines and (S)-amides in 96e99% and
>99.5% ee, respectively. The method proved to be fairly robust with
respect to the amount of acyl donor, water activity and the reaction
temperature. One of the substrates (2h) had to be resolved in tol-
uene due to limited solubility in hexane.
The Mitsunobu protocol gave clean inversion of the stereo-
chemistry of the alcohols (R)-4cef. The amines (S)-2cef could be
isolated in 90.5e98.5% ee. In the case of substrates containing
electron-donating substituents, racemisation occurred. The yield
decreased when both electron donating and strongly electron
withdrawing substituents were present. For the latter substrates,
a ﬂuorine elimination was identiﬁed as the major side reaction.
The drawback of a kinetic resolution is the limitation of a max-
imum 50% yield. Therefore, despite the fact that the enzymatic
resolution approach is one step shorter, the overall yields of the two
routes were comparable in the case of 2ceg. However, the resolu-
tion method appears more attractive since it gives the products in
higher ee and involves only two simple steps from the ketone
without the use of hazardous chemicals.
4. Experimental
4.1. Chemicals and equipment
The a-ﬂuoroacetophenones, 1aeh,24,25 and [RuCl2(mesity-
lene)]2,
47,48 were prepared as described previously. (R)-2-(4-
Nitrophenyl)oxirane, (S,S)-TsDPEN and phthalimide were from
Aldrich. 1-(4-Nitrophenyl)ethanone, 4-acetylbenzonitrile, DEAD
(40% solution in toluene) and Silica 60 were from Fluka. Triphe-
nylphosphine was from SigmaeAldrich.
C. antarctica lipase B (Novozym 435), C. antarctica lipase A
(Novozym 735) and Rhizomucor miehei lipase (Lipozyme RM-IM)
were kind gifts from Novozymes. Pseudomonas cepacia, Aspergillus
niger, Aspergillus oryzae, Candida rugosa, C. rugosa IM, Thermomyces
lanuginosa, P. ﬂuorescens were from Aldrich. The enzymatic resolu-
tionswere performed in an Infors-HTMinitron type AY70 incubator.
4.2. Analyses
1H and 13C NMR spectra were recorded with Bruker Avance 400
spectrometer operating at 400 MHz and 100 MHz, respectively. 19F
NMRwas performed on a Bruker Avance 500 operating at 470 MHz.
For 1Hand 13CNMRchemical shifts are inparts permillion rel toTMS,
while for 19F NMR the shift values are relative to hexaﬂuorobenzene.
Coupling constants are in hertz. HPLC was performed using an
Agilent 1100 series system with a DAD detector. GC was performed
using a Varian 3380. Accurate mass determination (ESI) was per-
formed on an Agilent G1969 TOF MS instrument equipped with
a dual electrospray ion source. Samples were injected into the MS
using an Agilent 1100 series HPLC and analysis was performed as
a direct injection analysiswithout any chromatography. FTIR spectra
were recorded on a Thermo Nicolet Avatar 330 infrared spectro-
photometer. All melting points are uncorrected and measured by
a Büchi melting point instrument. CD spectra were recorded on an
OLIS DSM 1000 spectrophotometer in a 1 cm cell, at concentration
0.01 mg/mL in MeCN.
The ee of the amines 2aeh was determined as follows: com-
pounds 2b and 2h were analysed as their triﬂuoroacetamides by
HPLC using a Daicel Chiralcel OD-H column with detection at
230 nm. Compound 2b (triﬂuoroacetamide): hexane/2-propanol
(85/15), ﬂow rate 1.0 mL/min, (S)-2b: 9.2 min, (R)-2a: 13.0 min.
Compound 2h (triﬂuoroacetamide): hexane/2-propanol (90/10),
ﬂow rate 1.0 mL/min, (S)-2h: 12.4 min, (R)-2a: 16.8 min. Com-
pounds 2a and 2cegwere analysed derivatised as their acetamides
on GC using a CP-Chirasil-Dex CB column at 10 psi. Isothermal
programs were used in each case. Compounds 2a and 2g: 160 C,
(R)-2a: 21.1 min, (S)-2a: 21.8 min, (R)-2g: 41.0 min, (S)-2g:
42.1 min, 2c: 125 C, (R)-2c: 26.5 min, (S)-2c: 28.9 min, 2d: 135 C,
(R)-2d: 19.6 min, (S)-2d: 21.3 min, 2e: 150 C, (R)-2e: 38.5 min, (S)-
2e: 40.9 min, 2f: 140 C, (R)-2f: 16.5 min, (S)-2f: 18.2 min.
The ee of the methoxyacetamides 3aeh was determined as
follows: compounds 3a and 3cef were analysed on GC using a CP-
Chirasil-Dex CB column at 10 psi. Isothermal programswere used in
each case. Compound 3a: 160 C, (R)-3a: 24.8 min, (S)-3a: 25.8 min,
3c: 125 C, (R)-3c: 38.0 min, (S)-3c: 40.0 min, 3d: 135 C, (R)-3d:
26.0 min, (S)-3d: 27.1 min, 3e: 150 C, (R)-3e: 49.0 min, (S)-3e:
51.5 min,3f: 140 C, (R)-3f: 19.5 min, (S)-3f: 20.9 min. Compound3b
was analysed byHPLC using a Daicel Chiralcel OD-H column, eluting
with hexane/2-propanol (90/10), ﬂow rate 1.0 mL/min, detection at
230 nm: (S)-3b: 31.7 min, (R)-3b: 38.5 min. Compounds 3geh:
analysed by an Astec Chirobiotic V2 column, 5 mm, 4.6250 mm
(Supelco, Pennsylvania, USA) for 3g eluting with hexane/EtOH
(concn 0.5% TFA), 91/9, ﬂow rate: 1.0 mL/min, detection at 230 nm,
(S)-3g: 47.7 min, (R)-3g: 49.2 min and for 3h eluting with hexane/
EtOH (concn 0.5% TFA), 98/2, ﬂow rate: 3.0 mL/min, detection at
230 nm, (R)-3g: 50.1 min and (S)-3h: 53.8 min.
The ee of the alcohols (S)-4aeh was determined by HPLC
analysis using a Daicel Chiralcel OD column (0.46 cm25 cm)
with mobile phase: hexane/2-propanol (98/2) at a ﬂow rate of
1.0 mL/min.49
The ee of 5aec and 5eehwas determined byHPLC using a Daicel
Chiralcel OD-H columnwith detection at 270 nm. Compounds 5a, 5e
and5f: eluent: hexane/2-propanol (90/10),ﬂowrate 1.0 mL/min, (S)-
5a: 11.2 min, (R)-5a: 12.6 min, (R)-5e: 8.9 min, (S)-5e: 10.1 min,
(R)-5f: 7.5 min, (S)-5f: 8.1 min. Compound 5b: eluent: hexane/2-
propanol (99/1), ﬂow rate: 1.0 mL/min, (S)-5b: 33.5 min, (R)-5b:
36.2 min.Compound5c: eluent: hexane/2-propanol (98/2),ﬂowrate
1.0 mL/min, (R)-5c: 11.3 min, (S)-5c: 14.0 min.Compound5g: eluent:
hexane/2-propanol (90/10), ﬂow rate 1.2 mL/min, (R)-5g: 22.7 min,
(S)-5g: 26.5 min. Compound 5h: eluent: hexane/isopropanol (95/5),
ﬂow rate 1.0 mL/min, (R)-5h: 26.9 min, (S)-5h: 29.8 min.
4.3. General procedures
4.3.1. Preparation of 2aeh. The following procedure is
representative:
1-(4-Bromophenyl)-2-ﬂuoroethanone (1e) (4.36 g, 20.1 mmol)
and titanium isopropoxide (12.0 mL,e40.0 mmol) were dissolved in
an ethanol/ammonia solution (2 M, 50 mL) and stirred under argon
atmosphere at room temperature for 24 h. Upon full conversion as
detected by 1H NMR spectroscopy, NaBH4 (1.13 g, 30.30 mmol) was
Table 5
Enantiomeric excess, molar extinction (De) and absorption maximum for the ﬁrst
Cotton effect (l) for (S)-5aeh
Compound R ee (%) De l (nm)
(S)-5a OMe 53.0 1.3 232
(S)-5b OBn 60.0 3.8 234
(S)-5c H 99.0 3.5 223
(S)-5d F 92.5a 1.6 223
(S)-5e Br 90.0 3.9 230
(S)-5f CF3 92.0 4.8 225
(S)-5g CN 87.5 2.7 237
(S)-5h NO2 84.0 1.4 228
a Analysed as 2d.
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added, and the reaction mixture was stirred under argon atmo-
sphere at room temperature for 24 h. The reaction mixture was
made acidic (pH¼2) using HCl (6 M), and washed with tert-butyl
methyl ether (TBME) (320 mL). The mixture was made alkaline
with NaOH pellets (pH¼10), saturated with sodium chloride and
extracted with TBME (530 mL). The organic phase was dried over
Na2SO4, and the solvent was evaporated under reduced pressure.
Puriﬁcation using silica-gel column chromatography (EtOAc/MeOH,
4/1, Rf 0.45), gave 3.11 g (14.3 mmol, 71%) of a colourless oil.
4.3.2. Small-scale enzymatic resolution. The racemic 1-aryl-2-ﬂuo-
roethylamines, 2aeh, (0.04 mmol), ethyl methoxyacetate
(1e4 mol equiv) and Novozym 435 (1 equivwt) were mixed in the
speciﬁed solvent (3 mL) and agitated in an incubator at 300 rpm at
the speciﬁed temperature. Samples (150 mL) were withdrawn after
1, 2 and 6 h. The samples were analysed for ee of the product and
remaining substrate. The water content of hexane was varied by
equilibrating on the presence of saturated salt solutions:
MgCl2$7H2O (aw¼0.33), LiCl (aw¼0.12) and dried over molecular
sieves 4 Å (aw¼w0).50
4.3.3. Preparative scale enzymatic resolution. The racemic amines
2beg (2.5 mmol), ethyl methoxyacetate (295 mg, 2.5 mmol) and
Novozym 435 (1 equivwt) were diluted with dry hexane (12 mL)
and stirred in an incubator at 300 rpm at 60 C. When 50% con-
version was reached, the reaction mixture was diluted with TBME
(20 mL) and extracted with water containing acetic acid (1 M,
515 mL). The combined water phases were washed with TBME
(215 mL). The organic phase was dried over Na2SO4, and the
solvent evaporated under reduced pressure, yielding the
methoxyacetamides (S)-3beg, which were puriﬁed by silica-gel
column chromatography (EtOAc/MeOH, 4/1). The water phase was
made alkaline with NaOH (pellets), saturated with sodium chloride
and extracted with TBME (515 mL). The organic phase was dried
over Na2SO4, and the solvent was evaporated under reduced
pressure, yielding the amines (R)-2beg, which were puriﬁed by
silica-gel column chromatography (EtOAc/MeOH, 4/1).
4.3.4. Asymmetric transfer hydrogenation28 of 1aee and 1geh. A
suspension of the [RuCl2(mesitylene)]2 (23 mg, 0.04 mmol) and (S,
S)-TsDPEN (44 mg, 0.12 mmol) in CH2Cl2 (8 mL)were stirred at 20 C
for 30 min. After removal of CH2Cl2, the a-ﬂuoroacetophenone
(4.0 mmol) in a mixture of HCO2H/Et3N (5/2 mol ratio, 10 mL) was
added. The reaction mixture was stirred vigorously at 40 C for the
speciﬁed number of hours before it was quenched with water
(10 mL) and extracted with CH2Cl2 (315 mL). The organic phase
was then washed with brine (20 mL) and dried over Na2SO4 before
the solvent was removed under reduced pressure. Puriﬁcation is
described for each individual compound.
4.3.5. Mitsunobu inversion (S)-5aeh from (R)-4aeh. Under an N2-
atmosphere PPh3 (859 mg, 3.3 mmol) and phthalimide (487 mg,
3.3 mmol) were dissolved in THF (20 mL). To this mixture was
added the 1-aryl-2-ﬂuoroethanol, (R)-4aeh, (3.0 mmol) dissolved
in THF (5 mL), followed by the DEAD solution (40% in toluene,
1.36 mL, 3.6 mmol). The mixture was stirred overnight at room
temperature, before the solvent was removed under reduced
pressure. The reaction mixture was then re-dissolved in CH2Cl2
(2 mL), K2CO3 (0.02 M,10 mL) added and themixture stirred for 1 h.
The mixture was extracted with CH2Cl2 (315 mL) and the organic
phase washed with brine (20 mL) and dried over MgSO4. The sol-
vent was removed under reduced pressure and the crude product
was puriﬁed by silica-gel column chromatography.
4.3.6. Hydrazinolysis of (S)-5aeh. The N-substituted phthalimides
5aeh (2.5 mmol) were dissolved in MeOH (40 mL) and N2H4 (1.0 M
in THF, 25 mmol) was added. The mixture was stirred at room
temperature until all the starting material had been consumed
(TLC) (2e10 h.). Then HCl (2 M, 10 mL) was added and the reaction
was stirred at room temperature overnight. Water (40 mL) was
added and the mixture extracted with Et2O (50 mL). The water
phase was made alkaline with NaOH (2 M, 30 mL) and extracted
with Et2O (350 mL). The combined organic phases were washed
with brine (30 mL), dried over MgSO4 and evaporated under re-
duced pressure. The products, (S)-1aeh were puriﬁed by silica-gel
column chromatography (EtOAc/MeOH, 9/1).
4.4. Racemic 1-aryl-2-ﬂuoroethylamines (2aeh)
4.4.1. 2-Fluoro-1-(4-methoxyphenyl)ethylamine (2a). The synthesis
was performed as described for 2e (Section 4.3.1) starting with 2-
ﬂuoro-1-(4-methoxyphenyl)ethanone (1a) (2.18 g 12.94 mmol).
This gave 1.96 g (11.58 mmol, 89%) of a colourless oil. Rf (EtOAc/
MeOH, 4/1) 0.47. 1H NMR (CDCl3) d: 1.70 (s, 2H, eNH2), 3.80 (s, 3H,
eOCH3), 4.22e4.53 (m, 3H, eCHCH2F), 6.89 (m, 2H, eC6H4e), 7.30
(m, 2H, eC6H4e).
13C NMR (CDCl3) d: 55.0 (d, J¼19.4), 55.6, 88.3 (d,
J¼174.5), 114.1 (2C), 128.0 (2C), 132.2 (d, J¼8.5), 159.2. 19F NMR
(CDCl3) d: 219.15 (m). IR (neat, cm1): 3381, 3315, 2954, 2904,
2838, 1611, 1513, 1463, 1249, 1179, 1032, 995, 833. HRMS (ESI):
169.0907 (calcd 169.0903, [Mþ]).
4.4.2. 1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethylamine (2b). The syn-
thesis was performed as described for 2e (Section 4.3.1) startingwith
1-(4-benzyloxyphenyl)-2-ﬂuoroethanone (1b) (0.76 g, 3.10 mmol).
This gave 0.64 g (2.61 mmol, 84%) of a white solid, mp 42e43 C, Rf
(EtOAc/MeOH, 4/1) 0.45. 1H NMR (CDCl3) d: 1.68 (s, 2H, eNH2),
4.22e4.54 (m, 3H, eCHCH2F), 5.07 (s, 2H, CH2Ph), 6.97 (m, 2H,
eC6H4e), 7.29 (m, 2H, eC6H4e), 7.30e7.34 (m, 5H, eC6H5).
13C NMR
(CDCl3) d: 55.0 (d, J¼19.0), 70.0, 88.3 (d, J¼174.5), 115.0 (2C), 127.0,
127.4 (2C), 128.0 (2C), 128.5 (2C), 132.5 (d, J¼8.5), 136.9, 158.5. 19F
NMR (CDCl3) d: 219.20 (m). IR (KBr, cm1): 3381, 3279, 3033, 2947,
2872, 1611, 1513, 1242, 1174, 1014, 839, 745, 697. HRMS (ESI):
245.1215 (calcd 245.1216, [Mþ]).
4.4.3. 2-Fluoro-1-phenylethylamine (2c). The synthesis was per-
formed as described for 2e (Section 4.3.1) starting with 2-ﬂuoro-1-
phenylethanone (1c) (0.49 g, 3.55 mmol). This gave 0.46 g
(3.28 mmol, 92%) of a colourless oil, Rf (EtOAc/MeOH, 4/1) 0.46.
1H
NMR (CDCl3) d: 1.72 (s, 2H, eNH2), 4.28e4.57 (m, 3H, eCHCH2F),
7.23 (m, 2H, Ph), 7.37 (m, 2H, Ph), 7.36 (m, 1H, Ph). 13C NMR (CDCl3)
d: 55.6 (d, J¼19.4), 88.2 (d, J¼174.1), 126.9 (2C), 127.9, 128.6 (2C),
140.2 (d, J¼8.1). 19F NMR (CDCl3) d: 219.85 (m). IR (neat, cm1):
3384, 3314, 3063, 3030, 2950, 2890, 1604, 1493, 1454, 997, 861, 760,
701. HRMS (ESI): 139.0799 (calcd 139.0797, [Mþ]).
4.4.4. 2-Fluoro-1-(4-ﬂuorophenyl)ethylamine (2d). The synthesis
was performed as described for 2e (Section 4.3.1) starting with 2-
ﬂuoro-1-(4-ﬂuorophenyl)ethanone (1d) (0.41 g, 2.61 mmol). This
gave 0.39 g (2.48 mmol, 95%) of a colourless oil. Rf (EtOAc/MeOH,
4/1) 0.46. 1H NMR (CDCl3) d: 1.68 (s, 2H, eNH2), 4.25e4.50 (m, 3H,
eCHCH2F), 7.04 (m, 2H, eC6H4e), 7.35 (m, 2H, eC6H4e).
13C NMR
(CDCl3) d: 55.0 (d, J¼19.4), 88.0 (dd, J¼174.5, 1.4), 115.4 (d, J¼21.2,
2C), 128.5 (dd, J¼8.1, 0.7, 2C), 135.9 (dd, J¼8.1, 2.8), 162.3 (d,
J¼246.2). 19F NMR (CDCl3) d: 115.14 (m), 219.87 (m.). IR (neat,
cm1): 3388, 3321, 3044, 2952, 2891, 1734, 1605, 1510, 1229, 1158,
1093, 1003, 846. HRMS (ESI): 157.0706 (calcd 157.0703, [Mþ]).
4.4.5. 1-(4-Bromophenyl)-2-ﬂuoroethylamine (2e). The synthesis is
described in Section 4.3.1. 1H NMR (CDCl3) d: 1.68 (s, 2H, eNH2),
4.22e4.52 (m, 3H, eCHCH2F), 7.27 (m, 2H, eC6H4e), 7.47 (m, 2H,
eC6H4e).
13C NMR (CDCl3) d: 55.1 (d, J¼19.8), 87.8 (d, J¼174.5),
121.7, 128.6 (d, J¼0.7, 2C), 131.7 (2C), 139.3 (d, J¼7.8). 19F NMR
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(CDCl3) d: 220.34 (m). IR (neat, cm1): 3383, 3330, 2950, 2890,
1590, 1488, 1406, 1073, 1004, 830. HRMS (ESI): 216.9904 (calcd
216.9902, [(79Br)Mþ]).
4.4.6. 2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethylamine (2f). The
synthesis was performed as described for 2e (Section 4.3.1) starting
with 2-ﬂuoro-1-(4-(triﬂuoromethyl)phenyl)ethanone (1f) (0.91 g,
4.40 mmol). This gave 0.62 g (2.99 mmol, 68%) of a colourless oil, Rf
(EtOAc/MeOH, 4/1) 0.49. 1H NMR (CDCl3) d: 1.71 (s, 2H, eNH2),
4.27e4.56 (m, 3H, eCHCH2F), 7.52 (m, 2H, eC6H4e), 7.57 (m, 2H,
eC6H4e).
13C NMR (CDCl3) d: 55.4 (d, J¼19.8), 87.7 (d, J¼175.2),
124.0 (q, J¼272.0), 125.5 (q, J¼3.8, 2C), 127.3 (d, J¼0.7, 2C), 130.1 (q,
J¼32.5), 144.4 (dq, J¼7.6, 1.3). 19F NMR (CDCl3) d: 63.18 (s, 3F),
221.06 (m). IR (neat, cm1): 3392, 3330, 2954, 2895, 1621, 1420,
1326, 1160, 1120, 1068, 1017, 842, 606. HRMS (ESI): 207.0668 (calcd
207.0671, [Mþ]).
4.4.7. 4-(1-Amino-2-ﬂuoroethyl)benzonitrile (2g). The synthesis
was performed as described for 2e (Section 4.3.1) starting with 1-
(4-cyanophenyl)-2-ﬂuoroethanone (1g) (1.03 g, 6.34 mmol). This
gave 0.84 g (5.13 mmol, 81%) of a white solid, mp 48e49 C, Rf
(EtOAc/MeOH, 4/1) 0.42. 1H NMR (CDCl3) d: 1.70 (s, 2H, eNH2),
4.27e4.55 (m, 3H, eCHCH2F), 7.53 (m, 2H, eC6H4e), 7.65 (m, 2H,
eC6H4e).
13C NMR (CDCl3) d: 55.4 (d, J¼19.8), 87.3 (d, J¼175.6),
111.8, 118.6, 127.8 (d, J¼0.7, 2C), 132.4 (2C), 145.8 (d, J¼7.0). 19F NMR
(CDCl3) d:221.61 (m). IR (KBr, cm1): 3381, 3317, 2954, 2863, 2227,
1609, 1502, 1412, 1359, 1099, 1050, 992, 832, 564. HRMS (ESI):
164.0750 (calcd 164.0750, [Mþ]).
4.4.8. 2-Fluoro-1-(4-nitrophenyl)ethylamine (2h). The synthesis
was performed as described for 2e (Section 4.3.1) starting with 2-
ﬂuoro-1-(4-nitrophenyl)ethanone (1h) (1.15 g, 6.26 mmol). This
gave 0.91 g (4.95 mmol, 79%) of a white solid, mp 52e53 C, Rf
(EtOAc/MeOH, 4/1) 0.40. 1H NMR (CDCl3) d: 1.72 (br s, 2H, eNH2),
4.28e4.60 (m, 3H, CHCH2F), 7.58e7.62 (m, 2H, eC6H4e), 8.21e8.24
(m, 2H, eC6H4e).
13C NMR (CDCl3) d: 55.3 (d, J¼20.1), 87.3 (d,
J¼175.6), 123.8 (2C), 128.0 (d, J¼0.7, 2C), 147.7, 147.8, (d, J¼7.1). 19F
NMR (CDCl3) d: 221.78 (m). IR (neat, cm1): 3379, 3113, 2952,
2852, 1599, 1510, 1346, 995, 855. HRMS (ESI): 185.0726 (calcd
185.0726, [MþHþ]).
4.5. (R)-1-Aryl-2-ﬂuoroethylamines ((R)-2aeg)
Compounds (R)-2aeh were obtained by lipase-catalysed reso-
lution as described in Section 4.3.3. The NMR spectroscopic prop-
erties corresponded with that reported for the corresponding
racemates.
4.5.1. (R)-2-Fluoro-1-(4-methoxyphenyl)ethylamine ((R)-2a). The
resolution was performed as described in Section 4.3.3, starting
with 2a (423 mg, 2.50 mmol), but with hexane (24 mL) and
Novozym 435 (846 mg). Reaction time was 24 h. This gave after
silica-gel column chromatography 180 mg (1.06 mmol, 43%) of (R)-
2a as a colourless oil, ee¼97.0%, [a]D20 37.4 (c 0.55, CHCl3).
4.5.2. (R)-1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethylamine ((S)-2b). The
resolution was performed as described in Section 4.3.3, starting
with 2b (613 mg, 2.50 mmol). Reaction time was 24 h. This gave
after silica-gel column chromatography 211 mg (0.86 mmol, 34%) of
(R)-2b as a white solid, mp 41.5e42 C, ee¼96.0%, [a]D20 29.1 (c
0.50, CHCl3).
4.5.3. (R)-2-Fluoro-1-phenylethylamine ((R)-2c)7. The resolution
was performed as described in Section 4.3.3, starting with 2c
(348 mg, 2.50 mmol). Reaction timewas 24 h. This gave after silica-
gel column chromatography 126 mg (0.91 mmol, 36%) of (R)-2c as
colourless oil, ee >99.5%, [a]D
20 40.5 (c 0.60, CHCl3).
4.5.4. (R)-Fluoro-1-(4-ﬂuorophenyl)ethylamine ((R)-2d). The reso-
lutionwas performed as described in Section 4.3.3, starting with 2d
(393 mg, 2.49 mmol). Reaction time was 6 h. This gave after silica-
gel column chromatography 169 mg (1.08 mmol, 43%) of (R)-2d as
a colourless oil, ee >99.5%, [a]D
20 39.7 (c 0.71, CHCl3).
4.5.5. (R)-1-(4-Bromophenyl)-2-ﬂuoroethylamine ((R)-2e). The res-
olution was performed as described in Section 4.3.3, starting with
2e (545 mg, 2.50 mmol). Reaction time was 6 h. This gave after
silica-gel column chromatography 213 mg (0.98 mmol, 39%) of (R)-
2e as a colourless oil, ee >99.5%, [a]D
20 28.5 (c 0.68, CHCl3).
4.5.6. (R)-2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethylamine ((R)-
2f). The resolution was performed as described in Section 4.3.3,
starting with 2f (518 mg, 2.50 mmol). Reaction time was 6 h. This
gave after silica-gel column chromatography 195 mg (0.94 mmol,
38%) of (R)-2f as a colourless oil, ee >99.5%, [a]D
20 27.4 (c 0.61,
CHCl3).
4.5.7. (R)-4-(1-Amino-2-ﬂuoroethyl)benzonitrile ((R)-2g). The res-
olution was performed as described in Section 4.3.3, starting with
2g (411 mg, 2.50 mmol). Reaction time was 24 h. This gave after
silica-gel column chromatography 150 mg (0.91 mmol, 37%) of (R)-
2g as a white solid, mp 46.5e47.0 C, ee¼99.0%, [a]D20 32.0 (c 0.56,
CHCl3).
4.5.8. (R)-2-Fluoro-1-(4-nitrophenyl)ethylamine ((R)-2h). The res-
olution was performed as described in Section 4.3.3, starting with
2h (460 mg, 2.50 mmol), but with toluene (12 mL) as solvent. Re-
action time was 48 h. This gave after silica-gel column chroma-
tography 200 mg (1.09 mmol, 43%) of (R)-2h as a pale yellow solid,
mp 53.0e53.5 C, ee >99.5%, [a]D20 20.1 (c 0.71, CHCl3).
4.6. (S)-1-Aryl-2-ﬂuoroethylamines ((S)-2aeh)
Compounds (S)-2aeh were obtained from the alcohols (R)-
4aeh by theMitsunobu inversion described in Sections 4.3.4e4.3.6.
The NMR spectroscopic properties corresponded with that repor-
ted for the corresponding racemate.
4.6.1. (S)-2-Fluoro-1-(4-methoxyphenyl)ethylamine ((S)-2a)10. The
hydrazinolysis was performed as described in Section 4.3.6 starting
with (S)-5a (200 mg, 0.67 mmol). This gave 83 mg (0.49 mmol,
73%) of (S)-2a as a pale yellow oil, ee¼53.5%, [a]D20 þ20.9 (c 0.54,
CHCl3), Rf (EtOAc/MeOH, 9/1) 0.37.
The hydrochloride salt of (S)-2awas obtained by treatment with
HCl saturated ether (5 mL) under stirring for 20 min. The solvent
was then evaporated under reduced pressure and the product
isolated as a white powder, which decomposed on melting. The 1H
NMR data corresponded with that reported.10 1H NMR (CD3OD) d:
3.82 (s, 3H, eOCH3), 4.59e4.69 (m, 2H, eCH2F), 4.81e8.83 (m, 1H,
eCHCH2F), 7.00e7.05 (m, 2H,eC6H4e), 7.38e7.43 (m, 2H, eC6H4e).
[a]D
20 þ17.7 (c 0.66, MeOH), lit.10 þ31.5 (c 0.66, MeOH).
4.6.2. (S)-1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethylamine ((S)-2b). The
hydrazinolysis was performed as described in Section 4.3.6 starting
with (S)-5b (205 mg, 0.55 mmol). This gave 97 mg (0.40 mmol,
72%) of (S)-2b as a white solid, mp 42e43 C, ee¼60.0%, [a]D20 þ16.0
(c 0.52, CHCl3), Rf (EtOAc/MeOH, 9/1) 0.40.
4.6.3. (S)-2-Fluoro-1-phenylethylamine ((S)-2c)9e11. The hydrazi-
nolysis was performed as described in Section 4.3.6 starting with
(S)-5c (672 mg, 2.50 mmol). This gave 228 mg (1.64 mmol, 66%) of
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(S)-2c as a colourless oil, ee¼98.5%, [a]D20 þ44.0 (c 0.60, CHCl3), Rf
(EtOAc/MeOH, 9/1) 0.40.
The hydrochloride salt of (S)-2cwas obtained by treatment with
HCl saturated ether (5 mL) under stirring for 20 min. The solvent
was then evaporated under reduced pressure and the product
isolated as a white powder, which decomposed on melting. The 1H
NMR data corresponded with that reported.10 1H NMR (CD3OD) d:
4,67e4.76 (m, 2H, eCH2F), 4.84 (m, 1H, eCHCH2F), 7.48e7.51 (m,
5H, Ph). [a]D
20 þ29.4 (c 0.53, MeOH), lit.10 þ29.1 (c 0.57, MeOH).
4.6.4. (S)-2-Fluoro-1-(4-ﬂuorophenyl)ethylamine ((S)-2d). The hyd-
razinolysis was performed as described in Section 4.3.6 starting
with (S)-5d (760 mg, 2.65 mmol). This gave 311 mg (1.98 mmol,
75%) of (S)-2c as a pale yellow oil, ee¼92.5%, [a]D20 þ36.4 (c 0.67,
CHCl3), Rf (EtOAc/MeOH, 9/1) 0.43.
4.6.5. (S)-1-(4-Bromophenyl)-2-ﬂuoroethylamine ((S)-2e). The hyd-
razinolysis was performed as described in Section 4.3.6 starting
with (S)-5e (836 mg, 2.40 mmol). This gave 436 mg (2.00 mmol,
83%) of (S)-2e as a pale yellow oil, which solidiﬁed at 0 C,
ee¼90.5%, [a]D20 þ27.4 (c 0.66, CHCl3), Rf (EtOAc/MeOH, 9/1) 0.40.
4.6.6. (S)-2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethylamine ((S)-
2f). The hydrazinolysis was performed as described in Section 4.3.6
starting with (S)-5f (840 mg, 2.49 mmol). This gave 366 mg
(1.77 mmol, 71%) of (S)-2f as a colourless oil, ee¼91.5%, [a]D20 þ25.7
(c 0.61, CHCl3), Rf (EtOAc/MeOH, 9/1) 0.45.
4.6.7. (S)-4-(1-Amino-2-ﬂuoroethyl)benzonitrile ((S)-2g). The hyd-
razinolysis was performed as described in Section 4.3.6 starting
with (S)-5g (609 mg, 2.07 mmol). This gave 256 mg (1.56 mmol,
75%) of (S)-2g as a solid, mp 47e49 C, ee¼87.5%, [a]D20 þ28.5 (c
0.54, CHCl3), Rf (EtOAc/MeOH, 9/1) 0.40.
4.6.8. (S)-2-Fluoro-1-(4-nitrophenyl)ethylamine ((S)-2h). The hydra-
zinolysis was performed as described in Section 4.3.6 starting with
(S)-5h (310 mg, 0.99 mmol). This gave 145 mg (0.79 mmol, 80%) of
(S)-2h as a white solid, mp 52e53 C, ee¼84.0%, [a]D20 þ15.9 (c 0.69
CHCl3), Rf (EtOAc/MeOH, 9/1) 0.34.
4.7. (S)-N-(2-Fluoro-1-arylethyl)-2-methoxyacetamides
((S)-3aeh)
4.7.1. (S)-N-(2-Fluoro-1-(4-methoxyphenyl)ethyl)-2-methoxy-
acetamide ((S)-3a). The compound was prepared as described in
Section 4.3.3. This gave 210 mg (0.87 mmol, 35%) of awhite solid,mp
94e95 C, ee>99.5%, [a]D20þ77.1 (c 0.58, CHCl3), Rf (EtOAc/MeOH, 4/
1) 0.63. 1H NMR (CDCl3) d: 3.43 (s, 3H, eCH2OCH3), 3.80 (s, 3H,
eOCH3), 3.92 (d, J¼15.1, 1H,eCH2Oe), 3.95 (d, J¼15.1, 1H,eCH2Oe),
4.63 (ddd, J¼47.5, 9.5, 4.3,eCH2F), 4.67 (ddd, J¼47.5, 9.5, 4.8,eCH2F),
5.27 (m, 1H, eCHCH2F), 6.88e6.92 (m, 2H, eC6H4e), 7.04 (d, J¼7.7,
1H, eNHe), 7.25e7.30 (m, 2H, eC6H4e).
13C NMR (CDCl3) d: 51.8 (d,
J¼19.4), 55.3, 59.1, 71.9, 84.7 (d, J¼175.7), 114.2 (2C), 128.2 (d, J¼1.2,
2C), 129.6 (d, J¼3.4), 159.4, 169.1. 19F NMR (CDCl3) d: 229.56 (td,
J¼47.2, 23.8). IR (neat, cm1): 3319,1655,1518,1367,1207,1111,1005,
833, 586. HRMS (ESI): 241.1122 (calcd 241.1114, [Mþ]).
4.7.2. (S)-N-(1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethyl)-2-methoxy-
acetamide ((S)-3b). The compound was prepared as described in
Section4.3.3. This gave 246 mg (0.77 mmol, 31%) of awhite solid,mp
109e110 C, ee>99.5%, [a]D20þ66.5 (c 0.53, CHCl3), Rf (EtOAc/MeOH,
4/1) 0.66. 1H NMR (CDCl3) d: 3.43 (s, 3H,eCH2OCH3), 3.92 (d, J¼15.1,
1H, eCH2Oe), 3.94 (d, J¼15.1, 1H, eCH2Oe), 4.63 (ddd, J¼47.5, 9.5,
4.8, 1H, eCH2F), 4.67 (ddd, J¼47.5, 9.5, 4.3, 1H, eCH2F), 5.01 (s, 2H,
eOCH2Ph), 5.26 (m, 1H, eCHCH2F), 6.95e6.99 (m, 2H, eC6H4), 7.00
(d, J¼7.9, 1H, eNH), 7.25e7.29 (m, 2H, eC6H4), 7.30e7.44 (m, 5H,
eCH2eC6H5).
13CNMR(CDCl3) d: 51.8 (d, J¼19.3), 59.1, 70.0, 71.9, 84.7
(d, J¼175.8), 115.1 (2C), 127.4 (2C), 128.0, 128.2 (d, J¼1.1, 2C), 128.6
(2C),129.9 (d, J¼3.4), 136.8,158.6,169.1. 19F NMR (CDCl3) d:229.60
(td, J¼47.3, 24.0). IR (neat, cm1): 3294, 1650, 1532, 1116, 1003, 829,
542. HRMS (ESI): 317.1430 (calcd 317.1427, [Mþ]).
4.7.3. (S)-N-(2-Fluoro-1-phenylethyl)-2-methoxyacetamide ((S)-
3c). The compoundwas prepared as described in Section 4.3.3. This
gave 170 mg (0.80 mmol, 32%) of a white solid, mp 111e112 C, ee
>99.5%, [a]D
20 þ58.4 (c 0.46, CHCl3), Rf (EtOAc/MeOH, 4/1) 0.62. 1H
NMR (CDCl3) d: 3.44 (s, 3H,eCH2OCH3), 3.94 (d, J¼15.1,1H,eCH2Oe),
3.96 (d, J¼15.1, 1H, eCH2Oe), 4.66 (ddd, J¼47.5, 9.5, 4.7, 1H, eCH2F),
4.70 (ddd, J¼47.5, 9.5, 4.3,1H,eCH2F), 5.32 (m,1H,eCHCH2F), 7.12 (d,
J¼5.1,1H,eNHe), 7.29e7.41 (m, 5H,eC6H5). 13C NMR (CDCl3) d: 52.3
(d, J¼19.2), 59.2, 71.9, 84.7 (d, J¼175.9), 126.9 (d, J¼1.1, 2C), 128.1,
128.8 (2C), 137.5 (d, J¼3.4), 169.2. 19F NMR (CDCl3) d: 229.87 (td,
J¼47.7, 24.3). IR (neat, cm1): 3301,1650,1532,1371,1217,1117,1005,
847, 588. HRMS (ESI): 211.1015 (calcd 211.1009, [Mþ]).
4.7.4. (S)-N-(2-Fluoro-1-(4-ﬂuorophenyl)ethyl)-2-methoxy-
acetamide ((S)-3d). The compound was prepared as described in
Section 4.3.3. Puriﬁcation gave 228 mg (0.99 mmol, 40%) of a white
solid, mp 79e80 C, ee >99.5%, [a]D20 þ61.1 (c 0.5, CHCl3), Rf (EtOAc/
MeOH, 4/1) 0.65. 1H NMR (CDCl3) d: 3.44 (s, 3H,eCH2OCH3), 3.93 (d,
J¼15.1,1H,eCH2Oe), 3.95 (d, J¼15.1,1H,eCH2Oe), 4.64 (ddd, J¼47.5,
9.5, 4.6, 1H, eCH2F), 4.69 (ddd, J¼47.5, 9.5, 4.1, 1H eCH2F), 5.29 (m, ,
1H,eCHCH2F), 7.03e7.09 (m, 2H,eC6H4e), 7.10 (d, J¼7.1,1H,eNHe),
7.31e7.36 (m, 2H,eC6H4e).
13C NMR (CDCl3) d: 51.7 (d, J¼19.3), 59.2,
71.8, 84.6 (d, J¼175.9), 115.7 (d, J¼21.6, 2C),128.7 (dd, J¼1.2, 8.2, 2C),
133.4 (d, J¼3.2),162.4 (d, J¼246.5),169.1. 19FNMR (CDCl3) d:230.38
(td, J¼47.6, 25.4), 117.17 (s). IR (neat, cm1): 3308, 1656, 1511, 1217,
1112, 984, 834, 604. HRMS (ESI): 229.0917 (calcd 229.0914, [Mþ]).
4.7.5. (S)-N-(1-(4-Bromophenyl)-2-ﬂuoroethyl)-2-methoxy-
acetamide ((S)-3e). The compound was prepared as described in
Section 4.4.3. Puriﬁcation gave 305 mg (1.05 mmol, 42%) of a white
solid, mp 111e112 C, ee >99.5%, [a]D20 þ63.9 (c 0.57, CHCl3). Rf
(EtOAc/MeOH, 4/1) 0.66. 1H NMR (CDCl3) d: 3.44 (s, 3H,eCH2OCH3),
3.93 (d, J¼15.2, 1H, eCH2Oe), 3.96 (d, J¼15.2, 1H, eCH2Oe), 4.64
(ddd, J¼47.5, 9.5, 4.5, 1H, eCH2F), 4.68 (ddd, J¼47.5, 9.5, 4.3, 1H,
eCH2F), 5.26 (m,1H,eCHCH2F), 7.12 (d, J¼7.5,1H,eNHe), 7.21e7.25
(m, 2H, eC6H4e), 7.48e7.52 (m, 2H, eC6H4e).
13C NMR (CDCl3) d:
52.0 (d, J¼19.1), 59.2, 71.8, 84.5 (d, J¼176.3), 122.1, 128.7 (d, J¼1.1,
2C), 132.0 (2C), 136.7 (d, J¼3.2), 169.2. 19F NMR (CDCl3) d: 230.60
(td, J¼47.2, 25.8). IR (neat, cm1): 3290,1653,1527,1368,1228,1112,
1008, 821, 594. HRMS (ESI): 289.0111 (calcd 289.0114, [Mþ]).
4.7.6. (S)-N-(2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethyl)-2-me-
thoxyacetamide ((S)-3f). The compound was prepared as described
in Section 4.4.3. Puriﬁcation gave 245 mg (0.87 mmol, 35%) of
a white solid, mp 108e109 C, ee >99.5%, [a]D20 þ47.5 (c 0.58,
CHCl3), Rf (EtOAc/MeOH, 4/1) 0.66.
1H NMR (CDCl3) d: 3.46 (s, 3H,
eCH2OCH3), 3.94 (d, J¼15.2, 1H, eCH2Oe), 3.97 (d, J¼15.2, 1H,
eCH2Oe), 4.68 (ddd, J¼47.5, 9.6, 4.3, 1H, eCH2F), 4.73 (ddd, J¼47.5,
9.6, 4.0, 1H, eCH2F), 5.35 (m, 1H, eCHCH2F), 7.21 (d, J¼7.2, 1H,
eNHe), 7.43e7.50 (m, 2H,eC6H4e), 7.60e7.66 (m, 2H,eC6H4e).
13C
NMR (CDCl3) d: 52.1 (d, J¼19.0), 59.2, 71.8, 84.5 (d, J¼176.2), 123.9
(q, J¼272.1), 125.8 (q, J¼3.8, 2C), 127.4 (d, J¼1.2, 2C), 130.4 (q,
J¼32.6), 141.6 (m), 169.3. 19F NMR (CDCl3) d: 230.98 (td, J¼46.4,
28.3), 65.86 (s, 3F). IR (neat, cm1): 3292, 1658, 1532, 1375, 1228,
1116, 1011, 838, 606. HRMS (ESI): 279.0895 (calcd 279.0882, [Mþ]).
4.7.7. (S)-N-(1-(4-Cyanophenyl)-2-ﬂuoroethyl)-2-methoxy-
acetamide ((S)-3g). The compound was prepared as described in
Section 4.4.3. Puriﬁcation gave 249 mg (1.05 mmol, 42%) of a white
solid, mp 76.5e77.0 C, ee >99.5%, [a]D20 þ82.8 (c 0.53, CHCl3), Rf
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(EtOAc/MeOH, 4/1) 0.63. 1H NMR (CDCl3) d: 3.46 (s, 3H,eCH2OCH3),
3.94 (d, J¼15.3, 1H, eCH2Oe), 3.98 (d, J¼15.3, 1H, eCH2Oe), 4.68
(ddd, J¼47.4, 9.7, 4.1, 1H, eCH2F), 4.72 (ddd, J¼47.4, 9.7, 3.8, 1H,
eCH2F), 5.34 (m,1H,eCHCH2F), 7.24 (d, J¼7.7,1H,eNHe), 7.46e7.50
(m, 2H, eC6H4e), 7.65e7.69 (m, 2H, eC6H4e).
13C NMR (CDCl3) d:
59.2, 71.7, 84.4 (d, J¼176.4),112.1,118.4,127.8 (d, J¼1.1, 2C),132.6 (2C),
143.0 (d, J¼3.0), 169.3. 19F NMR (CDCl3) d:231.46 (td, J¼46.4, 27.9).
IR (neat, cm1): 3310, 2232, 1655, 1532, 1372, 1226, 1117, 1014, 841,
563. HRMS (ESI): 236.0963 (calcd 236.0961, [Mþ]).
4.7.8. (S)-N-(2-Fluoro-1-(4-nitrophenyl)ethyl)-2-methoxyacetamide
((S)-3h). The compound was prepared as described in Section
4.4.3. Puriﬁcation by silica-gel column chromatography (EtOAc/
MeOH, 4/1) gave 217 mg (0.90 mmol, 36%) of a white solid, mp
95.0e95.5 C, ee >99.5%, [a]D20 þ70.8 (c¼0.69, CHCl3), Rf (EtOAc/
MeOH, 4/1) 0.62. 1H NMR (CDCl3) d: 3.47 (s, 3H,eCH2OCH3), 3.95 (d,
J¼15.3, 1H, eCH2Oe), 3.98 (d, J¼15.3, 1H, eCH2Oe), 4.71 (ddd,
J¼47.4, 9.7, 4.0, 1H, eCH2F), 4.75 (ddd, J¼47.4, 9.7, 4.0, 1H, eCH2F),
5.39 (m,1H,eCHCH2F), 7.28 (d, J¼7.2, 1H,eNHe), 7.52e7.56 (m, 2H,
eC6H4e), 8.21e8.26 (m, 2H, eC6H4e).
13C NMR (CDCl3) d: 52.1 (d,
J¼19.1), 59.3, 71.8, 84.4 (d, J¼176.6), 124.0 (2C), 128.0 (d, J¼1.0, 2C),
145.0 (d, J¼2.8), 147.7, 169.4. 19F NMR (CDCl3) d:231.62 (td, J¼46.4,
28.3). IR (neat, cm1): 3273, 2970, 1650, 1516, 1348, 1110, 1012, 851,
697. HRMS (ESI): 256.0860 (calcd 256.0859, [Mþ]).
4.8. (R)-1-Aryl-2-ﬂuoroethanols ((R)-4aeh)
In the course of this work, calculation errors in the optical ro-
tations data for (R)-4aeh in our previous study were discovered.49
Corrected values for these data are therefore included.
4.8.1. (R)-2-Fluoro-1-(4-methoxyphenyl)ethanol ((R)-4a)49. The re-
action was performed as described in Section 4.3.4 starting with 2-
ﬂuoro-1-(4-methoxyphenyl)ethanone (1a) (673 mg, 4.00 mmol).
Puriﬁcation by silica-gel column chromatography (CH2Cl2/MeOH,
99/1, Rf 0.47) gave 515 mg (3.03 mmol, 76%) of a colourless oil,
ee¼96.0%, [a]D20 47.1 (c 0.69, CHCl3), corr. ref. ee¼99.5%, [a]D20
55.0 (c 0.70, CHCl3). 1H NMR (CDCl3) d: 2.41 (br, 1H, eOH), 3.81 (s,
3H, eOCH3), 4.38 (ddd, J¼48.5, 9.5, 8.3, 1H, eCH2F), 4.49 (ddd,
J¼46.8, 9.5, 3.3, 1H, eCH2F), 4.97 (ddd, J¼13.2, 8.3, 3.3, 1H,
eCHCH2F), 6.87e6.91 (m, 2H,eC6H4e), 7.29e7.33 (m, 2H,eC6H4e).
4.8.2. (R)-1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethanol ((R)-4b)49. The
reactionwasperformed asdescribed in Section 4.3.4 startingwith1-
(4-benzyloxyphenyl)-2-ﬂuoroethanone (1b) (733 mg, 3.00 mmol).
Puriﬁcation by silica-gel chromatography (CH2Cl2/MeOH, 99/1, Rf
0.26) gave 450 mg (1.83 mmol, 61%) of a white solid, mp 70e71 C,
ee¼99.5%, [a]D2038.3 (c 0.59, CHCl3), corr. ref. ee¼97.0%, [a]D2033.2
(c 0.60, CHCl3).
1H NMR (CDCl3) d: 2.39 (dd, J¼2.9,1.1,1H,eOH), 4.40
(ddd, J¼48.5, 9.5, 8.3, 1H, eCH2F), 4.48 (ddd, J¼46.8, 9.5, 3.4, 1H,
eCH2F), 4.97 (m, 1H, eCHCH2F), 5.09 (s, 2H, eOCH2Ph), 6.95e7.01
(m, 2H, eC6H4e), 7.30e7.47 (m, 7H, Ar).
4.8.3. (R)-2-Fluoro-1-phenylethanol ((R)-4c)49. The reaction was
performed as described in Section 4.3.4 starting with 2-ﬂuoro-1-
phenylethanone (1c) (553 mg, 4.00 mmol). Puriﬁcation by bulb-to-
bulb distillation (35e40 C at 5.0103 mbar) gave 480 mg
(3.42 mmol, 86%) of a colourless oil, ee¼98.0%, [a]D20 56.8 (c 1.20,
CHCl3), corr. ref. ee¼96.5%, [a]D20 53.7 (c 1.20, CHCl3). 1H NMR
(CDCl3) d: 2.51 (br, 1H, eOH), 4.40 (ddd, J¼48.5, 9.5, 8.3, 1H,eCH2F),
4.51 (ddd, J¼46.8, 9.5, 3.3, 1H, eCH2F), 5.04 (ddd, J¼14.0, 8.3, 3.3,
1H, eCHCH2F), 7.33e7.36 (m, 5H, eC6H5).
4.8.4. (R)-2-Fluoro-1-(4-ﬂuorophenyl)ethanol ((R)-4d)49. The re-
action was performed as described in Section 4.3.4 starting with 2-
ﬂuoro-1-(4-ﬂuorophenyl)ethanone (1d) (752 mg, 4.82 mmol).
Puriﬁcation by bulb-to-bulb distillation (35e40 C at
3.0103 mbar) gave 603 mg (3.81 mmol, 79%) of a colourless oil,
ee¼93.0%, [a]D20 51.9 (c 0.59, CHCl3), corr. ref. ee¼99.0%, [a]D20
60.8 (c 0.60, CHCl3). 1H NMR (CDCl3) d: 2.63 (br, 1H, eOH), 4.37
(ddd, J¼48.4, 9.6, 8.2, 1H, eCH2F), 4.48 (ddd, J¼46.7, 9.6, 3.3, 1H,
eCH2F), 5.03 (ddd, J¼13.9, 8.2, 3.3, 1H, eCHCH2F), 7.01e7.08 (m, 2H,
eC6H4e), 7.32e7.36 (m, 2H, eC6H4e).
4.8.5. (R)-1-(4-Bromophenyl)-2-ﬂuoroethanol ((R)-4e)49. The re-
action was performed as described in Section 4.3.4 starting with
1-(4-bromophenyl)-2-ﬂuoroethanol (1e) (868 mg, 4.00 mmol). Pu-
riﬁcation by bulb-to-bulb distillation (60e65 C at 1.1102 mbar)
gave 688 mg (3.14 mmol, 79%) of a white solid, mp 41e42 C,
ee¼91.0%, [a]D2033.4 (c 0.90, CHCl3), corr. ref. ee¼98.5%, [a]D2035.9
(c 0.90, CHCl3).
1H NMR (CDCl3) d: 2.43 (dd, J¼1.1, 3.1, 1H, eOH), 4.36
(ddd, J¼48.1, 9.6, 8.2, 1H, eCH2F), 4.49 (ddd, J¼46.6, 9.6, 3.3, 1H,
eCH2F), 4.97 (m, 1H, eCHCH2F), 7.28e7.30 (m, 2H, eC6H4e),
7.45e7.53 (m, 2H, eC6H4e).
4.8.6. (R)-2-Fluoro-1-(4-(triﬂuoromethyl)phenyl) ethanol ((R)-4f)49. A
suspension of [RuCl2(mesitylene)]2 (23 mg, 0.04 mmol) and the (S,
S)-TsDPEN (44 mg, 0.12 mmol) in H2O (20 mL) were stirred at 40 C
for 1 h. Sodium formate (1.36 g, 20.0 mmol) and 2-ﬂuoro-1-(4-tri-
ﬂuoromethylphenyl)ethanone (1f) (825 mg, 4.0 mmol) were added
and the mixture was stirred vigorously at 40 C for 10 h before it
was cooled to room temperature and extracted with CH2Cl2
(320 mL). The organic phasewas thenwashedwith brine (20 mL),
ﬁltered through a plug of silica gel and dried over Na2SO4. The
solvent was removed under reduced pressure and the crude
product was puriﬁed by bulb-to-bulb distillation (40e45 C at
1.0102 mbar). This gave 429 mg (2.06 mmol, 52%) of a colourless
oil, ee¼92.5%, [a]D20 27.4 (c 0.69, CHCl3), corr. ref. ee¼93.0, [a]D20
28.6 (c 0.70, CHCl3). 1H NMR (CDCl3) d: 2.55 (d, J¼3.1, 1H, eOH),
4.42 (ddd J¼48.0, 9.6, 8.1, 1H, eCH2F), 4.55 (ddd, J¼46.7, 9.6, 3.4, 1H,
eCH2F), 5.11 (m, 1H, eCHCH2F), 7.50e7.53 (m, 2H, eC6H4e),
7.63e7.69 (m, 2H, eC6H4e).
4.8.7. 4-((R)-2-Fluoro-1-hydroxyethyl)benzonitrile ((R)-4g)49. The
reaction was performed as described in Section 4.3.4 starting with
1-(4-cyanophenyl)-2-ﬂuoroethanone (1g) (653 mg, 4.00 mmol).
Puriﬁcation by silica-gel column chromatography (CH2Cl2/MeOH,
99.5/0.5, Rf 0.43) gave 563 mg (3.41 mmol, 85%) of awhite solid, mp
59e60 C, ee¼87.0%, [a]D20 35.6 (c 0.70, CHCl3), corr. ref. ee¼91.5%,
[a]D
20 38.7 (c 0.70, CHCl3). 1H NMR (CDCl3) d: 2.62 (d, J¼3.3, 1H,
eOH), 4.40 (ddd, J¼48.0, 9.5, 8.0, 1H, eCH2F), 4.55 (ddd, J¼46.7, 9.5,
3.4,1H,eCH2F), 5.09 (m,1H,eCHCH2F), 7.46e7.56 (m, 2H,eC6H4e),
7.65e7.71 (m, 2H, eC6H4e).
4.8.8. (R)-2-Fluoro-1-(4-nitrophenyl)ethanol ((R)-4h)49. The reaction
was performed as described in Section 4.3.4 starting with 2-ﬂuoro-
1-(4-nitrophenyl)ethanone (1h) (733 mg, 4.00 mmol). Puriﬁcation
by silica-gel chromatography (CH2Cl2/MeOH, 95/5, Rf 0.52) gave
673 mg (3.63 mmol, 91%) of a white solid, mp 98e99 C, ee¼85.0%,
[a]D
20 24.7 (c 0.70, CHCl3), corr. ref. ee¼92.5%, [a]D20 25.3 (c 0.70,
CHCl3).
1H NMR (CDCl3) d: 2.65 (br, 1H, eOH), 4.42 (ddd J¼47.9, 9.6,
7.8, 1H, eCH2F), 4.56 (ddd, J¼46.5, 9.6, 3.4, 1H, eCH2F), 5.16 (ddd,
J¼3.4, 7.8, 14.5, 1H, eCHCH2F), 7.59e7.65 (m, 2H, eC6H4e),
8.22e8.28 (m, 2H, eC6H4e).
4.9. N-Substituted phthalimides (S)-5aeh
4.9.1. (S)-2-(2-Fluoro-1-(4-methoxyphenyl)ethyl)isoindoline-1,3-di-
one ((S)-5a). The synthesis was performed as described in Section
4.3.5 starting with (R)-4a (420 mg, 2.47 mmol), and reacting for
10 h prior to addition of HCl. Puriﬁcation by silica-gel column
chromatography eluting with CH2Cl2/MeOH (99.5/0.5, Rf 0.54)
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followed by i-Pr2O/pentane (7/3, Rf 0.28), gave 235 mg (0.79 mmol,
32%) of white solid, mp 75e76 C, ee¼53.0%, [a]D20 15.8 (c 0.50,
EtOAc), CD (MeCN): D3¼1.3 (232 nm). 1H NMR (CDCl3) d: 3.78 (s,
3H, eOCH3), 4.90 (ddd, J¼45.7, 9.6, 5.3, 1H, eCH2F), 5.52 (app. dt.
J¼47.0, 9.6, 1H, eCH2F), 5.63 (ddd, J¼12.1, 9.6, 5.3, 1H, eCHCH2F),
6.86e6.89 (m, 2H, eC6H4OMe), 7.43e7.47 (m, 2H, eC6H4OMe),
7.68e7.73 (m, 2H, phthal.), 7.81e7.86 (m, 2H, phthal.). 13C NMR
(CDCl3) d: 54.3 (d, J¼21.2), 55.3, 80.8 (d, J¼175.2), 114.2 (2C), 123.4
(2C), 127.2 (d, J¼7.8), 129.6 (2C), 131.9 (2C), 134.1 (2C), 159.8, 168.3
(2C). 19F NMR (CDCl3) d: 220.30 (td, J¼46.9, 12.1). IR (neat, cm1):
1773,1706,1610,1514,1363,1238,1087,1001. HRMS (ESI): 322.0836
(calcd 322.0850 [MþNaþ]).
4.9.2. (S)-2-(1-(4-(Benzyloxy)phenyl)-2-ﬂuoroethyl)isoindoline-1,3-
dione ((S)-5b). The synthesis was performed as described in Section
4.3.5 starting with (R)-4b (452mg, 1.84 mmol), and reacting for 8 h
prior to addition of HCl. Puriﬁcation by silica-gel column chroma-
tography (CH2Cl2, Rf 0.55) gave 255 mg (0.68 mmol, 37%) of a white
solid,mp 82e83 C, ee¼60.0%, [a]D2011.1 (c 0.47, EtOAc), CD (MeCN):
D3¼3.8 (234 nm). 1H NMR (CDCl3) d: 4.89 (ddd, J¼45.7, 9.6, 5.3, 1H,
eCH2F), 5.04 (s, 2H, eOCH2Ph), 5.52 (app. dt. J¼47.0, 9.6, 1H, eCH2F),
5.62 (ddd, J¼12.1, 9.6, 5.3, 1H, eCHCH2F), 6.92e6.96 (m, 2H,
eC6H4OBn), 7.29e7.41 (m, 5H, eCH2C6H5), 7.42e7.46 (m, 2H,
eC6H4OBn), 7.68e7.73 (m, 2H, phthal.), 7.81e7.85 (m, 2H, phthal.).
13C
NMR(CDCl3) d: 54.3 (d, J¼21.5), 70.0,80.8 (d, J¼175.2),115.2 (2C),123.4
(2C),127.4 (2C),127.5 (d, J¼7.8),128.0,128.6 (2C),129.7 (2C),131.8 (2C),
134.1 (2C), 136.7, 159.0, 168.2 (2C). 19F NMR (CDCl3) d: 220.29 (td,
J¼46.2,11.9). IR (neat, cm1): 1771,1708,1608,1508,1359,1242,1083,
997. HRMS (ESI): 398.1148 (calcd 398.1163, [MþNaþ]).
4.9.3. (S)-2-(2-Fluoro-1-phenylethyl)isoindoline-1,3-dione ((S)-5c). The
synthesis was performed as described in Section 4.3.5 starting with
(R)-4c (460 mg, 3.28 mmol), and reacting for 2 h prior to addition of
HCl. Puriﬁcation by silica-gel chromatography (CH2Cl2/MeOH, 99/1,
Rf 0.73) gave 681 mg (2.53 mmol, 77%) of a white solid, mp
69e70 C, ee¼99.0%, [a]D20 49.0 (c 0.61, EtOAc), CD (MeCN):
D3¼3.5 (223 nm). 1H NMR (CDCl3) d: 4.95 (ddd, J¼45.7, 9.1, 5.6,1H,
eCH2F), 5.55 (app. dt. J¼47.2, 9.1, 1H, eCH2F), 5.69 (ddd, J¼12.4, 9.1,
5.3, 1H, eCHCH2F), 7.29e7.38 (m, 3H, eC6H5), 7.48e7.51 (m, 2H,
eC6H5), 7.69e7.74 (m, 2H, phthal.), 7.82e7.87 (m, 2H, phthal.).
13C
NMR (CDCl3) d: 54.8 (d, J¼21.6), 80.8 (d, J¼174.8), 123.4 (2C), 128.2
(2C), 128.7, 128.9 (2C), 131.8 (2C), 134.2 (2C), 135.1 (d, J¼7.4), 168.2
(2C). 19F NMR (CDCl3) d: 219.83 (td, J¼46.2, 11.9). IR (neat, cm1):
1770,1704,1611,1493,1385,1357,1086,1000. HRMS (ESI): 292.0735
(calcd 292.0744, [MþNaþ]).
4.9.4. (S)-2-(2-Fluoro-1-(4-ﬂuorophenyl)ethyl)isoindoline-1,3-dione
((S)-5d). The synthesis was performed as described in Section 4.3.5
starting with (R)-4d (583 mg, 3.69 mmol), and reacting for 4 h prior
to addition of HCl. Puriﬁcation by silica-gel column chromatogra-
phy (CH2Cl2/MeOH, 99/1, Rf 0.62) gave 815 mg (2.84 mmol, 77%) of
a white solid, mp 58e59 C, ee¼92.5% (analysed as 2d), [a]D20 36.8
(c 0.73, EtOAc), CD (MeCN): D3¼1.6 (223 nm). 1H NMR (CDCl3) d:
4.93 (ddd, J¼45.5, 9.4, 5.8, 1H, eCH2F), 5.49 (app. dt, J¼47.0, 9.4, 1H,
eCH2F), 5.66 (ddd, J¼12.1, 9.4, 5.8, 1H, eCHCH2F), 7.01e7.07 (m, 2H,
eC6H4F), 7.48e7.53 (m, 2H, eC6H4F), 7.70e7.75 (m, 2H, phthal.),
7.82e7.87 (m, 2H, phthal.). 13C NMR (CDCl3) d: 54.0 (d, J¼22.3), 80.6
(d, J¼175.6), 115.9 (d, J¼21.6), 123.5, 130.2 (d, J¼4.1), 131.1 (dd, J¼4.1,
3.5), 131.7, 134.3, 162.8 (d, J¼248.3), 168.1 (2C). 19F NMR (CDCl3) d:
113.33 (s), 219.63 (td, J¼46.2, 11.8). IR (neat, cm1): 1774, 1707,
1605, 1511, 1389, 1223, 1100, 1000. HRMS (ESI): 288.0838 (calcd
288.0831, [MþHþ]).
4.9.5. (S)-2-(1-(4-bromophenyl)-2-ﬂuoroethyl)isoindoline-1,3-dione
((S)-5e). The synthesis was performed as described in Section 4.3.5
starting with (R)-4e (657 mg, 3.00 mmol), and reacting for 2 h prior
to addition of HCl. Puriﬁcation by silica-gel column chromatogra-
phy (CH2Cl2/MeOH, 99/1, Rf 0.65) gave 871 mg (2.50 mmol, 83%) of
a white solid, mp 66e67 C, ee¼90.0%, [a]D20 19.8 (c 0.60, EtOAc),
CD (MeCN): D3¼3.9 (230 nm). 1H NMR (CDCl3) d: 4.95 (ddd,
J¼45.8, 9.4, 5.8, 1H, eCH2F), 5.46 (app. dt, J¼47.0, 9.4, 1H, eCH2F),
5.64 (ddd, J¼12.1, 9.4, 5.8,1H,eCHCH2F), 7.37e7.40 (m, 2H, C6H4Br),
7.47e7.50 (m, 2H, C6H4Br), 7.71e7.75 (m, 2H, phthal.), 7.82e7.87 (m,
2H, phthal.). 13C NMR (CDCl3) d: 54.1 (d, J¼22.6), 80.5 (d, J¼175.6),
122.9, 123.5 (2C), 129.9 (2C), 131.7 (2C), 132.1 (2C), 134.2 (d, J¼6.7),
134.3 (2C), 168.1 (2C). 19F NMR (CDCl3) d: 220.87 (td, J¼46.3, 11.9).
IR (neat, cm1): 1770, 1708, 1591, 1491, 1385, 1355, 1077, 999. HRMS
(ESI): 369.9853 (calcd 369.9849, [MþNaþ]).
4.9.6. (S)-2-(2-Fluoro-1-(4-(triﬂuoromethyl)phenyl)ethyl)isoindo-
line-1,3-dione ((S)-4f). The synthesis was performed as described in
Section 4.3.5 starting with (R)-3f (717 mg, 3.45 mmol), and reacting
for 4 h prior to addition of HCl. Puriﬁcation by silica-gel column
chromatography (CH2Cl2, Rf 0.63) gave 905 mg (2.68 mmol, 78%) of
a colourless oil (solidiﬁed at 0 C), ee¼92.0%, [a]D20 32.4 (c 0.54,
EtOAc), CD (MeCN):D3¼4.8 (225 nm).1HNMR(CDCl3) d: 5.02 (ddd,
J¼45.8, 9.4, 6.1,1H,eCH2F), 5.48 (app. dt, J¼46.7, 9.4,1H,eCH2F), 5.74
(ddd, J¼12.1, 9.4, 6.1, 1H, eCHCH2F), 7.59e7.65 (m, 4H, eC6H4CF3),
7.72e7.77 (m, 2H, phthal.), 7.84e7.88 (m, 2H, phthal.). 13C NMR
(CDCl3) d: 54.1 (d, J¼23.0), 80.5 (d, J¼175.6),123.7,123.8 (q, J¼272.3),
125.9 (q, J¼3.9),128.6,130.9 (d, J¼32.9),131.7,134.4,139.1 (dq, J¼6.7,
1.4), 168.0 (2C). 19F NMR (CDCl3) d: 63.40 (s, 3F), 220.22 (td,
J¼46.1,11.8). IR (neat, cm1): 1777,1710,1620,1469,1385,1322,1067,
1013. HRMS (ESI): 360.0617 (calcd 360.0618, [MþNaþ]).
4.9.7. (S)-4-(1-(1,3-Dioxoisoindolin-2-yl)-2-ﬂuoroethyl)benzonitrile
((S)-5g). The synthesis was performed as described in Section 4.3.5
starting with (R)-4g (547 mg, 3.31 mmol), and reacting for 3 h prior
to addition of HCl. Puriﬁcation by silica-gel column chromatogra-
phy (pentane/acetone, 8/2, Rf 0.52) gave 647 mg (2.20 mmol, 66%)
of awhite solid, mp 89e91 C, ee¼87.5%, [a]D2024.4 (c 0.52, EtOAc),
CD (MeCN): D3¼2.7 (238 nm). 1H NMR (CDCl3) d: 5.04 (ddd,
J¼45.7, 9.4, 6.3, 1H, eCH2F), 5.40 (app. dt, J¼46.7, 9.4, 1H, eCH2F),
5.72 (ddd, J¼12.4, 9.1, 6.3, 1H, eCHCH2F), 7.61e7.68 (m, 4H,
eC6H4CN), 7.73e7.78 (m, 2H, phthal.), 7.85e7.89 (m, 2H, phthal.).
13C NMR (CDCl3) d: 54.0 (d, J¼23.3), 80.3 (d, J¼175.9), 112.7, 118.2,
123.7 (2C), 128.9 (2C), 131.5 (2C), 132.7 (2C), 134.5 (2C), 140.3 (d,
J¼6.0), 167.9 (2C). 19F NMR (CDCl3) d: 220.36 (td, J¼46.1, 12.2). IR
(neat, cm1): 2227, 1777, 1706, 1610, 1465, 1361, 1334, 1088, 999.
HRMS (ESI): 317.0694 (calcd 317.0697, [MþNaþ]).
4.9.8. (S)-2-(2-Fluoro-1-(4-nitrophenyl)ethyl)isoindoline-1,3-dione
((S)-5h). The synthesis was performed as described in Section 4.3.5
startingwith (R)-4h (648 mg, 3.50 mmol), and reacting for 3 h prior
to addition of HCl. Puriﬁcation by silica-gel column chromatogra-
phy using CH2Cl2/MeOH (99.5/0.5, Rf 0.49) followed by pentane/
acetone (8/2, Rf 0.50) gave 374 mg (1.19 mmol, 34%) of awhite solid,
mp 92e94 C, ee¼84.0%, [a]D20 6.5 (c 1.05, CHCl3), CD (MeCN):
D3¼1.4 (228 nm). 1H NMR (CDCl3) d: 5.08 (ddd, J¼45.5, 9.3, 6.3,
1H,eCH2F), 5.43 (app. dt, J¼46.5, 9.1, 1H, eCH2F), 5.78 (ddd, J¼12.4,
9.1, 6.3, 1H, eCHCH2F), 7.67e7.70 (m, 2H, eC6H4NO2), 7.74e7.79 (m,
2H, phthal.), 7.85e7.90 (m, 2H, phthal.), 8.21e8.24 (m, 2H,
eC6H4NO2).
13C NMR (CDCl3) d: 53.7 (d, J¼23.3), 80.4 (d, J¼176.3),
123.7 (2C), 124.1 (2C), 129.2 (2C), 131.5 (2C), 134.6 (2C), 142.2 (d,
J¼6.0),148.0,167.9 (2C). 19F NMR (CDCl3) d:221.22 (td,¼12.1, 46.0).
IR (neat, cm1): 1776, 1712, 1606, 1521, 1386, 1347, 1087, 999. HRMS
(ESI): 337.0605 (calcd 337.0595, [MþNaþ]).
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a b s t r a c t
Two series of allylamines/benzylamines have been synthesised and evaluated for their antifungal activity
towards Cryptococcus neoformans. All compounds are chiral derivatives of Butenaﬁne and Terbinaﬁne,
having additional substituents at the carbon connected to the central nitrogen atom. In both series, the
antifungal activity was strongly dependent on both the steric bulk and the electronic nature of the
substituents. Compared to the parent compounds (Butenaﬁne and Terbinaﬁne), the activity was main-
tained when the hydrogen was replaced with a methyl group. Lower activity was observed for ethyl,
whereas introduction of –CH2F, –CHF2, –CF3 or –CN substituents removed all antifungal activity. Testing
of (R)- and (S)-N-(4-tert-butylbenzyl)-N-methyl-1-(naphthalen-1-yl)ethanamine against C. neoformans,
Cryptococcus difﬂuens and Trichosporon cutaneum revealed that most of the activity resides in the (R)-
enantiomer. The (R)-enantiomer performed as well as, or better (lower MIC values) than Butenaﬁne
against each test strain, suggesting that antimycotics based on this compound might be an improvement
of existing Butenaﬁne-based formulations.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Treatment of an increasing number of infections associated
with immuno-compromised patients1 is causing a marked in-
crease in the number of fungal strains showing resistance to
presently available antimycotic agents.2–4 Among others, Crypto-
coccosis, caused by members of the Cryptococcus neoformans
species, is a serious and potentially fatal fungal disease afﬂicting
a large number of AIDS patients.5–7 C. neoformans has also become
the most common cause of meningitis in the developing world.8,9
Cryptococcus difﬂuens is less commonly associated with disease,
but has been frequently isolated from the skin of patients with
atopic dermatitis.10 Trichosporon species are usually found in soil
and fresh water and are known to cause white piedra and hy-
persensitive pneumonia. Invasive infections due to Trichosporon
are rare, but can be fatal to immuno-compromised patients, and
have been observed with growing frequency.11 Butenaﬁne (1a)
and Terbinaﬁne (2a) (Fig. 1) are well established antimycotic
agents used among others in topical treatment of dermatocytes
invading skin and nails. Their mode of action is by inhibiting the
enzyme squalene epoxidase in the ergosterol pathway responsible
for converting squalene into squalene 2,3-epoxide, which is sub-
sequently converted into lanosterol and ergosterol. Inhibition re-
sults in deﬁciency of the essential membrane component
ergosterol and also squalene accumulation plays an essential role
in the fungicidal action of these inhibitors.12 It has also been in-
dicated that the action of Butenaﬁne (1a) can be partly due to
permeabilisation of the fungal cell wall.13 Structure–activity
studies on Butenaﬁne (1a) and Terbinaﬁne (2a) analogues have
been performed.14–20 However, investigations of derivatives con-
taining a stereocentre in the vicinity of the central nitrogen atom,
are substantially less studied. The racemic derivatives rac-1b,21,22
and rac-2b,23 (Fig. 1) have previously been shown to have anti-
fungal activity, while the usefulness of (R)-2b has been indicated
by comparative molecular ﬁeld analysis.21,24
N N
Butenafine (1a) Terbinafine (2a)
N
1b-g
N
2b-g
R R
Figure 1. The structures Butenaﬁne (1a), Terbinaﬁne (2a), and the studied compounds
1b–g and 2b–g, R¼Me, Et, CH2F, CHF2, CF3, CN.
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2. Results and discussion
2.1. Synthesis of potential antifungal compounds
The synthesis of the target compounds 1b–g and 2b–g was
performed as shown in Schemes 1 and 2. Key intermediates were
the secondary methyl amines 6b–f. The amines, 6b–d, were made
from the corresponding ketones 3b–d by reductive amination in
methanol/acetic acid using NaBH3CN as reducing agent (53–76%
yield). The moderate yields were mainly due to background re-
duction of the ketones giving the corresponding secondary
alcohols.
1-(Naphthalen-1-yl)propan-1-one (3c) was obtained by ethyl-
ation of 1-cyanonaphthalene followed by hydrolysis,25 while 3d
was synthesised by ﬂuorination of the corresponding trimethylsilyl
enol ether 4b using Selectﬂuor (F-TEDA-BF4).26 The preparation
of a-ﬂuoroketone 3d was also attempted from 3c by using F-TEDA-
BF4 in reﬂuxing methanol.
26,27 This method gave the desired
product, however two other structurally related a-ﬂuoroketones
were also formed, resulting in a troublesome puriﬁcation. 19F NMR
spectroscopic analysis of the crude product suggested that addi-
tional ring ﬂuorination had taken place.
The amine 6ewas most conveniently prepared by diﬂuorination
of the imine 5b using N-ﬂuorodibenzenesulfonimide (NFSI) yield-
ing the diﬂuoroimine 5e. Reduction of 5e using NaBH3CN in glacial
acetic acid gave 6e in 73% overall yield from 3b. The use of F-TEDA-
BF4 as a ﬂuorinating agent was also investigated in the formation of
5e. However, this led to decomposition of the imine, yielding
mainly the a,a-diﬂuoroketone 3e. The triﬂuorinated amine, 6f, was
obtained from 2,2,2-triﬂuoro-1-(naphthalen-1-yl)ethanone (3f),
which in turnwas synthesised from 1-bromonaphthalene and ethyl
triﬂuoroacetate. Treatment of 3f with NaBH3CN/methylamine in
methanol did not give the desired product. However, high con-
version towards 5f was obtained when adding titanium tetrachlo-
ride to a preformed mixture of 3f and methylamine. Reduction of
the imine 5f using NaBH3CN in glacial acetic acid yielded the amine
6f in 63% from 3f.
To separate a possible size effect from an electronic effect in
interpretation of antifungal activity data, the cyano containing
compounds 1g and 2g (Fig. 1) were synthesised, starting with the
commercial available cyano derivative 6g. In terms of electronic
properties the cyano substituent mimics a CF2H or CF3 group, while
it occupies a smaller space than a methyl group.28
The potential antifungal agents 1b–g and 2b–g were obtained
by reacting the secondary amines 6b–g with the commercially
available 1-tert-butyl-4-(bromomethyl)benzene (7) and (E)-1-
chloro-6,6-dimethylhept-2-en-4-yne (8), respectively. All reactions
were performed in reﬂuxing acetonitrile using N,N-diisopropyle-
thylamine as base, see Scheme 2.
As expected, the reaction rate depended on the electronic
properties of the R-group of the amine, and on the alkylating agent.
Compounds 6b–c reacted with 7 to full conversion within 2 h,
while reactions using 6f–g and 8 took several days. Isolated yields
were in the range of 60–90% for 1b–g, while for 2b–g 40–63% were
experienced. The moderate yield of 2b–g can in part be explained
by the presence of 4% of the Z-isomer of 8, which led to a struc-
turally related product and a consequent loss in yield during pu-
riﬁcation. Moreover, in the synthesis of 1g and 2g, 1H NMR
spectroscopy indicated that some hydrolysis of the nitrile group
had taken place.
To evaluate the effect of stereochemistry on the antifungal ac-
tivity, the (R)- and (S)-enantiomers of N-(4-tert-butylbenzyl)-N-
methyl-1-(naphthalen-1-yl)ethanamine, (R)-1b and (S)-1b, were
synthesised from (R)-6b and (S)-6b with the same procedure as
outlined in Scheme 2.
2.2. Antifungal activity
The antifungal activity of compounds 1a–g and 2a–g was ini-
tially tested towards C. neoformans by the semisolid antifungal
susceptibility test (SAAS).29 The MIC values along with the calcu-
lated pKa0s for the compounds, and the steric bulk (Charton vol-
ume) of the substituents are shown in Table 1 (2a–g) and Table 2
(1a–g).
Testing of Terbinaﬁne (2a) towards C. neoformans gave a MIC50
value of 0.25 mg/mL, while compound 2b was a less efﬁcient in-
hibitor (MIC50: 0.5 mg/mL). Modifying the structure with an ethyl
substituent (entry 3), reduced the antifungal properties further,
Table 1
Antifungal activities (MIC) of 2a–g towards C. neoformans
Entry Comp. R Calcd pKa
a Rel sizeb MIC50 (mg/mL) MIC75 (mg/mL)
1 2a H 8.9 0 0.25 0.5
2 rac-2b Me 9.2 0.52 0.5 1.0
3 rac-2c Et 9.5 0.56 2–8c 16
4 rac-2d CH2F 7.6 0.62 >16 >16
5 rac-2e CHF2 5.8 0.68 >16 >16
6 rac-2f CF3 2.9 0.91 >16 >16
7 rac-2g CN 5.1 0.40 >16 >16
a The pKa values were estimated using the Marvin program suite.
b Charton volume is from tabulated values.28
c Trailing growth complicated assignment of MIC values.
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Scheme 2. Synthesis of rac-1b–g and rac-2b–g.
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whereas the compounds containing ﬂuorines or a cyano group
(entries 4–7), had no activity towards C. neoformans in the con-
centration ranges tested.
Testing of the derivatives 1a–g (Table 2) showed that Butenaﬁne
(1a) was more active than Terbinaﬁne (2a). Moreover, rac-1b
proved to have the same activity as 1a (MIC50 0.125 mg/mL). Syn-
thesis and antifungal activity testing of (S)-1b and (R)-1b revealed
that the activity of the racemate mainly relies on the activity of the
(R)-enantiomer (MIC50<0.031 mg/mL), and it was found to be sig-
niﬁcantly more potent than Butenaﬁne (1a). Compound (S)-1b also
inhibited fungal growth, and the MIC values were comparable with
that of 1c. However, trailing growth typical of a fungistatic activity,
complicated the analysis of the test results in both cases, making
endpoint assignments more difﬁcult. Compounds 1d–g had no
activity towards C. neoformans within the concentration range
tested. As observed in testing of 2d, introduction of one ﬂuorine
atom depleted the antifungal activity of the compound.
Assuming that the antifungal activity of these compounds is
mainly due to inhibition of squalene epoxidase, the results suggest
that both steric and electronic effects are of importance for the
antifungal properties of these compounds. A drop in activity was
seen going from the methyl substituted analogues, 1b and 2b, to
inhibitors having the more bulky ethyl substituents, 1c and 2c.
However, the cyano group occupies a smaller volume than amethyl
substituent, and the activity observed for 1g and 2g (MIC50>16),
indicates that electronic effects are of equal importance. The lack of
activity in testing of compounds 1d–f and 2d–f is therefore likely to
be due to both the unfavourable size and the electron withdrawing
nature of ﬂuoro-containing substituents. As structural information
of squalene epoxidases is unavailable, the effects can currently not
be explained at the molecular level.
When dealing with fungistatic agents and testing fungal species
for which there exist limited published data regarding antibiotic
susceptibilities, it seemed pertinent to include results from alter-
native test regimes. To verify the main results, the MIC values of
Butenaﬁne (1a), (rac)-1, (R)-1b and (S)-1b were also measured us-
ing the broth microdilution method.30 Two other fungal strains
representing two other species were included in the testing
(C. difﬂuens and T. cutaneum) to investigate the usefulness of (R)-1a
as an antifungal agent. The results are summarised in Table 3. The
SAAS and the broth microdilution method were in general agree-
ment with respect to the relative activity of the compounds tested
against C. neoformans. However, MIC values obtained using the two
methods differed in some instances by more than a single doubling
dilution. When (R)-1b and Butenaﬁne (1a) were tested against
C. neoformans using the broth microdilution method, MIC50 values
of 0.125 and 0.5 mg/mL were obtained, respectively.
Although endpoints in general were easier to assign with the
broth microdilution method, trailing growth complicated testing
towards C. difﬂuens. However, the results suggest that (R)-1b (MIC50
0.25 mg/mL) was more active than Butenaﬁne (1a). All compounds
tested towards T. cutaneum were active. Butenaﬁne (1a), (rac)-1b
and (R)-1b all gave a MIC50 value of 0.5 mg/mL. The relatively high
activity of (S)-1b towards T. cutaneum shows that the stereo-
chemistry of the inhibitor is less important than was the case for C.
neoformans and C. difﬂuens. This could indicate a wider or more
ﬂexible binding pocket for the inhibitors.
3. Conclusions
Two groups of chiral amines structurally related to Butenaﬁne
(1a) and Terbinaﬁne (2a) have been synthesised and tested as po-
tential antifungal agents. The activity towards C. neoformans
depended on both the steric bulk and electronic character of the
substituents. Racemic N-(4-tert-butylbenzyl)-N-methyl-1-(naph-
thalen-1-yl)ethanamine (1b) was found to have the same activity as
Butenaﬁne (1a) towards C. neoformans. Assessment of antifungal
activity using the SAAS method of the (R)- and (S)-enantiomers
concluded that most of the activity is due to (R)-1b, giving a MIC50
value of <0.031 mg/mL (MIC50 1a: 0.25 mg/mL). Compounds con-
taining electronwithdrawing groups at the stereogenic centre were
not active towards C. neoformans. Surprisingly, the insertion of one
ﬂuorine atom was sufﬁcient to remove all antifungal activity. This
could indicate that the nitrogen basicity is important for binding of
the compounds to the squalene epoxidase. Antifungal testing using
the broth microdilution method conﬁrmed that (R)-1b performed
as well as or better than Butenaﬁne (1a) against C. neoformans, C.
difﬂuens and T. cutaneum, suggesting that antimycotics based on
this compound might be an improvement of existing Butenaﬁne-
based formulations.
4. Experimental
4.1. General
1-Acetonaphthone (3b) was purchased from Fluka. LiHMDS,
Selectﬂuor (F-TEDA-BF4), 1-tert-butyl-4-(bromomethyl)benzene,
1-naphthonitrile, 1-bromonaphthalene, (R)- and (S)-N-methyl-1-
(naphthalen-1-yl)ethanamine ((R)-6b and (S)-6b), N-ﬂuo-
rodibenzenesulfonimide (NFSI) and trimethylsilyl chloride were
from Aldrich. 2-(Methylamino)-2-(naphthalen-1-yl)acetonitrile
(6g) was from UkrOrgSynthesis Building Blocks (Ukraine).
(E)-1-Chloro-6,6-dimethylhept-2-en-4-yne (trans-8, 94% pure) was
from Waterstone Technology. Terbinaﬁne$HCl was from Sigma,
while Butenaﬁne$HCl was from AK Scientiﬁc Inc. Column
Table 2
Antifungal activity (MIC) of 1a–g towards C. neoformans
Entry Comp. R Calcd pKa
a Rel sizeb MIC50 (mg/mL) MIC75 (mg/mL)
1 1a H 9.2 0 0.125 0.25
2 rac-1b Me 9.5 0.52 0.125 0.25
3 (R)-1b Me 9.5 0.52 <0.031 0.031
4 (S)-1b Me 9.5 0.52 0.5c 1–8c
5 rac-1c Et 9.8 0.56 0.25–4c 8
6 rac-1d CH2F 7.9 0.62 >16 >16
7 rac-1e CHF2 6.1 0.68 >16 >16
8 rac-1f CF3 3.2 0.91 >16 >16
9 rac-1g CN 5.4 0.40 >16 >16
a The pKa values were estimated using the Marvin program suite.
b Charton volume is from tabulated values.28
c Trailing growth complicated assignment of MIC values.
Table 3
Antifungal activities (MIC) of 1a, (rac)-1b, (R)-1b and (S)-1b towards C. neoformans, C. difﬂuens and T. cutaneum by the broth microdilution method
Comp. C. neoformans C. difﬂuens T. cutaneum
MIC50 (mg/mL) MIC75 (mg/mL) MIC50 (mg/mL) MIC75 (mg/mL) MIC50 (mg/mL) MIC75 (mg/mL)
1a 0.5 1.0 0.5a 4.0a 0.5 1.0
rac-1b 0.25 0.5 0.5a 2.0a 0.5 1.0
(R)-1b 0.125 0.25 0.25a 1.0a 0.5 1.0
(S)-1b 1.0a 2.0a 4.0a >16a 1.0a 2.0a
a Trailing growth complicated assignment of MIC values.
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chromatography was performed using silica gel 60A from Fluka,
pore size 40–63 mm.
4.2. Analyses
NMR spectra were recorded with Bruker Avance DPX 400 op-
erating at 400 MHz for 1H, 375 MHz for 19F and 100 MHz for 13C. For
1H and 13C NMR chemical shifts are in parts per million relative to
TMS, while for 19F NMR the shift values are relative to hexa-
ﬂuorobenzene. Coupling constants are in hertz. MS (EI/70 eV) Fin-
nigan MAT 95 XL, MS (ESI) Waters QTOF II and MS (CI): Waters
Prospec Q. FTIR spectra were recorded on a Thermo Nicolet Avatar
330 infrared spectrophotometer. Optical rotations were measured
using sodium D line at 589 nm on a Perkin–Elmer 243 B polarim-
eter. HPLC was performed using an Agilent 1100 series system
equipped with a Bruker DAD detector. The enantiomeric excess of
(R)-1b and (S)-1b was determined by an Astec CHIROBIOTIC V2
column, 5 mm, 4.6250 mm (Supelco, Pennsylvania, USA) eluting
with MeOH/water cont. 20 mM aq ammonium acetate, 60/40. Flow
rate: 0.8 mL/min, detection at 220 nm, retention times (S)-1b:
24.2 min and (R)-1b: 28.4 min. HPLC analysis of 1b–g and 2b–gwas
performed using the same HPLC system equipped with a Symmetry
C8 3.5 mm, 4.6150 mm column. Mobile phase: water/acetonitrile
30/70 containing 0.1% diethyl amine, ﬂow rate: 1.0 mL/min and
detection at 220 nm. Retention times (min): 1b: 37.2, 1c: 64.6, 1d:
34.4, 1e: 32.3, 1f: 37.0, 1g: 19.0, 2b: 23.9, 2c: 29.5, 2d: 17.9, 2e: 17.0,
2f: 27.0, 2g: 14.5.
4.3. Microbiology
4.3.1. Fungal isolates. Cultures of two quality control strains (C.
neoformans DSM 11959; Trichosporon cutaneum DSM 70698) and
a strain of Cryptococcus difﬂuens isolated from drinking water were
grown for 18–24 h at 35 C on Sabouraud’s dextrose agar (Oxoid,
Basingstoke, UK). Well-isolated colonies were used to make the
inoculum in each of the methods used for the determination of
minimum inhibitory concentrations (MICs).
4.3.2. Semisolid agar antifungal susceptibility test (SAAS). The test
was performed essentially as previously described.29 Five-millilitre
aliquots of semisolid heart infusion broth (Difco Laboratories,
Detroit, MI) containing 0.5% agar (Bacto Agar; Difco Laboratories) at
a pH of approximately 7.4 (without dextrose, buffer, or indicator)
were prepared with and without an antifungal drug in 16- by 125-
mm glass tubes. Analytical grade powders of Amphotericin B
(Sigma–Aldrich, St. Louis, MO) and the agents to be tested were
prepared as stock solutions in DMSO (Sigma–Aldrich) at 1.6 mg/mL.
The concentration range tested was 0.031–16 mg/mL and was
obtained by adding agent from 100-times stocks in DMSO into
tubes held molten at 50 C. A suspension equivalent to a 0.5
McFarland standard (determined photometrically) was prepared by
suspending the selected yeast in sterile water. The homogeneous
suspension was used for inoculation. A standard platinum loopful
(w0.001 mL) of the inoculum suspension was inserted deep into
each tube of medium containing a known concentration of drug, as
well as a drug-free control, by a centred down–up motion to form
a two dimensional inoculum. The tubes were tightly capped. A
loopful of the inoculum suspension was streaked onto SAB agar to
check the purity and viability of the inoculum. All cultures were
incubated for 72 h at 35 C. The growth in all tubes was compared
by visual inspection with that of the drug-free control in order to
determine the degree of growth inhibition. Growth was scored in
the following manner: 4þ, growth comparable to that of the drug-
free control; 3þ, growth approximately 75% that of the control; 2þ,
growth approximately 50% that of the control (MIC50); 1þ, growth
25% or less that of the control (MIC75); and 0, no visible growth.
4.3.3. Broth microdilution method. Testing was performed accord-
ing to the guidelines of the NCCLS document M27-A.30 Analytical
grade powders of Amphotericin B (Sigma–Aldrich, St. Louis, MO)
and the agents to be testedwere prepared as described above. Stock
solutions were diluted with RPMI 1640 medium (with L-glutamine
but without bicarbonate; Sigma–Aldrich) buffered to pH 7.0 with
0.176 M morpholinopropanesulfonic acid (MOPS, Sigma–Aldrich).
The ﬁnal concentration range tested was 0.031–16 mg/mL. Testing
was performed in 96-well microtitration plates (Nalge Nunc In-
ternational, Denmark). Yeast inocula were prepared in sterile 0.85%
saline and were diluted in RPMI 1640 medium to give a ﬁnal in-
oculum concentration in wells of 5102–2.5103 colony forming
units (CFU)/mL. The plates were lidded, and incubated at 35 C.
Endpoints were read visually at 72 h. Growth was scored as for the
SAAS method.
4.4. Synthesis of intermediates
4.4.1. 1-(Naphthalen-1-yl)propan-1-one (3c)25,31. 1-(Naphthalen-
1-yl)propan-1-one (3c) was prepared from 1-naphthonitrile
(10.00 g, 65.28 mmol) as described by Kloetzel et al.25 Distilla-
tion at 98–100 C (4103 mbar) gave 10.60 g (57.53 mmol,
88%) of a colourless oil. 1H NMR spectroscopy corresponded
with that reported.31
4.4.2. 2-Fluoro-1-(naphthalen-1-yl)ethanone (3d)32. Compound 3d
was synthesised from 3b (3.43 g, 20.15 mmol) via the trimethylsilyl
enol ether as described by Fuglseth et al.26 The product was puriﬁed
by silica-gel column chromatography (dichloromethane) giving an
oil. A following crystallisation (EtOAc/pentane) yielded 1.10 g
(5.84 mmol, 29%) of a white solid, mp 44–45 C (lit.33 82–84 C).
The 1H, 13C and 19F NMR data correspondedwith that reported.32 1H
NMR (CDCl3) d: 5.60 (d, J¼47.2, 2H), 7.50–7.61 (m, 2H), 7.65 (m, 1H),
7.80 (m, 1H), 7.89 (m, 1H), 8.05 (d, J¼8.3, 1H), 8.71 (m, 1H).
4.4.3. 2,2,2-Triﬂuoro-1-(naphthalen-1-yl)ethanone (3f)34. 2,2,2-Tri-
ﬂuoro-1-(naphthalen-1-yl)ethanone was prepared as described by
Konno et al. starting with 1-bromonaphthalene (4.15 g,
20.04 mmol).34 Puriﬁcation by silica-gel column chromatography
(EtOAc/pentane, 1/20) yielded 2.99 g (13.34 mmol, 67%) of a col-
oured oil. 1H, 13C and 19F NMR spectroscopy were in accordance
with that reported.34 1H NMR (CDCl3) d: 7.55–7.64 (m, 2H), 7.70 (m,
1H), 7.90–7.95 (m, 1H), 8.10–8.20 (m, 1H), 8.18–8.22 (m, 1H), 8.82
(m, 1H).
4.4.4. N-Methyl-1-(naphthalen-1-yl)ethanamine (6b)35. To a mix-
ture of methylamine in MeOH (30 mL, 2 M) were added acetic acid
(1.23 g, 20.48 mmol), 1-acetonaphthone (3b) (1.70 g, 9.99 mmol)
and NaBH3CN (0.38 g, 6.05 mmol). The reactionwas stirred at room
temperature for 70 h. The pH was adjusted to <2 using concd HCl.
After removal of MeOH the reaction mixture was diluted with
water (10 mL) and the mixture was extracted using tert-butyl
methyl ether (320 mL). The pH of the water phase was then ad-
justed to pH>10 using KOH. The water phase was saturated with
NaCl and extracted with tert-butyl methyl ether (515 mL). The
organic fraction was dried over Na2SO4, and the solvent was re-
moved under reduced pressure. This gave a 1.40 g (7.76 mmol, 76%)
of 6b as colourless oil, which was sufﬁciently pure for subsequent
step. 1H NMR (CDCl3) d: 1.50 (d, J¼6.6, 3H), 2.07 (br s, 1H), 2.42 (s,
3H), 4.53 (q, J¼6.6, 1H), 7.55–7.43 (m, 3H), 7.61 (d, J¼7.0, 1H), 7.75
(d, J¼8.1, 1H), 7.88 (m, 1H), 8.18 (d, J¼8.1, 1H). 13C NMR (CDCl3) d:
23.0, 34.5, 55.4, 122.7, 122.8, 125.3, 125.7, 125.8, 127.3, 129.0, 131.4,
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134.0, 141.1. HRMS (ESI): 186.1283 (calcd C13H16N
þ, MþHþ,
186.1277). IR (neat, cm1): 3061, 2972, 1678, 1136, 800, 770, 691.
4.4.5. N-Methyl-1-(naphthalen-1-yl)propaneamine (6c)35. Compound
6c was prepared as described for 6b starting with 3c (1.84 g,
9.99 mmol). This gave after silica-gel column chromatography
(MeOH) 1.28 g (6.42 mmol, 64%) of a pale yellow oil. 1H NMR
(CDCl3) d: 0.87 (t, J¼7.4, 3H),1.49 (br s,1H),1.88 (m, 2H), 2.34 (s, 3H),
4.34 (t, J¼6.4, 1H), 7.44–7.52 (m, 3H), 7.56–7.58 (m, 1H), 7.75
(d, J¼8.1, 1H), 7.86–7.88 (m,1H), 8.24 (d, J¼8.3, 1H). 13C NMR (CDCl3)
d: 10.8, 30.0, 34.8, 62.0, 123.2, 123.6, 125.2, 125.6, 125.7, 127.2, 128.9,
132.1, 134.0, 139.5. HRMS (ESI): 200.1437 (calcd C14H18N
þ, MþHþ,
200.1434). IR (neat, cm1): 2962, 1590, 1449, 1377, 1082, 775.
4.4.6. 2-Fluoro-N-methyl-1-(naphthalen-1-yl)ethanamine (6d).
Compound 6dwas synthesised as described for 6b starting with 3d
(1.00 g, 5.31 mmol) giving 0.57 g (2.80 mmol, 53%) of 6d as an oil.
1H NMR (CDCl3) d: 1.71 (br s, 1H), 2.42 (s, 3H), 4.47 (dt, J¼48.9, 9.3,
1H), 4.62 (ddd, J¼47.0, 9.3, 3.4, 1H), 4.81 (m, 1H), 7.47–7.58 (m, 3H),
7.73 (d, J¼7.0, 1H), 7.81 (d, J¼8.3, 1H), 7.89 (m, 1H), 8.22 (d, J¼8.5,
1H). 13C NMR (CDCl3) d: 34.5, 60.0 (d, J¼19.0), 86.5 (d, J¼175.0),
122.4, 124.91, 124.93, 125.57, 125.62, 126.3, 128.3, 129.1, 131.8, 134.0.
19F NMR (CDCl3) d: 217.7 (dt, J¼47.8, 14.2). IR (neat, cm1): 3060,
2948, 1589, 1144, 998, 800, 780, 691.
4.4.7. 2,2-Diﬂuoro-N-methyl-1-(naphthalen-1-yl)ethanamine
(6e).
4.4.7.1. Compound 5b. Methylamine (0.90 g, 28.98 mmol) was
dissolved inpentane (20 mL) and cooled to 0 C. TiCl4 (0.4 mL, 0.69 g,
3.64 mmol) was added dropwise over 5 min under rigorous stirring.
1-Acetonaphthone (3b) (0.83 g, 4.90 mmol) was then added in one
portion and the reaction mixture was stirred for 1 h allowing the
temperature to rise to ambient temperature. Diethyl ether (30 mL)
was added and the suspension was ﬁltered, followed by washing of
the inorganic residuewith additional ether (410 mL). The combined
ether fractions were concentrated under reduced pressure giving
0.82 g (89%) of N-(1-(naphthalen-1-yl)ethylidene)methanamine
(5b). The product was used in the next reaction without further pu-
riﬁcation. 1H NMR (CDCl3) d: 2.40 (q, J¼1.5, 3H), 2.92 (q, J¼1.5, 3H),
7.19 (dd, J¼7.0, 1.3, 1H), 7.50 (m, 4H), 7.86 (m, 2H).
4.4.7.2. Compound 5e. Amixture ofN-ﬂuorodibenzenesulfonimide
(NFSI, 4.75 g, 15.06mmol), K2CO3 (1.43 g, 10.35mmol), 3 Å molecular
sieve (3.00 g) and acetonitrile (30mL) was stirred for 15min at room
temperature. Then N-(1-(naphthalen-1-yl)ethylidene)methanamine
(5b) (0.64 g) in acetonitrile (20mL) was added dropwise and the
mixture was stirred at room temperature for 18 h, followed by
quenching with triethylamine (2.0 mL). The resulting mixture was ﬁl-
tered through Celite and the Celite was washed with diethyl ether
(315mL). The ﬁltrate was then washed with NaOH (0.5M, 20mL)
and the aqueous layer was back extracted with ether (430mL). The
combined organic fractions were dried over Na2SO4, and the solvents
were evaporated under reduced pressure. The oily product was used in
the next stepwithout puriﬁcation.1HNMR (CDCl3) d: 3.09 (t, J¼2.8, 3H),
6.32 (t, J¼55.6, 1H), 7.36 (d, J¼7.2, 1H), 7.54 (m, 4H), 7.93 (m, 2H).
4.4.7.3. Compound 6e. Crude N-(2,2-diﬂuoro-1-(naphthalen-1-
yl)ethylidene)methanamine (5e) (0.77 g, w3.5 mmol) was dis-
solved in absolute MeOH (35 mL). NaBH3CN (0.35 g, 5.40 mmol)
and glacial acetic acid (0.41 g, 6.90 mmol) were added and the
mixture was stirred at room temperature overnight. The solvents
were evaporated under reduced pressure and the crude product
was directly puriﬁed by silica-gel column chromatography (EtOAc/
pentane, 1/2) yielding a colourless oil 0.56 g (2.53 mmol, 73% yield
from 3c). 1H NMR (CDCl3) d: 1.75 (br s, 1H), 2.42 (s, 3H), 4.73 (td,
J¼10.7, 4.9, 1H), 6.00 (dt, J¼56.3, 4.9,1H), 7.55–7.50 (m, 2H), 7.57 (m,
1H), 7.77 (d, J¼8.5, 1H), 7.86 (d, J¼8.0, 1H), 7.91 (m, 1H), 8.24 (d,
J¼7.2, 1H). 13C NMR (CDCl3) d: 34.5, 62.3 (t, J¼21.9), 117.2 (t,
J¼245.8), 122.9, 125.5, 125.7, 126.4 (2C), 128.9, 129.0, 131.6, 132.3,
134.0. 19F NMR (CDCl3) d: 122.6 (dd, J¼279.9, 57.4), 124.2 (ddd,
J¼279.9, 57.4, 11.5). HRMS (ESI): 222.1093 (calcd C13H14F2Nþ,
MþHþ, 222.1089). IR (neat, cm1): 3353, 3053, 2972, 2851, 2795.
4.4.8. 2,2,2-Triﬂuoro-N-methyl-1-(naphthalen-1-yl)ethanamine
(6f).
4.4.8.1. Compound 5f. 2,2,2-Triﬂuoro-1-(naphthalen-1-yl)etha-
none (3f) (2.21 g, 9.86 mmol) and methylamine (2.60 g,
83.72 mmol) were dissolved in n-hexane (150 mL) and cooled to
0 C. TiCl4 (0.80 mL, 1.39 g, 7.33 mmol) in n-hexane (5 mL) was
addeddropwise under vigorous stirring. The orange suspensionwas
slowly warmed to room temperature and stirred for 2 h. Diethyl
ether (100 mL) was then added and the suspension was ﬁltered,
before the inorganic residue was washed with additional ether
(325 mL). The solventswere removed under reduced pressure and
the crude product (2.14 g, 91%) was used in the next reaction
without further puriﬁcation. 1H NMR (CDCl3) d: 3.15 (q, J¼1.9, 3H),
7.39 (d, J¼7.0,1H), 7.56 (m, 4H), 7.93 (m,1H), 7.98 (dd, J¼8.3, 0.8,1H).
4.4.8.2. Compound 6f. Crude N-(2,2,2-triﬂuoro-1-(naphthalen-
1-yl)ethylidene)methanamine (5f) (2.14 g, 9.02 mmol) was dis-
solved in dry MeOH. NaBH3CN (1.01 g, 15.58 mmol) and glacial
acetic acid (0.97 g, 16.10 mmol) were added and the reaction mix-
ture was stirred at room temperature overnight. The reaction was
quenched by addition of satd NaHCO3 (100 mL). Awhite precipitate
was ﬁltered off and the aqueous layer was extracted with diethyl
ether (575 mL). The combined organic layers were dried over
Na2SO4, ﬁltered and the solvents evaporated under reduced pres-
sure. The productwas puriﬁed by silica-gel column chromatography
(pentane/EtOAc, 9/1) yielding 1.49 g (6.23 mmol, 63% from 3f) of 6f.
1H NMR (CDCl3) d: 1.75 (br s, 1H), 2.46 (s, 3H), 4.98 (q, J¼7.2, 1H),
7.50–7.60 (m, 3H), 7.74 (d, J¼7.1,1H), 7.90 (m, 2H), 8.14 (d, J¼8.5,1H).
13C NMR (CDCl3) d: 34.8, 61.3 (q, J¼29.5), 122.7, 123.3, 125.3, 125.6,
125.8, 125.9 (q, J¼281.2), 126.7, 129.0, 129.5, 130.2, 134.0. 19F NMR
(CDCl3) d:76.0 (d, J¼6.9). HRMS (ESI): 240.0998 (calcd C13H13F3Nþ,
MþHþ, 240.0995). IR (neat, cm1): 3353, 3053, 2972, 2867, 2802.
4.5. Potential anti-fungicidal compounds
4.5.1. N-(4-tert-Butylbenzyl)-N-methyl-1-(naphthalen-1-yl)ethanamine
(1b). N-Methyl-1-(naphthalen-1-yl)ethanamine (6b) (370 mg,
2.00 mmol), N,N-diisopropylethylamine (391 mg, 3.03 mmol), 1-
(bromomethyl)-4-tert-butylbenzene (500 mg, 2.20 mmol) and
acetonitrile (5 mL) were mixed and stirred at reﬂux under a N2 at-
mosphere for 2 h. The solventwas removed at reduced pressure and
dichloromethane (5 mL) was added. The dichloromethane phase
was washed with water (5 mL) and the water phase was back
extracted with dichloromethane (35 mL). The combined organic
fractions were dried over Na2SO4, and concentrated in vacuum. The
crude product was puriﬁed by silica-gel column chromatography
(pentane/EtOAc, 9/1). This gave 540 mg (1.63 mmol, 82%) of col-
ourless oil. 1H NMR (CDCl3) d: 1.29 (9H, s), 1.55 (3H, d, J¼6.7), 2.20
(3H, s), 3.39 (1H, d, J¼13.5), 3.62 (1H, d, J¼13.5), 4.38 (1H, q, J¼6.7),
7.18 (2H,m), 7.28 (2H,m), 7.35–7.56 (3H,m), 7.65 (m,1H), 7.74 (1H, d,
J¼8.5), 7.85 (1H,m), 8.45 (1H, d, J¼7.8). 13CNMR (CDCl3) d: 16.5, 34.4,
38.4, 58.7, 60.4, 124.5, 124.7, 125.0 (2C), 125.2, 125.3, 125.4, 127.4,
128.4 (2C), 128.6, 131.9, 31.4 (3C), 134.1, 137.1, 140.7, 149.5. HRMS
(ESI): 332.2378 (calcd for C24H30N
þ, MþHþ, 332.2373). IR (neat,
cm1): 3045, 2948, 1516, 1249, 800 and 772.
4.5.2. N-(4-tert-Butylbenzyl)-N-methyl-1-(naphthalen-1-yl)ethan-
amine ((R)-1b). Compound (R)-1bwas synthesised as described for
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1b starting with (R)-6b (370 mg, 2.00 mmol) from Aldrich, giving
403 mg (1.22 mmol, 61%) of (R)-1b as a colourless oil. 1H and 13C
NMR were identical with that of rac-1b, ee: 99.5% (CHIROBIOTIC
V2), [a]D
25 56.1 (c 1.0, MeOH).
4.5.3. N-(4-tert-Butylbenzyl)-N-methyl-1-(naphthalen-1-yl)ethan-
amine ((S)-1b). Compound (S)-1bwas synthesised as described for
1b starting with (S)-6b (370 mg, 2.00 mmol) from Aldrich, giving
467 mg (1.41 mmol, 70%) of (R)-1b as a colourless oil. 1H and 13C
NMR spectra were identical with that of rac-1b, ee: 98.5% (CHI-
ROBIOTIC V2), [a]D
25 54.3 (c 1.0, MeOH).
4.5.4. N-(4-tert-Butylbenzyl)-N-methyl-1-(naphthalen-1-yl)propan-
1-amine (1c). Compound 1c was synthesised as described for 1b
starting with 6c (390 mg, 1.99 mmol). Puriﬁcation by silica-gel
column chromatography (pentane/EtOAc, 9/1) gave 562 mg
(1.63 mmol, 82%) of 1c as a colourless oil. 1H NMR (CDCl3) d: 0.78 (t,
J¼7.3, 3H), 1.29 (s, 9H), 2.10 (m, 2H), 2.22 (s, 3H), 3.37 (d, J¼13.1, 1H),
3.60 (d, J¼13.1, 1H), 4.12 (m, 1H), 7.16–7.18 (m, 2H), 7.24–7.29 (m,
2H), 7.43–7.51 (m, 3H), 7.58 (d, J¼6.8, 1H), 7.74 (d, J¼8.4, 1H), 7.83–
7.84 (m, 1H), 8.41 (m, 1H). 13C NMR (CDCl3) d: 11.1, 23.5, 31.4 (3C),
34.4, 38.8, 59.0, 65.9, 124.6, 124.9 (2C), 125.0, 125.2, 125.4, 125.6,
127.4, 128.4 (2C), 128.7, 132.6, 134.2, 137.2, 137.9, 149.5. HRMS (ESI):
346.2520 (calcd C25H32N
þ, MþHþ, 346.2529). IR (neat, cm1):
2960, 2871, 2783, 1510, 1361, 1267, 776.
4.5.5. N-(4-tert-Butylbenzyl)-2-ﬂuoro-N-methyl-1-(naphthalen-1-
yl)ethanamine (1d). N-(4-tert-Butylbenzyl)-2-ﬂuoro-N-methyl-1-
(naphthalen-1-yl)ethanamine (1d) was prepared as described for 1b
starting with 6d (200 mg, 0.98 mmol). The product was puriﬁed by
silica-gel column chromatography using pentane/EtOAc (20/1) as
eluent. This gave 294 mg (0.84 mmol, 86%) of an oil. 1H NMR (CDCl3)
d: 1.29 (s, 9H), 2.33 (d, J¼1.9, 3H), 3.53 (d, J¼13.4,1H), 3.71 (d, J¼13.4,
1H), 4.56 (ddd, J¼21.0, 6.8, 3.4, 1H), 4.79 (ddd, J¼47.8, 10.0, 3.4, 1H),
5.03 (ddd, J¼47.6, 10.0, 6.8, 1H), 7.18–7.24 (m, 2H), 7.28–7.35 (m, 2H),
7.43–7.60 (m, 3H), 7.69 (d, J¼7.0,1H), 7.81 (d, J¼8.2,1H), 7.88 (m,1H),
8.35 (d, J¼8.3, 1H). 13C NMR (CDCl3) d: 31.4 (3C), 34.4, 39.2, 59.3
(d, J¼1.8), 65.3 (d, J¼18.7), 84.9 (d, J¼175.6), 123.9, 125.1 (2C), 125.3,
125.6, 125.7, 126.0, 128.3 (2C), 128.4, 128.9, 131.8, 134.2, 135.1
(d, J¼7.8), 136.5, 149.7. 19F NMR (CDCl3) d: 213.3 (dt, J¼47.0, 20.3).
HRMS (ESI): 350.2284 (calcd for C24H29FN
þ, MþHþ, 350.2279).
IR (neat, cm1): 3045, 2964, 1508, 1197, 812 and 776.
4.5.6. N-(4-tert-Butylbenzyl)-2,2-diﬂuoro-N-methyl-1-(naphthalen-
1-yl)ethanamine (1e). Compound 1ewas prepared as described for
1b starting with 6e (448 mg, 2.02 mmol). The reaction was run for
48 h. The productwas puriﬁedbysilica-gel column chromatography
using pentane/EtOAc (20/1) as eluent. This gave 660 mg (1.80 mmol,
90%) of anopaqueoil,which solidiﬁed at 0 C.1HNMR(CDCl3) d: 1.29
(s, 9H), 2.39 (s, 3H), 3.66 (d, J¼13.8,1H), 3.81 (d, J¼13.8,1H), 4.69 (td,
J¼12.8, 4.4, 1H), 6.69 (dt, J¼55.3, 4.4, 1H), 7.15 (d, J¼8.2, 2H), 7.28 (d,
J¼8.2, 2H), 7.48 (t, J¼7.7,1H), 7.54 (m, 2H), 7.65 (d, J¼7.1, 1H), 7.84 (d,
J¼8.1, 1H), 7.88 (m, 1H), 8.20 (d, J¼8.3, 1H). 13C NMR (CDCl3) d: 31.3
(3C), 34.4, 38.8, 58.8, 65.6 (t, J¼21), 117.3 (t, J¼247.0), 124.1, 124.8,
125.1 (2C), 125.7, 126.2, 126.5, 128.3 (2C), 128.8 (2C), 131.8, 132.5,
134.1, 136.1, 149.8. 19F NMR (CDCl3) d: 120.8 (ddd, J¼285.7, 56.2,
9.2), 123.3 (dd, J¼285.7, 56.2). HRMS (ESI): 368.2182 (calcd
C24H28F2N
þ, MþHþ, 368.2184). IR (neat, cm1): 3053, 2956, 2859.
4.5.7. N-(4-tert-Butylbenzyl)-2,2,2-triﬂuoro-N-methyl-1-(naph-
thalen-1-yl)ethanamine (1f). Compound 1f was prepared as de-
scribed for 1b starting with 6f (720 mg, 3.01 mmol) and reacting for
5 days. The product 1f was puriﬁed by silica-gel column chroma-
tography using pentane/EtOAc (9/1) as eluent. This gave 950 mg
(2.46 mmol, 82%) of an off-white solid,mp63–65 C.1HNMR (CDCl3)
d: 1.32 (s, 9H), 2.47 (s, 3H), 3.81 (d, J¼13.8, 1H), 3.87 (d, J¼13.8, 1H),
5.17 (q, J¼8.7, 1H), 7.13(d, J¼8.2, 2H), 7.30 (d, J¼8.2, 2H), 7.51 (t, J¼7.7,
1H), 7.58 (m, 2H), 7.80 (d, J¼6.9, 1H), 7.90 (d, J¼8.2, 1H), 7.92 (m,1H),
8.06 (d, J¼8.5, 1H). 13C NMR (CDCl3) d: 31.4 (3C), 34.4, 38.1, 58.0, 64.5
(q, J¼26.1), 123.8, 124.8, 125.2 (2C), 125.8, 126.3, 126.5, 127.3
(q, J¼290.7), 128.2 (2C), 129.0, 129.3, 129.6, 132.3, 134.1, 135.9, 150.0.
19F NMR (CDCl3) d: 66.3 (s). HRMS (ESI): 386.2090 (calcd
C24H27F3N
þ, MþHþ, 386.2090). IR (neat, cm1): 3037, 2964, 2859.
4.5.8. 2-((4-tert-Butylbenzyl)(methyl)amino)-2-(naphthalen-1-yl)ace-
tonitrile (1g). Compound 1g was prepared as described for 1b
starting with 6g (191 mg, 0.97 mmol) and reacting for 4 h. The
product was puriﬁed by silica-gel column chromatography using
pentane/EtOAc (85/15) as eluent. This gave 250 mg (0.73 mmol, 75%)
of white solid, mp 75–77 C. 1H NMR (CDCl3) d: 1.32 (s, 9H), 2.27
(s, 3H), 3.64 (d, J¼12.9,1H), 3.82 (d, J¼12.9,1H), 5.52 (s,1H), 7.25–7.29
(m, 2H), 7.34–7.38 (m, 2H), 7.44–7.52 (m, 3H), 7.82–7.87 (m, 4H). 13C
NMR (CDCl3) d: 31.4 (3C), 34.6, 38.2, 59.0, 59.1, 115.3, 123.9, 124.7,
125.4 (2C), 126.2, 126.5, 127.0, 128.7, 129.0, 129.1 (2C), 130.0, 130.9,
134.0, 134.2, 150.9. HRMS (ESI): 343.2171 (calcd C24H27N2
þ, MþHþ,
343.2169). IR (neat, cm1): 2964, 2871, 1510, 1358, 1014, 778.
4.5.9. (E)-N,6,6-Trimethyl-N-(1-(naphthalen-8-yl)ethyl)hept-2-en-4-
yn-1-amine (2b). N-Methyl-1-(naphthalen-1-yl)ethanamine (6b)
(370 mg, 2.00 mmol), N,N-diisopropylethylamine (390 mg,
3.02 mmol) and E-1-chloro-6,6-dimethylhept-2-ene-4-yne (8)
(340 mg, 2.17 mmol) were mixed in acetonitrile (5 mL), and
reﬂuxed under a N2 atmosphere for 2 h. The solvent was removed
at reduced pressure and dichloromethane (5 mL) was added. The
dichloromethane phase was washed with water (5 mL). The water
phase was back extracted with dichloromethane (35 mL). The
combined organic fractions were dried over Na2SO4, and concen-
trated under reduced pressure. The crude product was puriﬁed by
silica-gel column chromatography using pentane/EtOAc (85/15) as
eluent. This gave 370 mg (1.21 mmol, 61%) of a pale yellow oil. 1H
NMR (CDCl3) d: 1.22 (s, 9H), 1.46 (d, J¼6.7, 3H), 2.25 (s, 3H), 2.97 (dd,
J¼14.5, 6.7, 1H), 3.16 (dd, J¼14.5, 6.2, 1H), 4.26 (q, J¼6.7, 1H), 5.58
(d, J¼15.9, 1H), 6.04 (dt, J¼15.9, 6.4, 1H), 7.37–7.52 (m, 3H), 7.56 (d,
J¼7.1, 1H), 7.73 (d, J¼8.2, 1H), 7.83 (m, 1H), 8.38 (d, J¼8.5, 1H). 13C
NMR (CDCl3) d: 17.8, 27.9, 31.0, 38.9, 56.8, 60.3, 77.3, 98.1, 111.9,
124.2, 124.4, 125.3 (2C), 125.5, 127.4, 128.7, 131.7, 134.1, 140.1, 140.7.
HRMS (ESI): 306.2212 (calcd C22H28N
þ, MþHþ, 306.2216). IR (neat,
cm1): 3053, 2964, 1443, 1192, 795 and 772.
4.5.10. (E)-N-6,6-Trimethyl-N-(1-(naphthalen-1-yl)propyl)hept-2-
en-4-yn-1-amine (2c). Compound 2cwas prepared as described for
2b starting with 6c (400 mg, 2.01 mmol). The product 1f was pu-
riﬁed by silica-gel column chromatography using pentane/EtOAc
(9/1) as eluent. This gave 350 mg (1.10 mmol, 55%) of an oil. 1H NMR
(CDCl3) d: 0.67 (t, J¼7.3, 3H), 1.22 (s, 9H), 1.89–2.09 (m, 2H), 2.26
(s, 3H), 2.94 (ddd, J¼1.3, 6.3, 14.7, 1H), 3.14 (ddd, J¼1.3, 5.8, 14.7, 1H),
4.02 (br m, 1H), 5.55 (dt, J¼1.3, 15.6, 1H), 6.02 (ddd, J¼5.8, 6.3, 15.6,
1H), 7.40–7.50 (m, 4H), 7.74 (d, J¼8.3, 1H), 7.83–7.85 (m, 1H), 8.39–
8.40 (m,1H). 13C NMR (CDCl3) d: 10.8, 24.4, 27.9, 31.0 (3C), 39.3, 57.0,
66.8 (br), 77.3, 98.1, 111.9, 124.3, 125.0, 125.2, 125.5, 125.6, 127.4,
128.7, 132.5, 134.1, 137.8, 140.2. HRMS (ESI): 320.2377 (calcd
C23H30N
þ, MþHþ, 320.2373). IR (neat, cm1): 2966, 2870, 2785,
1509, 1361, 1264, 790, 776.
4.5.11. (E)-N-(2-Fluoro-1-(naphthalen-1-yl)ethyl)-N-6,6-tri-
methylhept-2-en-4-yn-1-amine (2d). Compound 2d was prepared
as described for 2b starting with 6d (163 mg, 0.80 mmol). The
product 2dwas puriﬁed by silica-gel column chromatography using
pentane/EtOAc (20/1) as eluent. This gave 102 mg (0.32 mmol, 41%)
of a pale yellow oil. 1H NMR (CDCl3) d: 1.22 (s, 9H), 2.37 (s, 3H), 3.06
(dd, J¼14.7, 6.8,1H), 3.22 (ddd, J¼14.7, 5.9,1.7,1H), 4.46 (ddd, J¼20.9,
6.6, 3.3, 1H), 4.67 (d, 48.0, 10.1, 3.3, 1H), 4.89 (ddd, J¼47.5, 10.1, 6.6,
E. Fuglseth et al. / Tetrahedron 65 (2009) 9807–98139812
1H), 5.58 (dt, J¼15.9, 1.5, 1H), 6.02 (ddd, J¼15.9, 6.9, 5.9, 1H), 7.60–
7.40 (m, 4H), 7.79 (d, J¼8.3, 1H), 7.86 (m, 1H), 8.29 (d, J¼8.2, 1H). 13C
NMR (CDCl3) d: 27.9 (3C), 31.0, 39.6, 57.3, 65.0 (d, J¼20.5), 77.2, 85.1
(d, J¼175.9), 98.3,112.4,123.6,125.3,125.6,125.8,126.1,128.3,128.9,
131.7, 134.1, 134.5 (d, J¼7.5), 139.4. 19F NMR (CDCl3) d: 212.6 (dt,
J¼47.6, 20.6). HRMS (ESI): 324.2127 (calcd C22H27FNþ, MþHþ,
324.2122). IR (neat, cm1): 3055, 2969, 1460, 1203, 804 and 774.
4.5.12. (E)-N-(2,2-Diﬂuoro-1-(naphthalen-1-yl)ethyl)-N-6,6-tri-
methylhept-2-en-4-yn-1-amine (2e). Compound 2e was prepared
as described for 2b starting with 6e (370 mg, 1.67 mmol) and
reacting for 6 days. The product 2e was puriﬁed by silica-gel col-
umn chromatography using pentane/EtOAc, 40/1, then 9/1 as elu-
ent. This gave 362 mg (1.06 mmol, 63%) of an opaque oil. 1H NMR
(CDCl3) d: 1.22 (s, 9H), 2.39 (s, 3H), 3.13 (dd, J¼14.8, 6.8, 1H), 3.27
(dd, J¼14.8, 5.8, 1H), 4.55 (dt, J¼12.9, 4.3, 1H), 5.56 (dt, J¼16.0, 1.5,
1H), 5.96 (dt, J¼16.0, 6.4,1H), 6.30 (dt, J¼55.1, 4.3,1H), 7.40–7.57 (m,
4H), 7.78–7.87 (m, 2H), 8.20 (d, J¼8.4, 1H). 13C NMR (CDCl3) d: 27.9,
31.0 (3C), 39.3, 57.0, 65.7 (t, J¼21.2), 77.2, 98.6, 112.7, 117.0
(t, J¼246.9), 123.9, 124.9, 125.7, 126.3, 126.8, 128.9, 129.0, 131.6,
132.5, 134.1, 139.0. 19F NMR (CDCl3) d: 120.9 (dd, J¼285.7, 55.1),
123.3 (dd, J¼285.7, 55.1). HRMS (ESI): 342.2042 (calcd
C22H26F2N
þ, MþHþ, 342.2028). IR (neat, cm1): 3053, 2964, 2826.
4.5.13. (E)-N,6,6-Trimethyl-N-(2,2,2-triﬂuoro-1-(naphthalen-
1-yl)ethyl)hept-2-en-4-yn-1-amine (2f). Compound 2f was pre-
pared as described for 2b starting with 6f (430 mg, 1.80 mmol) and
reacting for 10 days. The product 2fwas puriﬁed by silica-gel column
chromatography using pentane/EtOAc 40/1, then 9/1 as eluent. This
gave 286 mg (0.80 mmol, 44%) of an opaque oil. 1H NMR (CDCl3) d:
1.22 (s, 9H), 2.43 (s, 3H), 3.28 (dd, J¼14.8, 6.2,1H), 3.37 (dd, J¼14.8, 6.6,
1H), 5.00 (q, J¼8.7, 1H), 5.90 (dt, J¼15.9, 6.2, 1H), 5.57 (dt, J¼15.9,
J¼1.5, 1H), 7.44–7.59 (m, 3H), 7.67 (d, J¼7.6, 1H), 7.85 (d, J¼8.5, 1H),
7.88 (d, J¼9.0, 1H), 8.05 (d, J¼8.6, 1H). 13C NMR (CDCl3) d: 27.8, 30.9,
38.3, 56.4, 64.3 (q, J¼26.8), 77.2, 98.7, 112.6, 123.4, 124.7, 125.7, 126.3,
126.5, 127.0 (q, J¼289.6), 129.0, 129.3, 129.4, 132.2, 134.0, 139.2. 19F
NMR (CDCl3) d: 67.3 (d, J¼8.0). HRMS (ESI): 360.1936 (calcd
C22H25F3N
þ, MþHþ, 360.1934). IR (neat, cm1): 3045, 2964, 2859.
4.5.14. (E)-N-6,6-Trimethyl-N-(1-(naphthalen-1-yl)propyl)hept-2-
en-4-yn-1-amine (2g). Compound 2gwas prepared as described for
2b starting with 6g (200 mg, 1.02 mmol) reacting for 5 days. The
product 2gwas puriﬁed by silica-gel column chromatography using
pentane/EtOAc (85/15) as eluent. This gave 145 mg (0.46 mmol,
45%) of a pale yellow oil. 1H NMR (CDCl3) d: 1.23 (s, 9H), 2.24 (s, 3H),
3.20 (ddd, J¼13.9, 7.8, 1.0, 1H), 3.31 (ddd, J¼13.9, 5.6, 1.8, 1H), 5.56
(s,1H), 5.77 (dt, J¼15.9,1.3,1H), 6.02 (ddd, J¼15.9, 7.8, 5.6,1H), 7.45–
7.59 (m, 3H), 7.79 (d, J¼7.3, 1H), 7.87–7.89 (m, 2H), 8.10 (d, J¼8.0,
1H). 13C NMR (CDCl3) d: 27.9, 30.9 (3C), 38.1, 56.9, 59.6, 76.7, 99.5,
114.5, 115.1, 123.8, 124.8, 126.3, 126.7, 126.9, 128.7, 128.8, 130.2,
130.8, 134.0, 137.1. HRMS (ESI): 317.2009 (calcd C22H25N2
þ, MþHþ,
317.2012). IR (neat, cm1): 2966, 2870, 1511, 1361, 1263, 792, 781.
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